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Abstract 
The blood brain barrier is a highly selective physical, transport and metabolic barrier, that 
limits the disposition of drugs to the CNS; a pertinent problem to the successful treatment of 
glioma. There has been an emergence of cell based in vitro models as potential tools to predict 
the in vivo permeation of therapeutics at the BBB, however most of the available models 
have only been characterised for just the physical barrier and not the metabolic barrier 
comprised of efflux transporters and drug metabolising enzymes. In addition, a review of all 
the available models found that there was a lack of multicellular models cultured using all 
human components. There was an urgent need to develop a model which is physiologically 
relevant and focusses on the metabolic barrier present at the blood and brain junctions with 
a goal to delivering chemotherapeutics to CNS tumours. The aim of the study was to design 
an all human, fully characterised and physiologically relevant in vitro BBB model for the 
prediction of permeability of drugs across the blood brain barrier to glioma. Cell cultures 
investigated included the glioma cell lines (U87MG, 1321N1), non-cancerous cell lines 
(SVGp12, hCMEC/D3), glioma short term cultures (BTNW914, BTNW370) human 
endothelial culture (HBMEC), human astrocytes (HA) and human pericytes (HBVP). The 
cell cultures were characterised and studied for the expression of activity levels for efflux 
transporters; ABCB1 and ABCG2 and drug metabolising enzymes; CYP3A4 and CYP2D6. 
The culturing conditions of cells was optimised by using human serum, human fibronectin 
to maximise the expression and activity of these proteins. The cell showing high expression 
and activity were used to design the mono-, co- and tri- culture in vitro BBB model on a 
transwell insert. The models were assessed on the basis of TEER, tight junction protein 
expression and expression and activity of efflux transporter and DMEs. These models were 
also constructed on 3D Alvetex scaffolds and exposed to shear stress by dynamic perfusion. 
Finally model was used to screen permeability of novel lipid NPs and a glioma specific 
targeting aptamer SA43.The human primary cultures (HBMEC, HBVP and HA) were 
selected to model the BBB and the tri-culture model gave the highest TEER of 258 Ω/cm2. 
The tri-culture model on alvetex scaffold with perfusion showed a TEER of 769 Ω/cm2. The 
screening of NPs found the docetaxel and curcumin lipid NPs were permeable through the 
barrier. In future, the developed BBB model will be further characterised and used 
commercially for screening of novel glioma therapeutics and drug delivery systems.   
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1 
 Introduction  
1.1  Brain tumour 
A brain tumour is defined as an abnormal mass or growth of cells in the brain arising from 
rapidly proliferating cells (Vescovi et al., 2006). These proliferating cells interfere and 
damage the healthy brain tissue and cause increased intracranial pressure (Figure 1.1). The 
term brain tumour covers a wide range of benign and malignant tumour types. Benign brain 
tumours are slow growing, are unlikely to recur or spread to other parts of the brain and can 
be typically treated with surgery depending on location (Duffner et al., 1985). Malignant 
brain tumours have a high mitotic index and are likely to metastasise to other parts of the 
brain and the spinal cord (Graham and Cloughesy, 2004). Malignant tumours are more likely 
to recur after surgery and therefore require radiotherapy and chemotherapy post tumour 
resection. 
 
Figure 1.1 A) Tumour invading healthy brain tissue. B) Tumour pressing on the healthy tissue and causing 
increased pressure within the brain (Abrey and Mason, 2003). 
Tumour 
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1.1.1 Classification of brain tumour 
The most fundamental differentiation of a brain tumour is between primary intracranial 
lesion, metastatic and secondary brain tumour (Abrey and Mason, 2003). The categories, 
primary (de novo) and secondary are more conceptual than diagnostic (Kleihues and Ohgaki, 
1999). These terminologies were first used by a German neurologist Hans-Joachim Scherer, 
who defined primary (de novo) as a tumour that lacked an identifiable precursor lesion and 
arose from a single step malignant transformation (Scherer, 1940; Scherer, 1938; Ohgaki and 
Kleihues, 2013). Secondary tumours were defined as progressive tumours which develop 
from a less malignant or a benign precursor (Scherer, 1940; Scherer, 1938).  
Brain metastases are ten times more common than primary brain tumours and are estimated 
to occur in up to 30 % of patients diagnosed with a solid brain tumour (Nathoo et al., 2004). 
For the adult population, the percentage of cases where brain metatastic tumour commonly 
originate from is as follows: lung; (50 %) breast (15 - 20 %), unknown primary tumour (10 
– 15 %), melanoma (10 %), and colon (5 %) (Wen and Loeffler, 2000; Bouffet et al., 1997). 
In children, common sources include the sarcomas, neuroblastoma, and germ cell tumours 
(Wen and Loeffler, 2000; Gil-Gil et al., 2014).  
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1.2 Hallmarks of cancer 
The study of cancer involves the recognition of cellular morphological changes, malignant 
transformations and sequential acquisition of genetic alterations (Kleihues and Ohgaki, 
1999). The cancer cell was initially thought to acquire six biological capabilities during 
multistep development of the tumour as seen in Figure 1.2. In 2011, Hanahan and Weinberg 
proposed an additional four new hallmarks including deregulation of metabolic pathways to 
generate energy, evasion of the immune system, chromosomal abnormalities and the role of 
chronic local inflammation to aid progression of the cancer (Hanahan and Weinberg, 2011). 
 
Figure 1.2 Illustration of the ten capabilities of cancer cells acquired during development of cancer (Hanahan 
and Weinberg, 2000; Hanahan and Weinberg, 2011). 
 
All of the aforementioned hallmarks illustrated in Figure 1.2 play an integral role in the 
biological development and growth of cancer, however the most fundamental trait of cancer 
cells is the ability to sustain chronic proliferation. The cancer cells are able to evade growth 
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suppressors such as PTEN, tumour suppressors such as TP53 and cell cycle regulators cyclin 
D and phosphoinositide 3-kinase (PI3K). Phosphatase and tensin homolog (PTEN) is a 
protein coded by the PTEN gene, which regulates the cell cycle by preventing growth and 
multiplication of cells (Rodríguez-Escudero et al., 2011). Tumour protein 53 (TP53), also 
known as p53, is a tumour suppressor protein which regulates the cell cycle (Ohgaki and 
Kleihues, 2007; Rivlin et al., 2011). The cancer cells show unregulated proliferation and 
promote cell division via over expression or over activity of activating growth factor 
receptors such as epidermal growth factor receptor (EGFR) (ErbB-1, HER1) and platelet 
derived growth factor receptor (PDGFR). Activated EGFR and PDGFR triggers intrinsic 
tyrosine kinase activity and downstream signalling cascades, resulting in increased DNA 
synthesis and cell proliferation (Ohgaki and Kleihues, 2013). Angiogenesis is required for 
the formation of new tumour vasculature, an important factor in the development of cancer. 
The VEGF gene which encodes for vascular endothelial growth factor (VEGF) is commonly 
upregulated in cancer. Angiogenic signalling proteins such as VEGF, bind to receptors 
expressed on the outside of endothelial cells, inducing vasculogenesis and angiogenesis. 
The malignant cancer cell possesses the unique property of metastasis which, unlike the 
benign cancer cell, involves the invasion and migration of cells and contributes largely to the 
lethality of cancer. The complex metastasis cascade involves the mechanism of physical 
translocation of cancer cell from the primary source of origin and its colonisation at the 
distant tissue (Fidler, 2003), and this normally takes place via the blood or lymphatic system 
(Karnezis et al., 2012). It is responsible for about 90% of the cancer associated mortality but 
yet has remained the most poorly understood component of cancer pathogenesis (Chaffer and 
Weinberg, 2011).  Migration is often associated with down regulation of genes encoding cell 
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adhesion proteins associated with cytostasis (E-cadherin) and up regulation of genes 
associated with migration and inflammation (N-cadherin) (Hanahan and Weinberg, 2011). 
1.3 Glioma 
The central nervous system is derived from neuroepithelium which has differentiated into 
glial restricted precursor cells or neuron restricted precursor cells (Figure 1.3).  Gliomas are 
a heterogeneous group of neoplasms originating from the glial cells of the central nervous 
system (Eggstein et al., 2004). Glioma contributes to 31 % of all types of brain tumours and 
more than 50 % of primary brain tumours (Louis et al., 2007).  
 
1.3.1 Types of Glioma 
The human brain is comprised of a complex network of neurons and glial cells. The gliomas 
are classified into various types based on the cell of origin, for example, astrocytes, 
oligodendrocytes, ependymal cells, and microglia, as shown in Figure 1.4 (Louis et al., 2007; 
Huse and Holland, 2010).  
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Figure 1.3 Types of neuroglial tumours classified by the cell of origin (Huse and Holland, 2010). 
 
Primary and secondary gliomas are distinct disease entities which affect different age groups 
as described in Table 1.1. Primary glioblastoma tend to be more prevalent in men, occur later 
in life and exhibit a short clinical history prior to surgery compared to secondary 
glioblastoma, which on average appear earlier in life, are more prevalent in women and have 
a longer presenting clinical history prior to surgery. 
Table 1.1 Synopsis of clinical data of primary and secondary glioblastoma (Nakada et al., 2011). 
 Primary glioblastoma         Secondary glioblastoma 
Clinical onset de novo secondary 
Preoperative clinical history   1.7 months   53 months (astrocytoma) 
Sex ratio (male: female)   1.4     0.8 
Age at diagnosis  55  39 
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Primary and secondary glioblastoma develop through different genetic pathways identified 
by distinct mRNA and protein expression profiles (Ohgaki and Kleihues, 2007). Multiple 
genetic alterations have been observed in the major signalling pathways which result in 
tumour growth and progression Figure 1.4. The genetic alterations significantly differ in 
primary and secondary glioblastoma. The TP53 mutations are frequent, with alterations 
observed in 65 % of secondary glioblastomas and 28 % of primary glioblastomas (Figure 
1.4).  
 
Figure 1.4 Genetic pathways to primary (de novo) and secondary glioblastomas at the population level (Grzmil 
and Hemmings, 2010) 
1.3.2 Grades of Glioma 
The biological behaviour of a neoplasm can be predicted by histological grading, which plays 
a key role in determining treatment options and prognosis for the patient. The World Health 
Organisation (WHO) in 2007 categorised tumours on a scale of malignancy from grades I to 
IV, where the most benign was designated as grade I and the most malignant was designated 
grade IV as described in Table 1.2. 
According to the WHO, grading was based on factors  such as the mitotic index, vascularity, 
invasive potential and the presence of necrotic potential (Louis et al., 2007). Grade I referred 
to lesions with a low proliferative potential and possibility of cure after surgical resectioning 
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of the tumour. Grade II included neoplasms which in spite of low level proliferative activity 
were infiltrative in nature and tended to recur and progress to a higher grade of malignancy. 
Grade III designation was for neoplasms and lesions with histological malignancy, nuclear 
atypia and mitotic activity. Grade IV was assigned to cytologically malignant neoplasms 
which were mitotically active and associated with pre- and post-operative disease evolution 
having a fatal outcome (Louis et al., 2007). Grade IV is the most malignant tumour type 
contributing to 51.9 % of primary brain tumour cases (Moore and Kim, 2010). The WHO 
grade I and II are referred as “low grade glioma” whereas WHO grade III and IV are “high 
grade glioma” (Abrey and Mason, 2003). Until recently, the classification of glioma has been 
strictly based on the morphology of the astrocytic tumour, however lately the WHO 
guidelines have mentioned the importance of molecular pathogenesis for consideration in the 
classification (Vartanian et al., 2014). As seen in Figure 1.5, the genetic alteration seen in 
different types of primary and secondary glioma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Pathways for the development of primary and secondary GBM showing genetic alterations in types 
of glioma.  
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Table 1.2 WHO Grading of Tumours of the Central Nervous System (Louis et al., 2007) 
Tumour Grade 
Astrocytic Tumours I II III IV 
Subependymal giant cell astrocytoma      
Pilocytic astrocytoma      
Pilomyxoid astrocytoma      
Diffuse astrocytoma      
Pleomorphic xanthoastrocytoma      
Anaplastic astrocytoma      
Glioblastoma      
Giant cell glioblastoma      
Gliosarcoma      
Oligodendroglial tumours 
Oligodendroglioma      
Anaplastic oligodendroglioma      
Oligoastrocytic tumours 
Oligoastrocytoma      
Anaplastic oligoastrocytoma      
Ependymal tumours 
Subependymoma      
Myxopapillary ependymoma      
Ependymoma      
Anaplastic ependymoma      
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1.3.3 Epidemiology 
Brain tumours account for 2 % of all the cancers diagnosed in adults. Each year in the UK, 
approximately 4,400 people are diagnosed with brain tumours (Jemal et al., 2010). Gliomas 
account for more than 50 % of primary brain tumours (Grier and Batchelor, 2006). The rate 
of incidence of primary brain tumours increases steadily with increasing age, whereas the 
survival rate decreases with increase in age of the patient (Schwartzbaum et al., 2006). The 
global incidence of malignant primary brain tumours in males is 5.8 per 100,000 and in 
females is 4.1 per 100,000 (Schwartzbaum et al., 2006).  In Europe, over a 12 month period 
in 2008, 4,785 people were diagnosed with malignant brain tumours and 4,552 people were 
diagnosed with other non-invasive types of brain tumour (Crocetti et al., 2012).  
A number of epidemiological studies have revealed that certain occupations such as 
physicians, farmers, firefighters, workers of petroleum industries have an increased brain 
tumour risk (Gomes et al., 2011). These occupation involve exposure to carcinogens such as 
radiation and chemicals such as petrochemicals, nitriles, nitrites, amides, lead, vinyl chloride, 
benzene, n-hexane, polycyclic aromatic hydrocarbons, polychlorinated biphenyls, N-nitroso, 
however, no epidemiological analyses have led to identification of a single environmental 
carcinogen which could be unequivocally linked to brain tumour development (Ohgaki and 
Kleihues, 2005).  In Europe, cases of primary brain tumour comprising of high grade glioma 
and brain metastasis observed range from 4.5 to 11.2 cases per 100,000 in men and from 1.6 
to 8.5 per 100,000 in women (Crocetti et al., 2012). 
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1.3.4 Treatment 
The standard form of treatment comprises of surgical resectioning of the tumour followed by 
multimodal regimen of radiotherapy and chemotherapy (Eyupoglu et al., 2013){(NICE), 
2007 #879}. Surgery and radiation continue to be the prime modalities of therapy for 
malignant brain tumours. Chemotherapy is another option for the treatment of glioma, but 
the role of such a therapy in malignant gliomas has been inconclusive (Kim and Glantz, 
2006). Various chemotherapy drugs used for glioma include procarbazine, lomustine, 
temozolomide and vincristine (Brown et al., 1993; Swartz et al., 2014).  In 2005, Stupp et 
al., presented results of a randomised study conducted by EORTC (European Organization 
for Research and Treatment of Cancer) and NCIC (National Cancer Institute of Canada), 
comparing the median patient survival time following concomitant temozolomide 
chemotherapy and radiotherapy, to radical radiotherapy alone.  It was found that 
temozolomide and radiotherapy combined increased the median survival period from 12.1 
months (radiotherapy alone) to 14.6 months (Stupp et al., 2005). Carmustine and 
temozolomide implants are recommended by the NICE guidelines as a possible treatment for 
people with newly diagnosed high-grade glioma, but only if 90 % or more of their tumour 
has been removed (NICE, 2008). Aggressive surgery followed by radiation therapy and 
adjuvant chemotherapy continues to offer glioblastoma patients the best hope of long-term 
survival (Reni et al., 2001; Grover et al., 2014). 
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1.3.5 Prognosis  
A report by Rachet et al., (2012) stated that over the past four decades, brain tumour treatment 
has not increased brain tumour patient median survival time, compared to patients with other 
types cancer, for example colon cancer, where a 10-fold increase in median survival time 
was observed over the same period  (Figure 1.6).  
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Cancer survival rates.  
Data provided in the graph are for adults aged 15-99 diagnosed in England and Wales which predicts the 
survival estimates. Brain tumour shows insignificant increase in the median survival rate over three decades 
(Rachet et al., 2009). 
 
There is a marked variability in prognosis amidst glioma patients due to the various factors 
including: 1) characteristics of the tumour and influence on patient, 2) characteristics of the 
patient, 3) factors related to the influence of the tumour on the patient and 3) factors related 
to treatment (Loiseau, 1996). 
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1.3.5.1 Characteristics of the tumour linked to prognosis 
Glioma comprises of cellular, molecular, genetic, epigenetic, and metabolic heterogeneity 
which poses challenges for existing therapeutics and personalised medicine (Vartanian et al., 
2014). For example the presence of aggressive infiltrating cells at the glioma margin, residual 
cells remaining following glioma resection and cancer stem-like cells capable of repopulating 
a glioma all contribute to increasing the likelihood of recurrence and poor patient prognosis  
(Taylor, 2010; Inda et al., 2014).  Histological grading has an influence on prognosis, for 
example the 5-year survival rate of grade IV glioblastoma patients is less than 3 % whereas 
for low grade pilocytic astrocytoma is 75 % (Burkhard et al., 2003; Brimelow, 2011). 
1.3.5.2 Characteristics of the patient linked to prognosis 
In glioma, factors which largely influence the survival duration of the patient are age and 
functional status (Gupta and Sarin, 2002). The prognosis for patients with glioma aged 65 
years or older is very poor. Only 2% of patients as compared to 30% of those under the age 
of 45 years at GM diagnosis show a survival period of more than 2 years (Schwartzbaum et 
al., 2006). 
1.3.5.3 Factors related to treatment and prognosis 
The major challenges of glioma treatment include tumour heterogeneity, location, 
subpopulations of resistant cells, aggressive relapse and poor efficacy of chemotherapy, 
again age is an important factor in prognosis, with respect to tolerance of radio- and 
chemotherapy regimens (Stummer and Kamp, 2009). In a clinical trial conducted by the 
Medical Research Council (MRC), Brada et al., (2001) reported that high grade glioma 
patients did not show any significant survival benefits after treatment with procarbazine, 
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lomustine, vincristine chemotherapy post-radiotherapy compared to radiotherapy on its own 
(Medical Research Council Brain Tumor Working, 2001). As previously mentioned in 
Section 1.3.5 Stupp et al., have shown that concomitant use of TMZ with radiotherapy in 
newly diagnosed glioblastoma multiforme (GBM) patient increases survival benefit 
significantly with minimal additional toxicity (Stupp et al., 2005). The two-year survival rate 
was increased from 10.4 % (radiotherapy alone) to 26.5 % (radiotherapy plus temozolomide). 
The multitude of possible reasons for poor response to chemotherapy have been the focus of 
brain tumour research for many years and are discussed further in Section 1.5. It is essential 
to understand the working of the underlying drug metabolism involved, to develop effective 
glioma therapeutic for improving the prognosis of the glioma. From here on in, this thesis 
will focus on the influence of drug metabolising enzymes and efflux transporters at the BBB 
and the role of the physical, transport and metabolic barrier imposed by the BBB in reducing 
the CNS bioavailability of chemotherapeutics at the site of action. 
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1.4 Blood brain barrier  
The studies of Paul Ehrlich in 1882 suggested the concept of blood brain barrier (BBB) 
providing evidence of the separation between circulation and CNS (Banks, 1999). In the early 
1970’s, Oldendorf introduced the concept of brain uptake index (BUI), to quantify the 
permeability of the BBB and to predict the rate of entry of different compounds (Oldendorf, 
1971). The BBB has since been described as a dynamic biological barrier which restricts the 
passage of blood-borne drugs, neurotoxic substances and peripheral immune cells from 
entering the brain, while selectively facilitating the transport of nutrients across the BBB into 
the brain (Shen and Zhang, 2010; Gynther, 2010). The physical protective barrier is due to 
the presence of tight junctions between endothelial cells at the blood and brain junction and 
the biological barrier controls the entry of molecules via tightly regulated transporters 
(Agarwal et al., 2008; Pardridge, 2005; Shen and Zhang, 2010). The BBB is also responsible 
for homeostasis of the microenvironment in the neural parenchyma and normal functioning 
of the brain (Eggstein et al., 2004).  
The BBB is present in all the regions in brain except the circumventricular organs where the 
blood vessels show fenestrations for diffusion (Ballabh et al., 2004; Gynther, 2010). The 
unique feature of the BBB lies in the structure of the neurovascular unit and the cerebral 
micro-vascular endothelial cells; these include additional cellular components such as 
astrocytes, perivascular microglia and pericytes that surround brain capillaries (Figure 1.7). 
The endothelial cells, astrocytic feet and the pericytes are compactly arranged and tightly 
integrated with the brain parenchyma on a common basement membrane (Banks, 1999) 
(Figure 1.7).  All these components contribute to the maintenance of functional and structural 
integrity of the BBB (Nakagawa et al., 2007a; Goldstein, 1988)  
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Figure 1.7 The neurovascular unit of the Blood Brain Barrier (Hartz and Bauer, 2010). 
 
1.4.1 Physical barrier 
The BBB comprises of different physical barriers which comprises of the different cell types 
and the located at the BBB. 
1.4.1.1 Endothelial Cells and Tight Junctions  
The BBB comprises of a very thin and compact continuous layer of endothelial cells between 
the blood capillary and parenchymal cells of the brain (Figure 1.8). The thickness of the cell 
layer that separates the luminal and abluminal membrane is about 200 nm  and therefore it 
takes a short time for a substance to pass though the BBB into the brain parenchyma 
(Pardridge, 1999; Burns et al., 1981). The specific characteristics distinguishing the cerebral 
endothelial cells from the peripheral endothelial cells is the presence of complex tight 
junctions (TJs) and the large number of mitochondria, which suggests high energy 
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metabolism in the brain endothelium and very low pinocytotic and transcytotic activity 
(Burns et al., 1981) (Figure 1.8). 
 
Figure 1.8 Diagrammatic representation of the cerebral capillary highlighting the structure of BBB comprising 
of TJs in the interendothelial cleft and high numerical density of TJs (Burns et al., 1981). 
 
The cerebral endothelial cells form TJs with each other, characterised by a high trans 
endothelial electrical resistance (TEER) of 1500 – 2000 cm2 (Zenker et al., 2003). The TJs 
proteins have been proposed to have two mutually exclusive functions: a fence function 
which prevents the mixing of membrane proteins between the apical and basolateral 
membranes; and a gate function which controls the paracellular passage of ions and solutes 
in between cells (Hartsock and Nelson, 2008). These proteins form the structural and 
functional integrity of the BBB via interaction of numerous plasma proteins that seal the 
paracellular pathway (Eggstein et al., 2004; Stamatovic et al., 2008). The TJs comprises of 
the transmembrane proteins claudin and occludin. These proteins interact with the 
cytoplasmic accessory proteins that link to the primary cytoskeleton protein actin, to maintain 
structural and functional integrity of the endothelium (Abbott, 2002) (Figure 1.9).   
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Occludin was found to interact with zonula occludens protein 1 (ZO-1) and is responsible for 
stabilising the tight junction. Claudin 1/3, 5 and 12 expressed in the BBB, appear to 
contribute to the high TEER (Abbott et al., 2006b). The interaction of these plasma 
membrane proteins regulates and allows paracellular transport to be modulated in response 
to different stimuli. In epithelial cells, TJs and adherens junctions are strictly separated from 
each other, but in endothelial cells these junctions are intermingled (Cecchelli et al., 1999; 
Miller, 2002). Adherens junctions contribute to stabilising and tightening endothelial cell 
structure (Luissint et al., 2012b). It has been reported that ZO-1 and catenin interact with 
each other, suggesting that TJs and AJs function together to maintain the BBB integrity 
(Luissint et al., 2012a). 
 
Figure 1.9 Assembly of transmembrane proteins, occluding, claudins forming the TJs between the endothelial 
cells (Chou and Messing, 2008).   
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1.4.1.2 Astrocytes 
Astrocytes are characteristic star shaped glial cells of the brain and spinal cord. The end feet 
of the astrocytes encircle 90-99 % of capillaries formed by the endothelial cells (Bauer et al., 
2004; Sobue et al., 1999; Pardridge, 1999) (Figure 1.9). The astrocytes were initially thought 
to play a structural role, but it has since been recognised that astrocytes contribute to the 
development and maintenance of the BBB (Burns et al., 1981; Wolburg et al., 1994). Three 
categories of functions performed by astrocyte include guidance and support of neuronal 
migration during development, maintenance of the neural microenvironment, and 
modulation of immune reactions by serving as antigen-presenting cells (Montgomery, 1994). 
Astrocytes are a major source of extracellular matrix such as fibronectin, laminin and 
cytotactin. The cells secrete extracellular matrix (ECM) which plays an important role in 
maintaining integrity of the BBB (Kimelberg and Nedergaard, 2010).  
1.4.1.3 Pericytes 
Pericytes are undifferentiated, contractile connective tissue cells that are located surrounding 
the endothelial cell layers of the brain capillary network (Allt and Lawrenson, 2000) (Figure 
1.9).  Pericytes, along with the endothelial cells, play a crucial role in the formation and 
functionality of the relatively permeable barrier. Pericytes are responsible for tight junction 
formation and vesicle trafficking among the endothelial cells (Nakagawa et al., 2009b; 
Nakagawa et al., 2007a; Nakagawa et al., 2007b).  
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1.4.2 Transport across the Blood Brain Barrier 
There are four major mechanisms of transport routes across the BBB: 1) passive diffusion 
(transcellular lipophilic route or paracellular aqueous route); 2) active transport; 3) 
endocytosis (receptor mediated or adsorptive) and 4) transcytosis or exocytosis (receptor 
mediated or adsorptive (Xiao and Gan, 2013). The expression of tight junction and other cell 
membrane domains between endothelial cells, seal the paracellular pathway leaving the 
transport of essential nutrients, blood gases and removal of xenobiotic molecules to the 
transcellular pathway (Hitchcock, 2008). Small lipophilic molecules can passively diffuse 
across the lipid bilayer Small, highly lipophilic, uncharged, small molecules (mol. wt ≤ 800 
Da) can penetrate the BBB by passive diffusion via the transcellular lipophilic route, but, in 
many cases, the molecules are returned to the blood by efflux pumps (Wong et al., 2013). 
 More polar, charged molecules may require access through the specialised active 
transporters such as GLUT-1 and LAT-1 (Begley, 2004). The movement of hydrophilic 
substances is facilitated by various endogenous transporter mechanisms located at the 
luminal and abluminal membrane of brain endothelial cells at the junction of the blood and 
brain (explained in detail in Section 1.5.4) (de Boer and Gaillard, 2007) (Loscher and 
Potschka, 2005c; Loscher and Potschka, 2005a; Loscher and Potschka, 2005b). Larger 
macromolecules may require receptor mediated (ATP-dependent) or adsorptive endocytosis 
and trancytosis routes (Gynther, 2010). All these pathways play an important role in 
maintaining the BBB integrity, however drug delivery across the BBB may be significantly 
impeded by the presence of the physical and metabolic barrier (Bodó et al., 2003; Borges-
Walmsley et al., 2003; Chang, 2003; Banks, 1999) (Figure 1.10).  
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Figure 1.10 Schematic illustration of transport across the brain endothelial cells (Wong et al., 2013).  
 
1.5 Drug metabolism and Disposition at the BBB 
The human body is exposed to numerous xenobiotics which may be harmful and therefore 
an elaborate detoxification system has evolved to detoxify and inactivate these foreign 
compounds. Following absorption into the bloodstream, xenobiotics are distributed by 
binding to plasma proteins and transported by blood flow to various tissues (Benedetti et al., 
2009). A drug is either eliminated directly through urine or bile or indirectly through 
biochemical transformation by enzymes in the liver and other tissues. Metabolism involves 
biotransformation of the xenobiotic into new more polar and often inactive chemical entities 
thus forming a metabolite which can be readily eliminated from the body (Lin and Lu, 1997). 
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Figure 1.11 Schematic representation of drug disposition within the body (Gunaratna, 2000). 
 
In 1959, Williams classified the drug metabolic reactions that are catalysed by enzymes into 
two general phases: Phase I and Phase II (Williams, 1959) (Figure 1.12). Since then, transport 
processes have also been classified as key process involved in the clearance of xenobiotics 
where drug uptake by transporters were referred to as Phase 0 and drug efflux by transporters 
were referred to as Phase III (Ritschel and Kerns, 2004). 
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Figure 1.12 Different phases involved in drug metabolism   
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1.5.1 Phase I and II metabolism 
In phase I reactions, the drug is broken down which involves unmasking, removal or addition 
of chemically reactive functional group as a result of oxidation, reduction or hydrolysis 
reactions. This biotransformation of the drug increases the polarity of the compound enabling 
its faster elimination from the body (Lin and Lu, 1997). Phase I reactions normally inactivate 
a parent drug, however occasionally reactive metabolites are formed which are more 
chemically active than the parent drug. Activation of the drug can also take place in cases 
where the drug administered is in its prodrug form (Benedetti et al., 2009; Rajkumar et al., 
1998). These reactions are primarily catalysed by cytochrome P450 enzymes (CYPs) 
(Deenen et al., 2011b) (Figure 1.13), but other Phase I drug metabolising enzymes include 
monoamine oxidase, flavin containing monooxygenase, alcohol dehydrogenase, aldehyde 
dehydrogenase, xanthine oxidase, perioxidase, NADPH-cytochrome P450 reducatase, 
esterases, amidases and epoxide hydrolase. 
  
Figure 1.13 The proportion of drugs metabolised by various enzymes in the Phase I metabolism process. 
The enzymes included are cytochrome P450 enzymes, aldehyde dehydrogenase (ALDH), Antidiuretic hormone 
(ADH),  dihydropyrimidine dehydrogenase (DPD) NAD(P)H dehydrogenase [quinone] 1 (NQO1) and other 
metabolic enzymes (Juran et al., 2006). 
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In Phase II metabolism, the drug or the phase I metabolite is conjugated with an endogenous 
group, thus inactivating, and further increasing the polarity of the drug enabling water soluble 
metabolites, to be readily excreted from the body in urine or bile (Ritschel and Kerns, 2004). 
The conjugation reaction involves acylation, glucoronidation, sulphation, glutathione 
conjugation and methylation requiring the participation of various enzyme groups as seen in 
Figure 1.14 (Williams, 1959; Xu et al., 2005).  
 
 
Figure 1.14 The proportion of drugs metabolised by various enzymes in the Phase II metabolism process. 
The enzymes included are glucuronosyltransferase (UGTs), thiopurine methyltansferase (TPMT), histamine N-
methyltransferase (HMT), N-acetlytransferaseisoenzymes (NAT1 and NAT2), Glutathione-S-transferases 
(GST) (Juran et al., 2006). 
 
1.5.1.1 Cytochrome P450 enzyme system. 
Cytochrome P450 enzymes (CYPs) are a super-family of thiolate-coordinated heme 
containing monooxygenase proteins with a molecular weight of approximately 50 Kd. The 
CYPs are believed to have been in existence for over 3.5 billion years (Gonzalez and Gelboin, 
1994). Endogenously, the CYPs play a role in the synthesis and metabolism of 
neurotransmitters, prostaglandins, vitamin D and cholesterols (Nebert et al., 2013). A subset 
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of these enzymes are also involved in the synthesis and metabolism of steroid hormones like 
oestrogen and testosterone (steroidogenesis) in the adrenal glands, gonads and peripheral 
tissue (Daniel and Timothy, 2006). CYPs are also responsible for metabolising a vast range 
of xenobiotics which include, 70-80% of prescribed drugs, drugs of abuse and toxins 
(Ferguson and Tyndale, 2011; Hedlund et al., 2001). CYPs have been found to cause 
activation of procarcinogens or inactivation of carcinogens during the tumorigenic processes 
(Oyama et al., 2004). CYPs are located either in the membrane of rough endoplasmic 
recticulum or in the inner membrane of the mitochondria (Meyer et al., 2007). As seen in 
Figure 1.15B, cytochromes contain iron protoporphyrin I and when the  ferrous haem 
complex is reduced to the ferric state and bound to carbon monoxide the pigment absorbs 
light at 450 nm, hence the nomenclature of these enzymes is cytochrome P450 (Figure 
1.15A). The gene nomenclature of CYP3A4 was defined as follows: CYP represents the 
cytochrome P450 superfamily; 3 represents the gene family, defined by ≥ 40 % homology in 
the amino acid sequence; A represents the gene subfamily, defined by ≥ 55 % homology in 
the amino acid sequence and 4 represents the individual gene number, defined by a unique 
amino acid sequence. 
    
Figure 1.15 A) Absorption spectra for cytochrome P450 and the shift in the absorption spectrum due to its 
ferrous–carbon monoxide complex (Munro et al., 2007). B) Structure of a porphyrin ring with a covalently 
bound haem in CYP enzymes (Johnston et al., 2011). 
A B 
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1.5.1.2 Induction and Regulation of CYP P450 Enzyme  
 Inducing CYP enzyme expression increases metabolism and decreases the bioavailability of 
drug, thus potentially affecting the chemotherapeutic effect of the drug (Meyer et al., 2007). 
Induction of CYP enzymes has a significant effect on the drug metabolism, drug-drug 
interaction, toxicity and carcinogenicity of foreign substances (Kapoor et al., 2007).  
The CYPs are regulated by a complex mechanism which includes the transcriptional, post-
transcriptional and post-translational mechanisms. Most of the genes of CYP enzymes are 
transcriptionally activated by xenobiotics. The xenobiotics act by a receptor dependent 
mechanism via either a aryl hydrocarbon receptor (AhR), constitutively active receptor 
(CAR), Farnesoid X-activated receptor (FXR), Pregnane X receptor (PXR) or peroxisome 
proliferator activated receptor (PPAR) as seen in Table 1.3 (Hedlund et al., 2001). Cytosolic 
steroid receptor, once bound to nuclear receptor such as AhR are activated by the xenobiotic 
binding in the cytoplasm which causes translocation to the nucleus, whereupon it binds to a 
co-activator and another nuclear receptor. This complex can then bind to a xenobiotic 
response element on the promotor of the CYP or transporter gene, leading to increased 
mRNA transcription and subsequent translation resulting in an increase in CYP protein. 
Table 1.3: Summary of nuclear receptor activating target gene (Hedlund et al., 2001). 
Target Gene Nuclear Receptor 
ABCB1  PXR, CAR 
CYP3A4 PXR, CAR, GR, HNF4α, VDR, FXR 
CYP 2E1 PXR, CAR, GR 
CYP 2B6 PXR, CAR 
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1.5.2 CYP Localisation and Activity in the Brain 
The percentage of CYP expression in the brain relative to the rest of the body is relatively 
low at 0.5-2 % (Ferguson and Tyndale, 2011); CYPs however, play an important role in onset 
of drug action due to pharmacological activation or inactivation via metabolism of CNS 
therapeutics (Mann et al., 2012; Agarwal et al., 2008). The brain comprises of regions of 
different cell types, density and function with a variable pattern of CYP expression. 
Expression is also dependent on individual genotype and exposure to environmental inducers 
or repressors (see Section 1.5.1.2) (Miksys and Tyndale, 2009; Strobel et al., 2001; Dutheil 
et al., 2008). As seen in Table 1.4; various CYP isoforms are found to localise in specific 
regions of the brain in human, rat and mouse and the cell type and potentially affect the 
metabolism in the brain microenvironment (Strobel et al., 1995). It has been proven that the 
more localised the enzyme becomes, the greater its impact on the xenobiotic concentration 
in those localised area of the brain (Britto and Wedlund, 1992; Rieder et al., 1998).   
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Table 1.4 Various CYP isoforms found localised in specific regions of the brain (Meyer et al., 2007) 
P450 Isoform Species Brain region 
CYP1A1 Mouse Abundant 
CYP1A1/2 Rat Striatum, Hypothalamus, Cerebral Cortex, 
Cerebellum 
CYP1A1 Human Brain cortex 
CYP1B1 Human Temporal lobe 
CYP2B1 Rat Blood-brain barrier, Brain stem, Frontal cortex, 
Striatum, Olfactory tubercle 
CYP2B6 Human/ Rat Cerebellum, Hippocampus 
CYP2B10 Mouse Hippocampus 
CYP2C11 Rat Abundant 
CYP2C29 Mouse Blood-brain barrier 
CYP2D4 Rat Olfactory bulb, substantia nigra, cerebellum 
CYP2D6 Human Cortex, Hippocampus, Cerebellum 
CYP2E1 Rat/Human Cerebellum,  
CYP2G Rat Olfactory bulb 
CYP2J9 Mouse Hippocampus, Cerebellum, Brainstem, Cerebral 
Cortex 
CYP3A11 Mouse Hippocampus, Cerebellum, Olfactory bulb, 
Hypothalamus 
CYP3A13 Mouse Hippocampus, Cerebellum, Olfactory bulb, 
Hypothalamus 
CYP3A4 Human Hypothalamus, cerebellum and olfactory lobes 
CYP4A Rat Cortex, Cerebellum, Brainstem, Hypothalamus 
CYP4x1 Human/Mouse Brain barriers 
CYP7B2 Rat/Mouse Hippocampus 
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Astrocytes have been shown to participate in the metabolic activity of the BBB (Bauer et al., 
2004; Kido et al., 2002), hence, astrocytes have been largely co-cultured with endothelial 
cells in in vitro models used to study the BBB. Pericytes cells also express certain metabolic 
enzymes like γ-glutamyl transpeptidase and glutamyl aminopeptidase that contribute to the 
metabolism at the BBB (Gynther, 2010). CYPs are also expressed in neurons, however, total 
CYP content in astrocytes is 2.7 fold higher than that in neurons (Kapoor et al., 2007). The 
CYP expression in glial cells does not show stringent region dependent expression pattern as 
seen in the neuronal CYPs (Dutheil et al., 2008). For the purpose of this thesis, the focus of 
further study was on the isoforms CYP2D6 and CYP3A4 as these two isoforms are 
responsible for metabolism of approximately 50 % of all prescribed drugs (Williams, 
1959)(Williams, 2004).   
1.5.2.1 CYP2D6 
Approximately 2 % of total CYP2D6 is expressed in the brain (Mann et al., 2012). CYP2D6 
metabolises about 20 % - 25 % of the drugs administered for neurological diseases, 
predominantly centrally acting opioids, and also neurotoxins and endogenous chemicals 
(Ingelman-Sundberg, 2004; Miksys and Tyndale, 2004). The expression of CYP2D6 varies 
for each individual due to polymorphic gene expression causing inter-individual variability 
in the sensitivity towards anticancer therapy and altered rate of metabolism of endogenous 
substrates (van Schaik, 2008).  Compared to liver, characterisation of CYP2D6 enzyme 
activity in the brain is difficult, due to low levels of CYP2D6 activity and variation depending 
on the regions of the brain (Britto and Wedlund, 1992). The CYP2D6 is found to be localised 
in the cortex, hippocampus and cerebellum regions of the brain which contribute to 2 %, 7% 
and 2.8 % respectively distribution of glioma (CBTRUS 2012). 
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1.5.2.2 CYP3A4 
CYP3A4 is the largest sub-family of all the cytochrome P450 enzymes and is responsible for 
metabolism of more than 50 % of centrally acting drugs (Strobel et al., 2001). CYP3A4 has 
localised expression and is observed in areas sensitive to steroid hormones, which include 
hypothalamus, cerebellum and olfactory lobes (Miksys and Tyndale, 2004). The distribution 
of glioma shows hypothalamus, cerebellum and olfactory lobes. The nuclear receptor, 
pregnane X receptor (PXR) is known to regulate the expression of CYP3A4 in the brain 
(Agarwal et al., 2008).  
CYP3A4 and the ABC transporter ABCB1 have common substrates, inhibitors and inducers 
and are often co-expressed which leads to an additive response to modulators of metabolism 
(van Schaik, 2008). CYP3A4 expression shows inter-individual variability which has a large 
impact on metabolism of low therapeutic index anticancer drugs, such as vincristine, 
irinotecan and etoposide. The variability of CYP3A4 can cause significant consequences , 
such as poor toxicity profile in the case of low CYP3A4 activity and poor efficacy leading to 
resistance in ultra-high CYP3A4 metabolism (Robertson et al., 2003). An extensive study of 
the expression and function of the localised CYPs is essential for developing effective 
treatment of glioma and prediction of response to therapy. 
 
1.5.3 Cytochrome P450 and Brain tumours  
1.5.3.1 Role in CNS Drug Metabolism 
Few CYPs have been identified in the tumour cells of the brain relative to expression 
elsewhere in the brain. Certain chemotherapeutics such as vinblastine, cisplatin, lomustine 
are metabolised by CYPs which causes activation or in-activation of the drug (Table 1.5). 
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Hence, study of the CYPs expressed by the blood brain barrier, non-cancerous brain cells 
and tumour cells could help determine the tumour sensitivity towards anticancer therapeutics 
(Oyama et al., 2004).  
Table 1.5 Chemotherapeutics for treatment of glioma and CYPs involved in their metabolism. 
Drug CYP enzyme Reference 
Vincristine CYP 3A4 (Egbelakin et al., 2011) 
Procarbazine CYP 2B6 (Rodríguez-Escudero et al., 2011) 
Irinotecan CYP 3A4 (Lu and Cederbaum, 2008) 
Temozolomide CYP 1A1, 1A2, 2E1 (Long and Dolan, 2001) 
Cisplatin CYP 2E1 (Najar et al., 2011) 
Etoposide CYP 3A4, 1A2 (Najar et al., 2011)  
Ifosfamide CYP 2B6 (Kerbusch et al., 2001)  
Tamoxifen CYP2D6 (Ingelman-Sundberg, 2004) 
 
1.5.3.2 Role in Tumour development 
The CYPs have been observed to participate in the development and progression of a tumour 
(McFadyen et al., 2004). Carcinogens such as poly aromatic hydrocarbons (see Section 1.3.3) 
exposed to cells are often metabolised and bioactivated by CYP enzymes. DNA binding 
metabolites are produced due to activation of carcinogens by the CYPs as depicted in Figure 
1.16. The DNA binding metabolites, frequently contain electrophiles or free radicals, capable 
of binding to electron rich regions in DNA or cysteine residues in protein causing 
carcinogenicity or cell death (Gonzalez and Gelboin, 1994). 
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Figure 1.16 Schematic representation of metabolic pathway of a carcinogen causing tumour genesis (Oyama et 
al., 2004). 
 
1.5.4 Transporters at the BBB 
An overview of the transporters at the brain and blood junction localised mainly in the 
luminal membrane of brain capillary endothelial cells can be seen in Figure 1.17 (Dean et 
al., 2001). The endogenous role of these transporters, is to contribute to the transport barrier, 
which regulates the transport of essential nutrients across the BBB. For example, essential 
polar nutrients are transported bidirectionally via GLUT1 (glucose carrier) and large neutral 
amino acid (LAT1), L-system (amino acid carriers) (Abbott, 2002). 
 
 
34 
 
Figure 1.17 Carrier-mediated transport machineries (efflux and the influx transporters) at the BBB sites of 
the BBB (Omidi and Barar, 2012). 
Phase 0 and Phase III metabolism involves the role of drug uptake and efflux transporters 
respectively, namely the solute like carrier (SLC) uptake transporters and ATP binding 
cassette (ABC) efflux transporters.  These two processes affect the bioavailability and 
distribution of drugs and hence are important factors to be considered during drug 
metabolism (Borges-Walmsley et al., 2003; Nelson and Gordon, 1983). Phase III is 
concerned with the elimination of the drug or metabolite from a cell back into circulation or 
bile by an ATP dependent efflux transporter (Ishikawa et al., 2004). Efflux transporters, 
along with metabolising enzymes of xenobiotics, are an important protective mechanism 
against toxic and potentially harmful xenobiotics (Fromm, 2004). Efflux transporters are 
however, commonly associated with reducing bioavailability of a drug and play a central role 
in restricting brain uptake and extrusion of xenobiotics (Loscher and Potschka, 2005a; 
Loscher and Potschka, 2005b; Löscher and Potschka, 2005). 
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1.5.4.1 Phase 0: Uptake Transporters 
Solute carrier (SLC) transporters are a group large group of membrane transporters encoded 
by 55 different gene families. Four gene families under the SLC transporters category 
function as sugar transporters known as the glucose transporter (GLUT) family. High 
expression of glucose transporter (GLUT-1) has been associated with tumour angiogenesis 
and glioma proliferation. This has been proposed as a surrogate marker for prediction of 
patient outcome as increased glucose transport would coincide with the increased metabolic 
demands of aggressive tumour (Jensen and Chkheidze, 2011). Organic anion transporting 
polypeptides (OATP) and organic cation transport protein (OCT) are influx transporters of 
the SLC family and glioma drugs such as imatanib and methotrexate are substrates for OCT-
1 (Roth et al., 2012). 
1.5.4.2 Phase III: Efflux transporters  
ATP-binding cassette (ABC)  are one of the largest transmembrane protein superfamilies 
comprising of 48 transmembrane proteins which are further divided into 7 sub-families based 
on organisation of domains and amino acid homology ABCA to ABCG (Loscher and 
Potschka, 2005b; Dean et al., 2001) . The endogenous role of the ABC transporters family 
includes antigen presentation, detoxification, lipid transport and leukotriene transport 
(Higgins and Linton, 2003). These transporters utilise energy from ATP and transport 
molecules across the cell membrane. ABCB1 and ABCG2 are two prominent members of the 
ABC family expressed on brain endothelial cells, which safeguard the blood brain barrier 
limiting the entry of xenobiotics (Agarwal et al., 2011; Pardridge, 2003; Pardridge, 2005). 
A number of transporters of the ABC family were identified as multi-drug resistant proteins, 
where alteration in the expression of these transporters caused a change in the clearance of 
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clinically important drugs at the BBB (Table 1.6) (Gerk and Vore, 2002). ABCB1 and ABCG2 
are transporters that actively efflux a wide range of lipophilic compounds and limit the drug 
uptake of the endothelial cells by effluxing substances out of the cells into the blood 
capillaries (Dean et al., 2001; Lockhart et al., 2003). Recently, research has focussed on 
ABCB1 and ABCG2 and their role as a barrier for the disposition of glioma therapeutics to 
the CNS.  
Table 1.6 ABC transporters involved in drug resistance and cancer therapy (Hartz and Bauer, 2010). 
Protein Gene Substrates 
P-glycoprotein ABCB1 Colchicine, doxorubicin, vinblastine, digoxin, paclitaxel 
BCRP ABCG2 Mitoxantrone, toprtecan, doxorubicin, rodamine, daunorubicin 
 
1.5.4.2.1 Regulation of Efflux transporters 
The regulation of expression of efflux transporters is done in a highly dynamic manner. The 
expression of efflux transporters are under tight transcriptional regulation by group of orphan 
nuclear receptors such as pregnane X receptor (PXR) in rodents and steroid and xenobiotic 
receptor [SXR] constitutive androstane receptor (CAR), and farnesoid X-activated receptor 
(FXR) in humans (Synold et al., 2001; Schuetz and Strom, 2001; Ekins and Erickson, 2002; 
Sonoda et al., 2003). The transcriptional regulation occurs by binding of the xenobiotic to 
orphan nuclear receptors by the same mechanism as outlined in Section 1.5.1.2 (Scotto, 
2003). The presence of a xenobiotic results in upregulation of efflux transporter expression, 
hence increasing efflux activity of the drug out of the cell, enabling adaptation to the 
changing environment, and promoting tissue detoxification and protection (Miller, 2010), 
however this induction mechanism is considered as the main reason for CNS 
pharmacoresistance (Borges-Walmsley et al., 2003; Mertsch and Maas, 2002). 
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1.5.4.3 ABCB1 Transporter 
ABCB1 (also called as P-glycoprotein, MDR-1) was discovered as a prototypic transporter 
in 1970s and was found to be involved in resistance to anticancer therapeutics (Juliano and 
Ling, 1976). ABCB1 acts as an energy dependent extrusion pump, predominantly localised 
on the luminal surface of the endothelial cells, which have polyspecificity for a large number 
of chemotherapeutics drugs of the CNS as its substrate (Allt and Lawrenson, 2000). ABCB1 
has a predominant role as the gate keeper of the blood brain barrier (Demeule et al., 2002). 
Cordon-Carlo et al, (1989) first identified expression of ABCB1 in the endothelial cells of 
the BBB junction using immunohistochemistry, which suggested the protein was an 
operative component of the BBB (Cordon-Cardo et al., 1989). ABCB1 was also found to be 
expressed in the intestine, liver, kidney, brain and placenta (Staud et al., 2010). ABCB1 
serves as a defence mechanism by protecting the brain from intoxication of potentially 
harmful lipophilic xenobiotics, which otherwise would penetrate into the brain by simple 
diffusion (Schinkel, 1999).  
There are several isoforms of human ABCB1: type I also known as ‘’MDR 1 Pgp’’ encoded 
by the ABCB1 gene, with high activity which causes a drug resistance phenotype.Type II also 
known as ‘’MDR2 Pgp’’ is encoded by the MDR2 gene, and expressed in the canalicular 
membrane of hepatocytes and functions as a phosphotidylcholine translocase (Begley, 2004; 
Bodó et al., 2003; Schinkel, 1999). ABCB1 shows various functional polymorphisms and is 
considered the most important ABC transporter in humans for drug disposition (Fromm, 
2004; Deenen et al., 2011a).  
Three major functions of ABCB1 have been elucidated: i) expression in the luminal 
membrane of enterocytes limits the entry of drug in the body post oral administration. ii) 
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expression in the canalicular membrane of hepatocytes and in luminal membrane of proximal 
tubule in the kidneys promotes the elimination of drug in the blood in to the bile and urine, 
and most importantly, iii) expression at the BBB restricts the accumulation of substrates in 
the endothelial cells. ABCB1 activity limits the entry of ABCB1 substrate drugs such as 
colchicine, doxorubicin, vinblastine, digoxin, paclitaxel, which are potentially beneficial for 
the treatment of gliomas or any CNS related diseases (Gaillard and de Boer, 2000; Bendayan 
et al., 2002). ABCB1 activity is likely to be a determinant of the success of drug therapy, 
where increased activity results in bioavailability and low intracellular drug concentration 
(De Lange, 2004; Fromm, 2004). The expression of these ATP dependent transporters causes 
removal of its substrate out of the cell, which for the treatment of brain cancer results in 
ineffective therapeutic concentration. 
For example, a number of studies have illustrated the role of ABCB1 for drug penetration of 
anticancer drugs such as doxorubicin, paclitaxel and vinblastine by studying ABCB1 
knockout mice. Kemper et al., reported that the drug concentration in the knockdown mice 
was higher than that in the wild type mice (Kemper et al., 2003; Begley, 2004). Burgio et al., 
showed the impact of ABCB1 inhibitor on the access of etoposide to rat brain by brain 
microdialysis (Burgio et al., 1998).  Schinkel et al., observed that when ABCB1 knockdown 
mice were treated for a mite infestation by ivermectin (neurotoxic antiparasite drug), all mice 
died due to accumulation of ivermectin in the brain, hence concluded that ABCB1 played a 
crucial role as an efflux transporter (Schinkel, 1999).  
1.5.4.4 ABCG2 Transporter 
ABCG2 (also called breast cancer resistance protein (BCRP) or mitoxantrone resistance 
protein, MRP) is another member of the ABC superfamily and plays an important role in the 
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transport of substance across the BBB (Bhatia et al., 2012). It was first discovered in a breast 
cancer cell line which was chemotherapy resistant, hence it was also called a breast cancer 
receptor protein (Noguchi et al., 2009; Doyle and Ross, 2003). Similar to ABCB1, ABCG2 is 
predominantly found on the luminal membrane of the BBB and is responsible for efflux of 
xenobiotics and protection the brain from hazardous substances (Cornford and Hyman, 2005; 
Warren et al., 2009). ABCG2 is also found to localise in the placenta, bile caniculi, colon, 
small bowel, and brain micro-vessel endothelium (Haimeur et al., 2004; Cooray et al., 2002).  
The expression of ABCG2 transporter in endothelial cells was reported by Eisenblatter et al. 
(Eisenblatter and Galla, 2002; Eisenblatter et al., 2003). Eisenblätter et al. (2003), have 
demonstrated the active extrusion of daunorubicin from porcine brain endothelial cells is 
mediated mainly by ABCG2 compared to ABCB1 suggesting an important role of ABCG2 in 
the efflux transport of xenobiotics from the brain (Eisenblatter et al., 2003). A number of 
studies were done to understand the role of ABCG2 as a transport barrier at the BBB. ABCG2 
showed over expression in mdr1a knockout mice. Cisternino et al. (2004), reported that mice 
when treated with GF120918 (ABCG2 inhibitor) showed increased penetration of ABCG2 
substrate prazosin and mitoxantrone in the brain (Cisternino et al., 2004). ABCG2 is a 
physiological transporter at the BBB that restricts the permeability of the brain to its 
substrates in vivo and plays an important role in disposition of glioma therapeutics in out of 
the brain. Similar studies were carried out by Lee et al. (2005), indicating that ABCG2 played 
a role in active efflux of dehydroepiandrosterone sulphate and mitoxantrone in mice (Lee et 
al., 2005).  
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1.6 In vitro modelling of the BBB 
Recently, there has been an emphasis on the need to gradually shift from in vivo testing to in 
vitro systems with the aim to reduce, refine and replace animal models in research and 
development. For specific and detailed understanding of the drug metabolism and transport 
in the CNS, in vitro analysis of CYP and transporter activity is a valuable tool for the accurate 
prediction of the in vivo drug disposition if the therapeutics are substrates for the CYPs or 
transporter proteins (Kapoor et al., 2007; Meyer et al., 2007).  
The full characterisation of BBB in vitro is vital for the extrapolation of understanding of 
typical and atypical neurological function in vivo. Research on the BBB has been focussed 
on developing effective drug delivery for neurological disorders. Currently, the FDA 
mandates screening of novel therapeutic compounds in animal models to assess the effect of 
drugs on the CNS (Crofton et al., 2004). Traditional CNS drug validation studies in animals 
involve study of behavioural/sensory changes and examination of histological samples from 
the brain tissue of the animal (Coecke et al., 2005). Such studies involve large investment of 
money, care and housing of animals and ethical issues. To avoid such labour intensive and 
expensive testing in the CNS drug development, there has been a need to design an in vitro 
model for high throughput screening of novel CNS therapeutics (Xu et al., 2011). 
The complexity involved in modelling an in vitro BBB with characteristics and 
microenvironment mimicking the in vivo structure is a significant hurdle (Malina et al., 
2009).  
1.6.1 Assessment of in vitro BBB models 
Since there are numerous hurdles in the development of in vitro BBB model, it is essential 
to develop robust methods for the assessment of the designed models. The measurement of 
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trans endothelial electrical resistance (TEER) is a simple method for determining the 
formation of TJs between endothelial cells adhered to the basement membrane (Gaillard and 
de Boer, 2000; Wilhelm et al., 2011a). TEER can quantitatively measure the tightness of the 
barrier and acts as a surrogate marker of the health of the cells by measuring the electrical 
resistance and capacitance across the BBB (Hayashi et al., 2004; Garberg et al., 2005a; 
Nakagawa et al., 2007a; Nakagawa et al., 2009a).  
Traditionally, chopstick electrodes were used to measure the TEER across the cell 
monolayer, comprised of two electrodes, one shorter than the other, placed in different 
chambers of the insert to give a reading of the resistance developed across  cells grown on a 
transwell insert as a BBB mimic (Figure 1.18). 
 
Figure 1.18 Measurement of TEER using an EVOM-2 
Another method used to measure TEER in similar set up is the Cellzscope. Cellzscope 
provides real time TEER measuremeants across cells grown on a transwell insert by placing 
an electrode on each side of the membrane,one in the upper compartment and one in the 
lower, and application of a small AC voltage can measure the electric impedance of the cell 
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system, as seen in Figure 1.19. Apart from TEER values, cellzscope also provides real time 
capacitance values of the model parameter which provides additional information about the 
cell layer properties. The two quantities, resistance TEER and capacitance (Ccl), are 
combined to give the complex impedance Z of the cell layer. 
 
Figure 1.19 Diagrammatic representation of the electric resistance and capacitance across the cell monolayer in 
Cellzscope.   
The final system used to measure the TEER, is the electric cell-substrate impedance sensing 
(ECIS) system, which measures in real-time, the activities of cells grown in tissue culture. In 
addition, information on morphological changes, cell locomotion, and cell cytoskeleton 
changes can be detected. ECIS measures TEER from one end of the designed model, 
therefore it can only measure TEER in two-dimensional BBB models from a monolayer of 
cells (Figure 1.20). 
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Figure 1.20 Monolayer of cells through which the ECIS reads the membrane capacitance and resistance.  
 
To assess the permeability of molecules through the formed BBB barrier, the flux of 
fluorescent tagged molecules can measured across the transwell BBB model (Hoffmann et 
al., 2011). Carman et al. (2011), described the use of dextran tagged with FITC to determine 
the passive permeability across the barrier (Carman et al., 2011).  
Immunohistochemistry using fluorescent labelled antibody can be utilised to observe the 
formation, expression and localisation of the tight junction proteins under altered growth 
conditions, thereby helping to optimising the model (Eigenmann et al., 2013).  
 
1.6.2 Current existing BBB models 
An ideal in vitro model should exhibit properties such as reproducibility of solute 
permeability, restrictive paracellular transport, functional expression of transporters, easy to 
culture and have a physiologically relevant architecture (Wilhelm et al., 2011b; Berezowski 
et al., 2004a). Lately, there has been an impressive increase in BBB modelling with a wide 
range of variations in the type of BBB models designed with difference in species, type of 
 
 
44 
culture, cell line, culturing conditions, as shown in Table 1.7 (Toth et al., 2011). Modelling 
of BBB includes different methods such as in silico (computer-aided) models, static mono-, 
co and tri-cultures, use of various dynamic or flow associated mono-, co- and tri-cultures 
(Cucullo et al., 2007).  
Table 1.7 List of patented models of in vitro BBB (Toth et al., 2011). 
No. Cell types used TEER  Major Novelty reference 
1 2 cell types: primary brain endothelial 
cells and astrocytes 
> 200 Ω/ 
cm2 
BBB model 
tightened by 
cAMP signalling 
Rubin et al, 1991 
2 3 cell types: primary brain endothelial 
cells, astrocytes & pericytes 
> 350-600 
Ω/ cm2 
Triple co-culture 
to mimic the 
anatomical BBB 
Niwa et al, 2007 
3 2 cell types: primary brain or 
embryonic stem cell derived 
endothelial cells and neural 
progenitor cells 
> 100-250 
Ω/ cm2 
Multicellular BBB 
model 
Shusta et al, 
2008 
4 1 cell type: monolayer of 
immortalized bovine brain endothelial 
cell line 
NA Immortalized 
brain endothelial 
cell line 
Yazdanian et al, 
2000 
5 2 cell type: temperature sensitive 
immortalized rat brain endothelial cell 
line, and rat astrocyte cell lines 
>106 Ω/ 
cm2 
Co-culture of 
conditionally 
immortalized cell 
lines 
Terasaki et al, 
2001 
6 1 cell type: monolayer of human 
brain endothelial cell line 
>40 Ω/ 
cm2 
Human BBB 
model 
 
Couraud et al, 
2006 
7 1 cell line: monolayer of mouse 
primary or immortalized endothelial 
cells 
NA BBB model 
tightened  by 
Wnt/β catenin 
signalling 
Dejana et al, 
2010 
8 1 cell line: co-culture of brain 
endothelial cells and astrocytes 
under luminal flow condition 
NA Dynamic BBB 
model 
Janigro et al, 
2003 
From the above tabulated models, it can be summarised that, there is a need to develop a 
three dimensional model which recapitulates the neurovascular unit and which can have a 
balance of high TEER values and low permeability. It should also essentially be cost effective 
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and easy to maintain giving high throughput results, so that it can be used commercially for 
screening cancer therapeutics. 
1.7 Rationale for the project 
The main aim in designing a physiologically relevant in vitro BBB model is for studying the 
cellular in vivo mechanisms involved in the disposition of drug across the BBB. This would 
help in predicting the bioavailability of drug across the blood brain barrier. The activity of 
drug efflux transporters in the BBB contribute considerably to chemotherapy resistance 
frequently observed when treating gliomas. Various experimental and diagnostic tools have 
been designed to study the drug efflux transporter function in the brain by designing an in 
vitro model for the BBB. All the in vitro and in vivo methods used to study drug efflux 
transporters show considerable differences in the substrate and inhibitor specificity from one 
species to another (Cecchelli et al., 1999; Dehouck et al., 1992). To avoid hampering 
extrapolation of efflux transporters in different species, it has been recommended that the 
materials used for the designing the model should be derived from human tissue (Garberg et 
al., 2005a). This may provide unambiguous information on transporter function at the blood 
brain barrier (Loscher and Potschka, 2005c). 
 Two experimental approaches have been used for studying transport mechanism in the 
endothelial cells of the blood brain barrier. The first experimental approach was used to study 
the accumulation of compounds in the cells which explains the transport of compounds in 
and out of the cell (Takakura et al., 1991; Reichel et al., 2003). The second approach was to 
set up involved the culturing of brain endothelial cells in monolayer on the filter membrane. 
This method is largely used in the in vitro model designing of the blood brain barrier 
(Cecchelli et al., 1999). The study of the blood brain barrier function using in vitro models 
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was initially done by investigation in brain capillaries which were isolated from rat brain. 
Thereafter, the brain capillaries have been isolated from various species like pig, cow, fish 
have been used (Reichel et al., 2003). The capillaries isolated include the brain endothelial 
cells, basement membrane ensheathing pericytes and attached astrocytic process. The TEER 
value of in vitro model is compared to in vivo model to determine the development of a 
successful in vitro model of the BBB. Since then a number of models have been designed 
however, all of them failed to reach the level of tightness that is reported in the blood brain 
barrier in vivo (Garberg et al., 2005b). 
The penetration of drugs into the human brain through the blood-brain barrier (BBB) is a 
major obstacle limiting the development of successful neuro pharmaceuticals. This restricted 
permeability is due to the delicate intercellular junctions, efflux transporters and metabolising 
enzymes present at the BBB. The pharmaceutical industry and academic research rely heavily 
on permeability studies conducted in animals and in vitro models of the BBB (Shawahna et 
al., 2012). Therefore, designing a model which predicts drug efficacy and toxicity of brain 
tumour drug treatment is highly important. The model should be a bridge between the in vitro 
and in vivo studies. 
 
1.7.1 Aim 
To develop a fully characterised, physiologically relevant and functional in vitro model 
for prediction of permeability of drugs across the blood brain barrier. The designed model 
will be used to study drug metabolism and transport in glioma, and hence prediction of the 
efficacy of novel drugs, nanoparticles for the treatment of glioma.  
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1.7.2 Objectives 
 To study growth characteristics and phenotype of the cell lines and short term cultures 
to be used for the development of the BBB model. 
 To study protein expression profiles of drug metabolising enzymes (CYP3A4 and 
CYP2D6) and efflux transporters (ABCB1 and ABCG2) in cancerous and non-
cancerous cell lines and short term cultures in various culture conditions and optimise 
the culture conditions for maximal expression 
 To study the activity profiles of drug metabolising enzymes (CYP3A4 and CYP2D6) 
and efflux transporters (ABCB1 and ABCG2) in cancerous and non-cancerous cell 
lines and short term cultures in various culture conditions optimise the culture 
conditions for maximal activity.  
 To develop an in vitro BBB model of human origin using short term cultures by 
different modelling systems and determine the best developed model by assessing 
their protein expression profiles for TJs, efflux transporters and DMEs and activity 
profiles. 
 To validate the developed model for different characteristics of a BBB model and test 
its efficiency using nanoparticles and aptamers. 
 To develop a brain tumour barrier BTB model by studying the effect of tumour cells 
in a BBB model. 
 
1.7.3 Overview 
As seen in Figure 1.21, the flow chart shows an overview of the study conducted in 
developing a fully characterised physiologically relevant in vitro BBB model.  
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Figure 1.21 Summary of the conducted experiments. 
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 Materials and Methods  
2.1 Tissue Culture 
2.1.1  Cell Lines  
Immortalised human cell lines 1321N1 (malignant astrocytoma, sub-clone of grade IV 
U118MG), U87MG (astrocytoma grade IV/glioblastoma), SVGp12 (non-cancerous foetal 
astrocyte) were obtained from the European Collection of Cell Cultures (ECACC, Salisbury, 
UK). The immortalised human cerebral microvascular endothelial cell line (hCMEC/D3) cell 
line and short term human astrocyte culture (SC1800) were a generous donation from the 
Neuro oncology Department of University of Portsmouth. The hCMEC/D3 is a cell line 
generated from primary human brain capillary endothelial cells via a lentiviral vector system 
(Urich et al., 2012). In addition, commercially available short-term cell lines derived from 
primary tissue including human microvascular endothelial cells (HMBEC), human brain 
vascular pericytes (HBVP) and human astrocytes (HA) were purchased from (Sciencell, 
Buckingham, UK). Short-term cell lines BTNW914 (female, aged 67, GBM patient) and 
BTNW370 (female, aged 65, gliosarcoma grade IV patient) were established from human 
glioma biopsies obtained from the Brain Tumour North-West (BTNW) tissue bank at Royal 
Preston Hospital. Informed patient consent, NHS and university ethical approval was 
obtained for the study of glioma phenotype. 
2.1.2 Media and Supplements 
All cell culture media and supplements used for cell culture were purchased from Lonza, 
Nottingham, UK unless otherwise mentioned (Table 2.1). Phosphate buffered saline (PBS), 
ethanol, all plastic-ware including tissue culture flasks, well plates, centrifuge tubes, 
stripettes, pasteur pipettes, and 1.5 ml tubes, were purchased from Fisher scientific, 
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Leicestershire, UK. All lab consumables were purchased from Sigma, Dorset, UK unless 
mentioned otherwise. 
Table 2.1 Summary of cell culture supplements used. 
Reagents Abbr. / storage 
temperature 
Cell line Suppliers 
Dulbecco’s modified 
eagle’s medium 
DMEM, 2-8 °C 1321N1 Lonza, Slough, UK 
Eagle’s minimum 
essential medium 
EMEM, 2-8°C U87MG, SVGp12 Lonza, Slough, UK 
Endothelial basal media EBM-2, 2-8°C hCMEC/D3 Lonza,, Slough,  UK 
Endothelial Growth 
Media-2 Single quots 
EGM-2, -20°C HBMEC, hCMEC/D3 Lonza,, Slough, UK 
Pericyte cell medium PCM, 2-8°C HBVP Sciencell, 
Buckingham, UK 
Pericyte cell growth 
supplement 
PCGS, -20 °C HBVP Sciencell, 
Buckingham , UK 
Astrocyte basal media ABM-2, 2-8°C SC1800 (HA) Lonza, Slough,, UK 
Astrocyte Growth Media-
2 Single quots 
AGM-2, -20°C SC1800 (HA) 
 
Lonza, Slough,, UK 
Ham’s F-10 medium 2-8°C BTNW370, BTNW914 Lonza, Slough, UK 
Foetal bovine serum 
 Cat no:10082139 
FBS, -20°C 1321N1, SVGp12, 
U87MG 
Gibco, Paisley, UK 
Foetal bovine serum 
Cat no:10100139 
FBS, -20°C BTNW370, BTNW914 Gibco, Paisley, UK 
Human serum  HS, -20°C HBMEC,hCMEC/D3 
HBVP, SC1800 (HA) 
Lonza Slough,, UK 
L-glutamine -20 °C 1321N1, SVGp12, 
U87MG 
Lonza, Slough, UK 
Sodium pyruvate 2-8 °C SVGp12, U87MG Lonza, Slough, UK 
Non-essential amino acid NEAA, 2-8 °C SVGp12, U87MG Lonza, Slough,  UK 
Hank’s balanced salt 
solution 
HBSS, 2-8 °C All cell lines Lonza, Slough,  UK 
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The 1321N1 cell line was maintained in Dulbeccos’s Modified Eagle’s Medium (DMEM) 
supplemented with 10 % (v/v) foetal bovine serum (FBS) and 2 mM L-glutamine, while the 
U87MG and SVGp12 cell lines were maintained in Essential Minimum Eagle Medium 
(EMEM) supplemented with 10 % (v/v) FBS, 2 mM L-glutamine, 1 mM sodium pyruvate 
and 1 % (v/v) non-essential amino acids (NEAA). All the cell lines were cultured in 75 cm2 
tissue culture treated flasks and maintained in a 37 oC humidified incubator supplied with 5 
% CO2 (Thermo Scientific Nunc, UK). For all the experiments, each of the immortalised cell 
lines were used between passages 2-18. Short-term endothelium, pericytes and astrocytes cell 
lines were grown in endothelial cell media, pericyte media and astrocyte media, respectively 
(Sciencell, UK). In addition, cell line and primary culture media was supplemented with 5 % 
(v/v) human serum (HS) and growth supplement (Table 2.1). The patient biopsy derived short 
term cultures of GBM, BTNW914 and BTNW370 were cultured in Ham’s F-10 medium 
supplemented 10 % (v/v) FBS (Gibco, Paisley, UK).  
 
2.1.3 Cryopreserving and Thawing Cells 
The confluent cells were passaged as described in section 2.1.4. The pellet of cells obtained 
after centrifugation was resuspended in freezing medium. The freezing medium comprised 
of serum used in respective media (foetal bovine serum or human serum) and 10 % dimethyl 
sulphoxide (DMSO). Cell suspensions were stored in cryotubes in Mr. Frosty (Nalgene, UK) 
freezing container filled with isopropanol at -80 °C overnight. The cryovials were placed in 
the liquid nitrogen dewer (-190 °C) the following day. Frozen cells were rapidly thawed in a 
water bath at 37 °C and seeded in a 75 cm2 tissue culture flask in a laminar flow cabinet, with 
10 mL of growth medium for every 1 ml of defrosted cells. The growth medium was changed 
after 12-24 h for complete removal of the cryopreservatives. 
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2.1.4 Subculturing of Cells 
Cells were passaged once 70-80 % confluency was reached. The subculturing of cells was 
under aseptic conditions in a laminar flow cabinet. Growth media, 0.25 mM trypsin and 0.1 
M PBS, pH 7.4 were prewarmed at 37 °C in a water bath. The spent medium was aspirated 
from the flask and cells were washed with 0.1 M PBS, pH 7.4. The PBS was removed and 
0.25 mM trypsin was added to the cells. The flask was incubated at 37 °C for 5 min and cells 
were examined under inverted light microscope to check for detachment of cells. Growth 
media appropriate for the cell line was added to the flask to neutralise the trypsin reaction in 
the flask. The cell suspension was then mixed using pipette to ensure homogeneity of 
detached cells and centrifuged at 179 x g for 5 min using a bench centrifuge (ALC, 
Buckinghamshire, UK). After centrifugation, the pellet of cells was retained. The cells were 
resuspended in 5 ml fresh growth medium and a 20 µl aliquot was retained to determine the 
cell count and cell viability using trypan blue stain. The cells were seeded at a density of 5 x 
104 cells/ ml in a 75 cm2 flask which was incubated at 37 °C and 5 % CO2 in a humidified 
incubator until confluent. 
 
2.2 Cell Counting 
From the trypsinised cell suspension, 10 µl was aliquotted in a 1 ml sterile 1.5 ml tube to 
which 10 µl of 0.4 % trypan blue dye was added.  A newbauer’s haemocytometer was used 
for counting cells, with those excluding trypan blue counted as viable. The cells were counted 
under the inverted light microscope at 10 X magnification (Leica DMIL, Milton Keynes, 
UK). The number of viable cells in the centre grid (1 mm2) of each chamber was counted, an 
average from five chambers was calculated and this number was multiplied with the 
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haemocytometer factor 1 x104.The cell count was then corrected for dilution factors to obtain 
the number of cells per 1 ml of suspension. The cells were seeded at densities of 2000 cells/ 
200 µl/ well in 96 microtiter plates, 20,000 cells/ ml/ well in 24 well plates and 1 x 106 cells/ 
ml/ flask in 75 cm2 flasks. 
 
2.2.1 Spheroid Culture 
A confluent flask of monolayer cells was passaged (see section 2.1.4) and seeded to grow as 
spheroids. The spheroids were cultivated by two methods, hanging drop and agar coated 
plates. 
2.2.1.1 Hanging Drop Method 
Cell suspension was diluted in media to a concentration of 3000 cells/25 μl of cell suspension 
was seeded for each spheroid on the lid of a petri dish. A total of 20 spheroids were seeded 
per dish. The bottom of the petri dish was filled with 2 ml of respective culture media to 
maintain a humidified atmosphere in the dish. The lid was placed on the petri dish with the 
drops of cell suspension hanging upside down. The spheroids were allowed to grow for 6 
days at 37 °C and 5 % CO2 in a humidified incubator and the media was changed on the third 
day following seeding, the formed spheroids were then used for experiments. 
2.2.1.2 Agar Coated Plates 
Tissue culture plates were coated with 1 % sterile agar and left to cool one day prior to 
seeding cells for spheroids. Passaged cells were seeded onto the agar coated 24-well plates 
at a density of 3,000 cells/ well. The plates were incubated at 37 °C and 5 % CO2 in a 
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humidified incubator for 6 days, the media was changed after 3 days on the sixth day the 
spheroids were used for experiments. 
 
2.2.2 Growth Curves 
To study the growth pattern of the immortalised cell lines 1321N1, U87MG, SVGp12, and 
hCMEC/D3 and short-term cell lines HBMEC, HBVP, SC1800 growth curves were 
established. The cells were seeded at a density of 20,000 cells/ mL/ well in a 24 well tissue 
culture plate at 37 °C and 5 % CO2 in a humidified incubator. Each day the cells in the wells 
were trypsinised and were stained with 0.4 % trypan blue dye and counted using a 
haemocytometer (refer to Section 2.2). For every time point, an average cell count from three 
wells was calculated up to day 10 and the growth medium was changed every three days to 
maintain cells in a healthy environment. The experiment was performed in triplicate and cell 
count verses time was plotted to study growth kinetics. 
 
2.3 Immunostaining of cells 
2.3.1 Fixation of cells 
The cells were seeded at a density of 1 x 104 cells/ ml on 1 mm thick coverslips in a 24 well 
plate. Upon cells reaching 50 % confluence, the spent media was removed and the coverslips 
were washed with 0.1 M PBS three times. Cells on the coverslips were then fixed by 
incubation with 4 % paraformaldehyde (PFA) for 15 min at room temperature followed by 
washing with 0.1 M PBS three times ready for immunostaining. 
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2.3.2 Fluorescent immunostaining 
The fixed cells on coverslips were washed with 0.1 M PBS, pH 7.4 three times and incubated 
with 0.1 M glycine for 10 min for quenching background fluorescence. Cells were washed 
with 0.1 M PBS, pH 7.4 five times, then permeabilised by incubating with 0.1 % triton X-
100 for 10 min at room temperature, followed by washing with 0.1 M PBS, pH 7.4 five times. 
Cells were blocked by incubating with 10 % goat serum for 1 h, followed by three washes 
with 0.1 M PBS, pH 7.4. Cells were then incubated with respective dilutions of primary 
antibody (Table 2.2) for 1 h at room temperature and at the end of the incubation period were 
washed with 0.1 M PBS, pH 7.4 three times. The cells were then incubated with 1:1000 
dilution of secondary antibody Alexa Fluor® 488 F(ab')2 Fragment of Goat Anti-Rabbit IgG 
(Life technologies, UK) for 30 min in the dark. The cells were then washed with 0.1 M PBS, 
pH 7.4 three times and mounted on a microscope slide using with VECTASTAIN mounting 
media (Vector Laboratories, Peterborough, UK). The slides were incubated for 24 h in dark, 
before analysis, the corners of the coverslip were tacked with nail varnish to prevent the cells 
from drying. 
Table 2.2 List of rabbit polyclonal primary antibodies, their concentration and dilutions used for 
immunostaining. 
Primary antibody 
Antibody dilutions in 0.1 M 
PBS, pH 7.4 Manufacturer 
GFAP  1 : 300 Abcam, Cambridge, UK 
HLA 1 : 250 Santacruz, Middlesex, UK 
MDR 1 : 250 Abcam, Cambridge, UK 
BCRP 1 : 200 Abcam, Cambridge, UK 
Occludin 1 : 250 Abcam, Cambridge, UK 
Claudin-5 1 : 250 Abcam, Cambridge ,UK 
Isotype Control 1 : 100 Santacruz, Middlesex, UK 
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2.3.3 3,3-Diaminobenzadine (DAB) staining 
The fixed cells on coverslips were washed with 0.1 M PBS, pH 7.4 three times and incubated 
with 10 % horse serum for 30 min, followed by three washes with 0.1 M PBS, pH 7.4. The 
cells were then incubated for 10 min with 0.1 % H2O2 in 0.1 M PBS, pH 7.4 to quench 
endogenous peroxidase activity. The cells were washed with 0.1 M PBS, pH 7.4 once and 
incubated with respective dilutions of primary antibody for 30 min or 24 h as outlined in 
Table 2.3. The cells were then washed with 0.1 M TBS, pH 7.4 three times and incubated 
with 1:500 dilution of biotinylated secondary antibody for 30 min. After the incubation, the 
cells were washed with 0.1 M TBS, pH 7.4  three times and incubated with VECTASTAIN 
Elite ABC Kit (Vector Laboratories, Peterborough, UK) for 30 min. The cells were then 
washed with 0.1 M TBS three times and stained with DAB (Vector Laboratories, UK) for 10 
min at room temperature. The stained cells were washed with distilled water five times and 
cells were counter stained with haematoxylin. These cells were dehydrated with a series of 
ethanol washes (50 %, 70 % and absolute) and xylene and then mounted on a glass slide 
using a Distyrene Plasticizer Xylene (DPX) mount media. 
Table 2.3 List of concentrations and dilutions and incubation period of rabbit polyclonal primary antibodies 
used for DAB staining. 
Antibody Dilutions Incubation period Manufacturer 
GFAP 1 : 500 24 h Abcam, Cambridge, UK 
HLA 1 : 20 30 min Santacruz, Middlesex, USA 
MDR 1 : 250 30 min Abcam, Cambridge, UK 
BCRP 1 : 250 30 min Abcam, Cambridge, UK 
EMA 1: 350 30 min Abcam, Cambridge, UK 
CD34 1 : 300 30 min Abcam, Cambridge, UK 
Biotinylated 
secondary antibody 
1: 500 30 min Abcam, Cambridge, UK 
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2.4 Protein extraction 
2.4.1 Protein linearity experiment 
Cells were grown in five T-75 flasks and the cells were extracted from one T-75 flask each 
day from day 3 to day 7. The cells were lysed using RIPA buffer (see appendix) and the 
protein concentration was quantified using the Bradford assay (see Section 2.4). The 
concentration of protein content was plotted to determine its relationship with cell number. 
2.4.2 Optimisation of protein extraction method 
Cells were cultured in T-75 flasks which were harvested when the flask was confluent for 
protein extraction. All protein extractions were carried out on ice to avoid protein degradation 
and maximise the yield of the proteins. Different methods were investigated for optimisation 
of protein extraction. In all cases the protein concentration was quantified using the Bradford 
assay (see Section 2.4). 
2.4.2.1 Method I 
The confluent flask of cells was kept on ice and medium was aspirated from the flask. The 
cells were washed with ice cold 0.1 M PBS, pH 7.4 to remove traces of serum and the cells 
were scraped from the flask using a sterile cell scraper. The scraped cells were collected in a 
precooled 1.5 ml tube to which 500 µl of ice cold RIPA lysis buffer was added. The samples 
were agitated at 40 rpm on a shaker (VXR Vibrax, Oxfordshire, UK) for 30 min at 4 °C to 
facilitate membrane lysis. The samples were then spun in a microcentrifuge (Sanyo, 
Leicester, UK) at 11451 x g for 20 min at 4 °C. After centrifugation the supernatant, which 
comprised of all cellular and membrane proteins, was collected in a precooled 1.5 ml tube, 
ready for determination of protein concentration.  
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2.4.2.2 Method II 
The confluent flask of cells was kept on ice and medium was aspirated from the flask. Cells 
were trypsinised as previously described in Section 2.1.4. The cell suspension was 
centrifuged at 179 x g for 5 min and the pellet was resuspended in ice cold RIPA buffer, 
ready for assay of protein content.  
2.4.2.3 Method III 
A similar protocol, as described in Section 2.3.2, was followed, except the cells were 
centrifuged at 21074 x g instead of 11451 x g to determine whether an increased protein yield 
can be obtained, with a higher centrifugal force. 
2.4.2.4 Method IV 
A similar protocol, as described in Section 2.3.2 was followed except following resuspension 
in RIPA buffer, the cells were sonicated on ice using a probe sonicator (Sanyo, Leicester, 
UK) at 50 hertz for three repetitions of 30 s duration. After centrifugation, at 11451 x g for 
20 min at 4 °C, the supernatant, which comprised of all cellular and membrane proteins, was 
assayed for protein concentration. 
 
2.4.3 Polycarbonate transwell and alvetex scaffold inserts 
At the end of the TEER measurements (see Section 2.9.1) the co-cultured cells were lysed 
for protein extraction. The inserts were washed twice with HBSS, pH 7.2 (see appendix) and 
then incubated with 100 µl RIPA buffer for 15 min at 4 ºC. The inserts were scraped and the 
cells which were suspended in RIPA buffer were collected in 1.5 ml tubes. The samples were 
spun in a microcentrifuge (Sanyo, Leicester, UK) at 11451 x g for 20 min at 4 °C. After 
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centrifugation the supernatant, which comprised of all cellular and membrane proteins, was 
collected in precooled 1.5 ml tubes and assayed for protein content. 
 
2.5 Protein quantification by Bradford assay 
The Bradford assay is a protein concentration estimation assay which involves binding of 
coomassie brilliant blue G-250 dye to the proteins in the sample (Bradford, 1976). A set of 
bovine serum albumin (BSA) protein standards diluted in RIPA lysis buffer (0.1 to 2 mg/ 
mL) were used as a reference. Samples and standards were diluted in Bradford reagent (1 in 
51 dilutions) in a 96-well plate. The absorbance was read at 612 nm using a plate reader 
Tecan GENios Pro® (Tecan, Theale, UK). The absorbance of BSA samples were plotted 
against concentration of BSA and a line of best fit was determined by linear regression, to 
allow determination of the extracted protein concentration. Protein concentrations were then 
corrected for dilution factors. 
 
2.6 Western blotting 
Western blotting technique was used for detection of cytochrome P450 enzymes and efflux 
transporters protein expression in the extracted protein lysate. Western blotting involved 
identification of protein of interest by probing with specific antibodies after electrophoretic 
separation of the sample and blotting over a nitrocellulose membrane. This study involved 
the detection of cytochrome P450 enzymes; CYP3A4, CYP2D6, the efflux transporters; 
ABCB1 and ABCG2 and tight junction proteins; occludin and claudin-5. 
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2.6.1 Sample preparation 
The 2 mg/ ml protein aliquots from cells,  stored at -20°C, were thawed and mixed with 2 x 
Laemmli sample loading buffer (see appendix 4) at a ratio 1:1. The 1.5 ml tubes containing 
sample and sample buffer were heated on a block (Techne, Staffordshire, UK) for 5 min at 
90°C, to denature complex structured proteins to linear proteins. Each well of 10 % 
polyacrylamide gel was loaded with 10 µg protein sample. 
 
2.6.2 Gel electrophoresis 
Gel electrophoresis involves separation of macromolecules on the basis of their size. The 
electrophoresis used in this experiment was sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS PAGE). SDS PAGE is a discontinuous electrophoresis which involves 
two different gels; stacking gel and resolving gel. The stacking gel stacks the sample and 
resolving gel separates the proteins in the sample on the basis of molecular size. A 4 % 
stacking gel and 10 % resolving gels were prepared as per the recipe described in         
appendix (4). 
Firstly, the resolving gel was poured into a vertical setup and allowed to polymerise with the 
aid of chain initiator tetramethylethylenediamine (TEMED) in the presence of the catalyst 
ammonium persulphate (APS). It was covered with water to avoid contact with atmospheric 
oxygen that inhibits polymerisation. After the resolving gel had polymerised, the stacking 
gel was poured and the comb was inserted. Once the gels were set, they were placed in an 
electrophoresis tank and the tank was filled with 1.5 M tris glycine buffer, pH 7.4. The 
samples were carefully loaded in the wells and the gels were run at a constant voltage of 120 
V for 2 h. Ten μl of prestained molecular weight ladder (New England Biolabs, UK) and 5 
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µl of western blotting ladder (Invitrogen, Paisley, UK) were also loaded as a reference marker 
for molecular weight of the proteins. The western blotting ladder consists of 9 recombinant 
proteins, each of which contains an IgG binding site. The IgG binding site binds to the 
secondary antibody used for detection of the target protein, allowing direct visualization of 
the standards on the western blot. Once the samples were separated and the tracking dye 
reached the bottom of the gel, the power supply was disconnected and the gel was transferred 
onto nitrocellulose membrane. 
 
2.6.3 Transfer of proteins 
The gel was transferred onto a nitrocellulose membrane by the wet method, which involved 
the soaking of a 0.2 µm nitrocellulose membrane (BioRad, UK), Whatmann filter paper and 
sponges in transfer buffer (1.5 M tris glycine buffer, pH 7.4). The sandwich of gel and 
nitrocellulose membrane between the filter papers was closed and placed in the transfer tank 
which was filled with transfer buffer. Transfer took 1 h at 90 V in an ice bath. 
 
2.6.4 Visualisation of transferred proteins 
To ensure the proteins had successfully transferred to the nitrocellulose membrane, the blot 
was stained with Ponceau S red stain at room temperature with mild shaking at 40 rpm for 
10 min. Ponceau red stain is a sodium salt of diazo dye and is used for reversible detection 
of transferred protein on a nitrocellulose membrane. The blot was then washed with distilled 
water, until protein bands were visible. Once the transfer of proteins was confirmed the blot 
was destained by repeated washes with distilled H2O. This blot was then probed with 
antibodies for the protein of interest.  
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2.6.5 Probing antibodies and detection of proteins 
The nitrocellulose membrane was washed with distilled H2O and incubated with blocking 
buffered solution (1 M tris buffer saline with 0.1% tween 20 and 5% non-fat milk), which 
blocked all the non-specific binding sites of the proteins, for 1 h at room temperature. After 
1 h, the blot was washed with washing buffer (1 M tris buffer, pH 7.4, 0.1% tween 20) 
(TBST) three times for 10 min each at room temperature and incubated with the relevant 
primary antibody (refer to dilutions of the primary antibody used in Table 2.4), overnight at 
4 °C. Following incubation, the blot was washed with TBST five times  for 10 min each at 
room temperature to remove the unbound antibody and incubated with a secondary antibody 
conjugated to horseradish peroxidase (1:10000 dilution) (Table 2.4) for 1 h at room 
temperature, before washing three times with TBST.  
Table 2.4 List of concentration and dilution of rabbit polyclonal primary antibodies (Abcam, UK) and 
secondary antibody used for probing nitrocellulose membrane blots. 
 
Antibody Antibody dilution (Antibody 
diluted in 0.1 M TBST, pH 7.4) 
CYP 3A4 1:3500 
CYP 1B1 1:3000 
CYP 2E1 1:3000 
CYP 2D6 1:3000 
BCRP (ABCG2) 1:2000 
MDR-1 (ABCB1) 1:3000 
β actin (loading control) 1:5000 
Occludin 1:2000 
Claudin-5 1:1000 
Secondary Antibody (donkey 
polyclonal secondary antibody to 
rabbit IgG/ mouse IgG) 
1:10000 
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The blot was then rinsed with distilled H2O and the proteins were detected using an ECL plus 
kit (GE Healthcare, UK) as per the manufacturer’s instructions. The blot was incubated with 
ECL solution for 5 min and imaged in a gel doc XPS (Bio Rad, Town, UK) to visualise bands 
of proteins of interest by chemiluminescence. 
 
2.7 Activity assay for drug metabolising enzymes (CYP3A4 
and CYP2D6) 
The functional activity of CYP3A4 and CYP2D6 in cell lines was assayed in 96-well plates 
by incubation with a substrate probe for the CYP of interest and measurement of the rate of 
formation of fluorescent metabolite. The probe used for the CYP3A4 enzyme was 7-
benzyloxy-4-trifluoromethyl- coumarin (BFC) (BD Gentest©, Oxford, UK), which formed 
the fluorescent metabolite 7-hydroxy-4-trifluoromethylcoumarin (HFC) (BD Gentest©, 
Oxford, UK). The activity of CYP2D6 was determined using 3-[2-(N, N-diethyl-N-
methylammonium) ethyl]-7-methoxy-4-methylcoumarin (AMMC) (BD Gentest©, Oxford, 
UK), which formed the fluorescent metabolite 3-[2-(N,N-diethyl-N-methylammonium) 
ethyl]-7-hydroxy-4-methylcoumarin (AHMC) (BD Gentest©, Oxford, UK). All substrates 
and metabolite were dissolved in DMSO to give a 10 mM stock and diluted 1 in 400 to ensure 
final solvent concentration in the reaction well did not exceed the threshold of 0.1 %. The 
co-factor 10 mM NADPH (stored -80 ºC) was freshly prepared in 0.1 M PBS buffer (pH 7.4) 
and added to the flat bottom, transparent 96-well plate containing pre-warmed (37 ⁰C) protein 
sample (varied according to the protocol below), substrate (varied according to the protocol 
below) and 0.1 M potassium phosphate buffer, pH 7.4 (see Appendix) to initiate the enzyme 
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reaction. The formation of HFC was measured at excitation wavelength of 410 nm and 
emission wavelength of 510 nm and the formation of AHMC was measured at excitation 
wavelength of 390 nm and emission wavelength of 460 nm in a Tecan GENios Pro® plate 
reader (Tecan, Theale, UK). Measurements were made at 37 ⁰C every 30 s for 30 min with 
orbital shaking for 5 sec before each reading. The plates were read from the top, and gain 
was optimised on the first run and was set at 35 for all subsequent runs.  
 
2.7.1 Protein linearity optimisation 
The positive controls, overexpressed human recombinant CYP3A4 and CYP2D6 in 
bactosomes (Cypex, UK) were used at various concentrations ranging from 0 to 1 mg/ ml to 
verify the optimal protein concentration to ensure the rate of enzyme activity was linear with 
respect to time. The following components were added to each well of a 96-well plate and 
left for 5-min in the plate reader to pre-warm to 37 ⁰C: 125 μl of 50 mM of substrate (BFC 
or AMMC) at a final concentration of 25 mM, 25 μl CYP2D6 or CYP3A4 bactosome at a 
range of final concentrations between 0 to 1 mg/ ml protein and 75 μl of 0.1 M potassium 
phosphate (pH 7.4) to make a final reaction volume of 250 μl. To initiate the reaction, 25 μl 
of 10 mM NADPH stock was added to each well to give a final concentraion of 1 mM. Wells 
were measured for formation of the fluorescent metabolite (HFC or AHMC) as described in 
Section 2.6. 
 
2.7.2 Substrate linearity optimisation 
To determine the optimum substrate concentration to ensure the measured rate of enzyme 
activity was in the linear range, a range of BFC or AMMC concentrations were investigated 
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in bactosomes, using a previously optimised protein concentration 1 mg/ ml. In a 96-well 
plate, 125 μl of substrate (BFC or AMMC) ranging in concentrations, between 0 µM and 150 
µM, were incubated with 25 μl of 1 mg/ml protein and 75 μl of 0.1 M potassium phosphate 
(pH 7.4). 10 mM NADPH stock was added in each well to give a final concentration of 1 
mM and to initiate the reaction. Samples were measured for formation of the fluorescent 
metabolite (HFC or AHMC) as mentioned previously in Section 2.6. 
 
2.7.3 Enzyme kinetic study 
In a 96-well plate, cells were seeded at a density of 5000 cells/ well before being incubated 
at 37 °C and 5 % CO2 in a humidified incubator until exponential growth was well 
established. Once the cells were 80 % confluent (which was predicted by the growth curve 
of cells), the cells were washed with 100 µl of 0.1 M potassium phosphate buffer (pH 7.4). 
125 µl of 50 µM substrate (BFC/ AMMC), diluted in the appropriate culture medium, was 
added to the wells in triplicate giving final concentration of 25 µM. 100 µl of 0.1 M potassium 
phosphate buffer (pH 7.4) was added to each well giving a final reaction volume of 250 µl. 
The plate was measured for fluorescent metabolite formation every 10 min for 120 min on 
Tecan GENios Pro® plate reader (Tecan, Theale, UK). The negative controls included a 
vehicle control, cells, media or buffer and 0.1 % DMSO, substrate blank (cells and media) 
and enzyme blank (substrate and media). All final reaction volumes were maintained at 250 
µL, and volume differences were made up using 0.1 M potassium phosphate buffer, pH 7.4.  
2.7.3.1 Enzyme kinetic study in mono-, co-, tri- and alvetex cultures. 
The assessment of CYP activity in different cultures was assessed by replacing the growth 
medium with the substrate (BFC or AMMC) dissolved in the culture medium. The co-
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cultures were washed with 0.1 M potassium phosphate buffer (pH 7.4) and 25 µM substrate 
(BFC or AMMC), diluted in the appropriate culture medium, and 0.1 M NADPH was added 
to the wells in triplicate giving a final reaction volume of 200 µl. The plate was measured for 
fluorescent metabolite formation every 10 min for 120 min on the Tecan GENios Pro® plate 
reader (Tecan, Theale, UK). 
2.7.3.2 Standard curve for metabolites 
A standard curve of the metabolites was prepared using standard concentrations of HFC or 
AHMC between 0 to 40 µM, added to 0.1 mg/ mL cellular protein to a final well volume of 
200 µL in a 96-well plate. The plate was measured for metabolite fluorescence using the 
Tecan GENios Pro® plate reader (Tecan, Theale, UK). The relative fluorescent units (RFU) 
were plotted on a XY scatter plot against metabolite concentration graph and a line of best 
fit was fitted using linear regression. 
2.7.3.3 Data analyses and interpretation 
The fluorescence emission readings from the kinetic experiment were converted into rate of 
metabolite formation per min by dividing the slope of the linear line of best fit from the 
kinetic plot (Section 2.6.3.1). The rate of ΔRFU / min was converted into pmol HFC or 
AHMC produced per min by dividing by the slope of the line of best fit obtained for the 
standard curve (Section 2.6.3.2) and finally this was normalised to 1mg/ml of protein 
dividing by the total cell number in the model being investigated to give the final rate of 
enzyme activity in pmol HFC or AHMC/ min/ 106 cells.. The Michaelis-Menton plot of rate 
of enzyme activity verses substrate concentration was plotted using GraphPad Prism™ 6.05, 
and the Vmax and Km were estimated for recombinant CYP2D6 and CYP3A4 in bactosomes 
to ensure the kinetics assay for the positive control was producing values comparable to the 
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literature. Thereafter, all models were compared against this control using the optimal 
substrate concentration of 25 µM. 
2.8 Activity assay for efflux transporter (ABCB1 and 
ABCG2) 
The Multidrug Resistance Direct Dye Efflux Activity Kit (Merck Millipore, Oxford, UK) 
was used to measure the functional activity of ABCB1 and ABCG2 by assaying the ability of 
the cell to extrude fluorescent ABCB1 and ABCG2 substrate dyes, 3,3'-
Diethyloxacarbocyanine Iodide [DiOC2(3)] solution and rhodamine 123 solution 
respectively. A non-fluorescent substrate vinblastine was used as a competitive inhibitor of 
efflux activity of ABCB1 and ABCG2 transporter and DMSO was included as a vehicle 
control.  
The cell lines were only assayed for transporter activity when in the exponential phase of 
growth as predicted by the growth curve of cell lines, at the time point at which with maximal 
protein expression was observed and when the TEER reached the maximum value (Section 
2.9.1). At this point, cells were extracted from the insert by scraping from the cell culture 
dishes and trypsinised from different mono-, co-, tri- or alvetex culture model. The 
transporter, activity measurements were carried out on the cell suspension of approximately 
2.5 x 105 cells. The cells were centrifuged at 200 x g for 5 min using a microcentrifuge 
(Sanyo, Leicester, UK) and the supernatant was discarded. The cell pellet was resuspended 
to a final concentration of 1 x 106 cells/ml in 10 μg/ml cold DiOC2(3) or 100 μg/ml rhodamine 
123 loading buffer. Cells loaded with DiOC2(3) or rhodamine 123 and were incubated for 15 
min or 2 h respectively on ice. After the incubation period, the cells were centrifuged at 200 
x g for 5 min and the supernatant was discarded. The cells were resuspended in 2.5 ml cold 
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efflux buffer (1X RPMI-1640 and 30 % BSA and 0.1 % gentamycin) and again centrifuged 
at 200 x g for 5 min. At this point, the resuspended cells were distributed into different tubes 
for each different treatment. These tubes were centrifuged at 200 x g for 5 min, the 
supernatant was discarded and the cell pellet was resuspended in the following media at 1 ml 
per test containing 2.5 x 105 cells: 
A. 37 ºC-Warmed Efflux Buffer containing DMSO 
B. 37 ºC-Warmed Efflux Buffer containing vinblastine 
C. Ice-Cold Efflux Buffer 
D. 37 ºC-Warmed Efflux Buffer (sample) 
Tubes A, B and D were immediately transferred to a 37 ºC incubator maintained at a steady 
oscillation of 60 rpm whereas tube C was kept on ice at all times. The tubes were incubated 
for 60 min and at the end of the incubation 5 ml of cold efflux buffer was added to each tube, 
before being placed on ice to terminate the reaction. The tubes were then centrifuged at 200 
x g for 5 min in a refrigerated centrifuge at 4 ºC and the supernatant was discarded. The cells 
were resuspended in 1 ml per test (2.5 x 105 cells) cold efflux buffer and centrifuged at 200 
x g for 5 min at 4 ºC (ALC PK120, Buckinghamshire, UK). The supernatant was discarded 
and the cells were resuspended in 250 µl of cold efflux buffer. Cell suspensions were 
transferred into the wells of a black walled 96-well plate, thereafter samples where measured 
on a Tecan GENios Pro® plate reader (Tecan, Theale, UK) at an excitation wavelength of 
485 nm and an emission wavelength of 530 nm. The gain was set to 45 and the plates were 
read from the top to determine the fluorescent dye effluxed out of the cells in 60 min. The 
activity was calculated as % fluorescence relative to the control and plotted. 
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Inside (apical) chamber 
2.9 Co-culture on transwell for BBB model 
The cells were co-cultured on 12 mm transwell with 8 μm pore size, polycarbonate membrane 
insert in 48-wells plates (Figure 2.1) (Corning, UK).  
 
 
 
 
Figure 2.1 Diagrammatic representation of a transwell insert. 
Prior to establishing the transwell models, short-term cultures were grown until day 6, to 
ensure cells were in the exponential phase of growth. The transwell cultures utilised the 
human microvascular endothelial cells (HMBEC, passage 2-7) human brain vascular 
pericytes (HBVP, passage 2-9) and human astrocytes (HA, passage 2-7). The short-term 
cultures from primary cells were used at lower passage number P2 to P15 as recommended 
by the supplier. The HBMEC cells were seeded at a density of 75,000 cells/ well in mono-
culture and 50,000 cells/ well in co-culture and tri-culture. In co-culture, the HBVP were 
seeded at a density of 25000 cells/ well and the HA were seeded at a density of 25000 cells/ 
well. In tri-culture, the HBVP were seeded at a density of 12,500 cells/ well and the HA were 
seeded at a density of 12,500 cells/ well. The final cell number in each model was always the 
same and the ratios of the different cell components differed. The inserts were coated with 5 
µg of the extracellular matrix (ECM) glycoprotein fibronectin for 2 to 4 h and washed with 
HBSS, pH 7.4.  
Co-cultures were defined as ‘in-contact’ if two cell populations grown together, on either 
side of an insert, as the pore sizes were large enough to allow physical contact between the 
Outside (basolateral) chamber 
Transwell inserts  
8 µm pore size 
 
 
71 
cell population. For seeding in-contact co-cultures i.e. two different cell cultures seeded on 
either side of the insert and the large pores of the membrane allowed physical contact between 
cells (refer to Figure 2.2), the inserts were inverted and seeded on the basolateral side.  The 
inserts were incubated in an inverted position for 4 h to enable attachment of the cells, and 
then transferred to the culture plates and incubated for a further 48 h humidified incubator at 
37 ºC with 5 % CO2.  After 48 h, the endothelial cells were seeded in the apical inner chamber 
of the insert. Co-cultures were defined as ‘out of contact’ if there was no direct physical 
contact, for example one cell population on the transwell insert and the other seeded on the 
bottom of the well in the basolateral chamber. For seeding out of contact co-cultures (refer 
to Figure 2.2), the cells were seeded on the bottom of the well and incubated in a humidified 
incubator at 37 ºC with 5 % CO2. After 48 h, the endothelial cells were seeded on the apical 
side of the insert. All of the co-cultures were cultured in medium of respective cultures 
utilised, mixed at a ratio of 1:1. 
 For tri-cultures (refer to Figure 2.2), the cells were seeded on the basolateral side of the 
insert, with simultaneously seeding of cells in the bottom well, and both of them were 
incubated in a humidified incubator at 37 º C with 5 % CO2. After 48 h, the insert was placed 
in the well and the endothelial cells were seeded on the apical side of the insert. The tri-
cultures were cultured in medium of respective cultures mixed in a ratio of 1:1:1. (refer to 
Table 2.1 for list of media). After 24 h the mono, co- and tri-cultures were measured for their 
trans endothelial electrical resistance (TEER) using the EVOM-2 (Merck Millipore, Oxford, 
UK) across five location on the insert for each of the models every day for 15 days (refer to 
Section 2.9). Each model was set-up in triplicate to assess intra-assay variability and every 
experiment was repeated three times to assess inter-assay variability. The different set up of 
transwell models is shown in Figure 2.2. 
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a) Monoculture of HBMEC cells 
 
b) Co-cultures of HBMEC with HA (out of contact) 
 
 
 
 
c) Co-cultures of HBMEC with HA (in contact) 
 
 
 
  
Endothelial cells 
Astrocyte cells 
Astrocyte cells 
Endothelial cells 
Endothelial cells 
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d) Co-cultures of HBMEC with HBVP (out of contact) 
 
 
 
 
e) Co-cultures of HBMEC with HBVP (in contact) 
 
 
 
 
f) Tri-culture of HBMEC with HBVP (out of contact) and HA (in contact) 
 
 
 
 
Figure 2.2 A scheme of the proposed in vitro BBB transwell models. 
a) Monoculture of HBMEC cells b) Co-cultures of HBMEC with HA (out of contact) c) Co-cultures of HBMEC 
with HA (in contact) d) Co-cultures of HBMEC with HBVP (out of contact) e) Co-cultures of HBMEC with 
HBVP (in contact) f) Tri-culture of HBMEC with HBVP (out of contact) and HA (in contact). 
 
2.9.1 Alvetex perfusion BBB model 
The Alvetex perfusion model (Reinnervate, Durham, UK) comprises of a perfused plate with 
a peristaltic pump to maintain a shear flow of media on the cells growing in the three 
dimensional (3D) scaffold. The cells were seeded on a three-dimensional transwell scaffold, 
precoated in fibronectin, as previously described in Section 2.8; (Figure 2.2c and f), and then 
Endothelial cells 
Endothelial cells 
Pericyte cells 
Pericyte cells 
Pericyte cells 
  Astrocyte cells 
Endothelial cells 
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transferred into a perfusion plate. The plate was connected to inlet tubing (diameter 16 mm) 
and outlet tubing (diameter 25 mm) which were connected to a reservoir of media containing 
mixtures of culture media in equal proportion. Using a peristaltic pump (Watson-Marlow, 
Cornwall, UK), the pressure of the shear flow was set to 20 dyne/ cm2 and the flow was 
maintained for a period of 15 days. The shear flow was selected on the basis of literature 
review. The medium in the reservoir was changed every 5 days. The TEER was measured 
every day for a period 15 days and on the 15th day the cells from the transwell were retrieved 
by trypsinisation (see Section 2.3.2.2) and lysed for western blotting. The cell lysates were 
analysed for expression of the tight junction proteins occludin and claudin-5, efflux 
transporters ABCB1 and ABCG2 and drug metabolising enzymes CYP3A4 and CYP2D6.  
 
2.9.2 Electric Cell-substrate Impedance Sensing (ECIS) for BBB 
model 
ECIS® is a real-time, label-free, impedance-based method to study morphological changes, 
cell locomotion, and other behaviours directed by the cell cytoskeleton of cells grown in 
tissue culture (Applied Biophysics, Troy, USA). . The blood brain barrier models were set 
up using 8W10E+ arrays. Each well in the array was washed with 200 µl Hanks buffered salt 
solution pH 7.4 (HBSS) twice and incubated with 200 µl of 10 mM L-cysteine for 10 min at 
room temperature. The wells were washed with 200 µl HBSS and coated with 5 µg/ ml 
fibronectin and incubated for an hour at 37 ºC. After incubation, the wells were washed with 
HBSS twice and the cells (endothelial cells, astrocytes and pericytes) were seeded at a density 
25,000 cells/well. Cells grown up to 80% confluency in T75 flasks were passaged to seed for 
the ECIS. The cells were trypsinised and seeded in different culture combinations as shown 
in Table 2.5. The seeding density of endothelial cells in mono-culture was 75,000 cells/ well 
 
 
75 
and in the co- and tri- cultures were 50,000 cells/ well. The seeding density of astrocytes and 
pericytes in co-cultures was 25,000 cells/ well and in tri-cultures was 12,500 cells/ well. The 
ECIS machine measured the real-time changes in TEER over a period of 100 h.  
Table 2.5 The layout of the chip in the ECIS plate. E: endothelial cells, A: astrocytes, P: pericytes and ECM: 
extra cellular matrix. 
 
 
 
 
 
2.9.3 Cellzscope for BBB model 
Cellzscope (nanoAnalytics, Münster, Germany) measures the impedance of the co-cultures 
across the permeable inserts by means of electrical resistance measurements, complemented 
by recording the electric capacitance Ccl. The transwell models for Cellzscope were set up as 
described in Section 2.8. The transwell inserts were then moved to the 24 well array of the 
Cellzscope and real-time TEER readings were taken for 100 h. At the end of this time, the 
cells were removed from the insert, lysed using RIPA buffer and stored at -20 ºC for further 
analysis. 
 
With ECM: fibronectin 
E E+ A+ P 
E E+ A+ P 
E + A E+ P 
E+ A Control 
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2.10 Testing integrity of designed co-culture models 
2.10.1 Measurement of TEER 
The Millicell ERS-2 (Electrical Resistance System) is a meter and electrode system designed 
to reliably measure trans endothelial electrical resistance (TEER) of endothelial cells in 
culture. The electrode was sterilised with 70 % ethanol and air dried in the laminar hood for 
15 min. The electrode was then dipped in each well, with the shorter end on the apical side 
of the insert and the longer end touching the base of the well. The electrode was held at 90º 
to the cell culture plate until the TEER value on the meter stabilised. This was repeated five 
times in each well to find an accurate TEER value. An increase in TEER, detected with the 
electronic circuit of the Millicell ERS-2 meter and its electrode, is an indication of cell 
monolayer health and confluence. The values obtained from the Millicell ERS-2 were used 
to calculate the resistance of the unit area.  
Resistance = Resistance (Ω) × Effective Membrane Area (cm2) 
 
2.10.2 Permeability of FTIC dextran 
The mono-, co- and tri-culture models were set up and permeability was assessed using 1 
mg/ ml FITC-dextran (mol wt. 10,000) prepared in media. The media from the apical side of 
the transwell insert was removed and media containing FITC-dextran was introduced in the 
culture set up (Figure 2.3). 
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Figure 2.3 Diagrammatic representation of transwell insert used for permeability assay.  
The fluorescent tagged dextran was seeded on apical side and the media was samples on the basolateral side to 
measure the Papp of the model. 
The co-cultures were incubated in standard tissue culture conditions and at different time 
intervals (1 h, 2 h, 3 h,) the media from the basolateral side of the transwell insert was 
sampled. The fluorescence of the sampled media was read at excitation wavelength 492 nm 
and emission wavelength 518 nm on a Tecan GENios Pro® plate reader with the gain set at 
55 (Tecan, Theale, UK). The apparent permeability of each model was calculated using the 
formula (Borges-Walmsley et al., 2003) 
                         Papp =                1                 X                      dQ 
                                             A x C0                                                     dt 
 
where, A                  = surface area of the polycarbonate membrane (cm2)  
C0                     = concentration of the FITC-dextran on the apical side (µg/ml) 
           dQ/dt             = the amount of sodium fluorescein passing across the cell layer in a 
                                    defined time period (1 h, 2 h, 3 h)   
 
2.10.3 Permeability of nanoparticles (NPs) across the BBB 
models 
Various in vitro BBB models were tested for barrier function and permeability by addition 
of a short DNA oligonucleotide glioma selective aptamer, (prepared in house by C. L. 
Lawrence, L. Shaw and J.E. Alder) or nanoparticles (NPs) synthesised in house by Prof 
Kamalinder Singh and Dr Ka-Wai Wan. The lipid NPs were loaded with docetaxel, curcumin 
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or asiatic acid. The docetaxel loaded NPs were also tagged with rhodamine123 and 
transferrin ligand. 
2.10.3.1 Toxicity screening  
Prior to testing the paracellular permeability of aptamers and NPs across the tri-culture BBB 
model, the potential effect on cell proliferation and viability of the aptamer and NPs was 
determined by measuring the viability of endothelial cell lines following incubation with 
different concentration of aptamers, NPs and Evans Blue dye (control) all diluted in media 
using the CellTiter 96® AQueous One Solution Cell Proliferation Assay 3-(4,5-
Dimethylthiazol-2-yi)-5-(3-Carboxymethoxyphenyl)-2-(4-sulfophenyL)-2H-tetrazolium, 
inner salt assay (MTS assay).  
Table 2.6 List of NPs, aptamer and Evans blue concentration used for toxicity screening. 
Molecules Concentration of drug loaded in NP or aptamer 
Docetaxel loaded lipid nanoparticle with 
ligand transferrin  
3.3 µg/ml 0.33 µg/ml 0.033 µg/ml 
Docetaxel loaded lipid nanoparticle  3.3 µg/ml 0.33 µg/ml 0.033 µg/ml 
Curcumin loaded lipid nanoparticle 2.87 µg/ml 0.287 µg/ml 0.0287 µg/ml 
Empty lipid nanoparticle 1.2 µg/ml 0.12 µg/ml 0.012 µg/ml 
Asiatic acid loaded lipid nanoparticle 1.2 µg/ml 0.12 µg/ml 0.012 µg/ml 
SA43 Aptamer 100 nM 10 nM 1 nM 
Evans Blue 33.3 µg/ml 3.33 µg/ml 0.333 µg/ml 
The cell lines were trypsinised and seeded in 96-well microtitre plates at a density of 20,000 
cells/ well. The aptamer and NPs were prepared at varying concentrations and added to the 
cells as detailed in Table 2.6. Cells were incubated at 37 ºC, 5 % CO2 in a humidified 
incubator for 5 days, with an MTS assay performed in triplicate on day 0, 2, 3 and 5 to 
determine the anti-proliferative effects of the aptamer and NPs. On the day of the assay the 
 
 
79 
MTS was thawed on ice and 40 µl of MTS assay was added to the required wells, and the 
plate was incubated at 37 ºC, 5 % CO2 in a humidified incubator for 4 h. The plate was read 
for the absorbance at 492 nm wavelength on a Tecan GENios Pro® plate reader (Tecan, 
Theale, UK). The cell survival was calculated using the formula;  
Cell survival (%)   =                   Absorbance of treated cells x 100                  
                                    Absorbance of vehicle control group (untreated cells + solvent) 
2.10.3.2 Cellular uptake study 
Cellular uptake was assessed in tri culture model previously described in Section 2.9. The 
inserts were incubated and checked for their TEER values using EVOM each day, until they 
reached a peak and plateaued. On day 6, when the TEER values peaked, tri-culture barrier 
was incubated with Evans Blue Dye (EBD) to determine if the barrier formed is intact. The 
aptamer, NPs and control was used aptamer or NPs were introduced to the well and time 
dependent TEER measurements were taken. The TEER values were measured at 0.25 h, 0.5 
h, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h and 24 h. The concentration of NPs used for the cellular uptake 
studies were selected on the basis of their IC50 values calculated from the MTS assay (Table 
2.7). The concentration of aptamer was determined by studying the minimum detection limit 
of aptamer on the glioma cells (unpublished data) and concentration of the control Evans 
Blue Dye was adapted from book (Yuan and Rigor, 2011).  
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Table 2.7 List of NPs and their concentrations used for the cellular uptake studies. 
Nanoparticles Concentration 
Docetaxel loaded lipid nanoparticle with ligand transferrin tagged with 
rhodamine 
0.33 µg/ml 
Docetaxel loaded lipid nanoparticle tagged with rhodamine 0.33 µg/ml 
Curcumin loaded lipid nanoparticle 0.287 µg/ml 
Empty lipid nanoparticle 0.12 µg/ml 
Asiatic acid loaded lipid nanoparticle 0.12 µg/ml 
SA43 Aptamer 10 nM 
Evans Blue 3.33 µg/ml 
 
2.10.3.3 Co-localisation study 
Endothelial cells were seeded on coverslips at a density of 20,000 cells/ coverslip. Following 
attachment of the cells to the coverslip, the media in the wells was changed. The aptamer and 
NPs at the concentration mentioned in Table 2.7 were dissolved in the culture medium and 
added the mono-culture. After 24 h, the endothelial cells were fixed as described in section 
2.3.1 and immunostained as described in section 2.3.2. 
 
2.11 Brain tumour barrier 
The tri-culture model was set up, as described in Section 2.9, and short term cultures derived 
from patient biopsies of glioma, BTNW914 and BTNW370 were introduced to the barrier. 
The short term cultures were grown separately to spheroids by culturing on agar plates as 
described in Section 2.2.1.2. The spheroids were introduced in the basolateral side of the 
insert above the pericyte monolayer (Figure 2.4) of the insert. 
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Figure 2.4 Diagrammatic representation of brain tumour barrier 
A Tri-culture of HBMEC with HBVP (out of contact) and HA (in contact) and GBM spheroids laid over the 
pericytes. B Tri-culture of HBMEC with HBVP (out of contact) and HA (in contact) and GBM spheroids laid 
over the endothelial cells. 
 
2.11.1 TEER measurement  
The brain tumour model was studied for its TEER measurement for 10 days. The media was 
changed every three days of the BTB model. 
 
2.11.2 Permeability of NPs tested in BTB model. 
The NPs were also incubated in tri-culture GBM models with and without inhibitor for efflux 
transporters. Two μM of vinblastine was used was used as the efflux transporter inhibitor. 
After 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h and 3 h, at each time point the fluorescence of the spheroids 
were washed with 0.1 M PBS, pH 7.4 three times. The spheroids were sampled in 96 well 
plate and read under the plate reader for their fluorescence at excitation wavelength of 511 
nm and emission wavelength of 534 nm. The gain was set to 45 and the plates were read from 
the top to determine the fluorescence of the NPs. The activity was calculated as % 
fluorescence relative to the stock concentration of the NPs and then plotted. The following 
concentrations were used as described in Table 2.8.  
Pericyte cells 
Endothelial cells 
Astrocyte cells 
GBM spheroids 
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Table 2.8 Concentration of NPs used in the BTB model permeability studies. 
Nanoparticles Concentration 
Docetaxel loaded lipid nanoparticle with ligand transferrin tagged with 
rhodamine 
0.33 µg/ml 
Docetaxel loaded lipid nanoparticle tagged with rhodamine 0.33 µg/ml 
Curcumin loaded lipid nanoparticle 0.287 µg/ml 
 
2.12 Statistical Analyses 
All data were expressed as mean values ± standard deviation (mean ± SD) with n = 3 of 
triplicate experiments. Statistical analysis was carried out using the one way ANOVA with 
Bonferroni post-test analyses was performed. Probability values of p < 0.05 were considered 
statistically significant.  
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CHAPTER 3  
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 Characterisation of continuous and 
primary cell lines. 
3.1 Introduction  
Cell culture is a readily accessible tool for scientific research which includes testing new drug 
therapies and studying mechanism of diseases (Capes-Davis et al., 2010). Ensuring the cell 
lines used in experiments have a defined origin and are routinely screened for possible 
contamination is an essential criteria for researchers (Higgins et al., 2010). More recently, in 
some publications, the generation of erroneous and misleading results has been identified and 
was found to be due to cellular cross-contamination, misidentified cell lines, and the use of 
cultures at high-passage levels (Healey, 2010; Kaplan and Hukku, 1998), hence, initial 
characterisation of the cultures was a prerequisite for this research. 
 The aim of this chapter was to characterise the cell lines for origin and cell type (both human 
and glial) and to determine the exponential growth phase prior to use in downstream 
experiments. The cell lines comprised of human glioma 1321N1 and U87MG and human 
glial SVGp12, patient derived short term glioma cultures, including BTNW914 and 
BTNW370and short-term cultures derived from primary tissue, including human brain 
microvascular endothelial cell lines (HBMEC), human brain vascular pericytes (HBVP) and 
human cerebral astrocytes (HA). 
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3.2 Results 
3.2.1 Growth kinetics and morphology of continuous cell lines 
Growth curves were established to study the kinetics of cell line growth, namely to determine 
the duration of the initial lag phase, to estimate population doubling time during exponential 
growth, and finally the point of plateau phase where the cells became confluent and the 
growth rate slowed down. 
The glioma cell lines U87MG (Figure 3.1A) and 1321N1 (Figure 3.1B) showed exponential 
growth from day 3 to day 6 and from day 2 to day 8, respectively. The non-cancerous cell 
line SVGp12 (Figure 3.1C) and hCMEC/D3 (Figure 3.1D) showed an exponential growth 
phase from day 2 to day 6 and from day 2 to day 5. When comparing the growth 
characteristics of all cells, U87MG had a doubling time of 30.2 h whereas 1321N1 had the 
longest exponential phase and the highest cell count at the end of the experiment on day 10 
and a doubling time of 24.6 h. SVGp12 grew the slowest with a doubling time of 35.7 h, and 
had the smallest mean cell count at day 10. hCMEC/D3 grew the fastest with a doubling time 
of 20.4 h, and had the smallest mean cell count at day 10  
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Figure 3.1 Growth analysis of human cell lines. 
A. U87MG, grade IV glioma cell line. B. 1321N1, grade II glioma cell line. C. SVGp12, non-cancerous foetal 
glial cell line. D. hCMEC/D3, endothelial cell line. The data points are means of three replicates (n=3) and the 
error bars represent ± standard deviation (±SD) of three inter--experimental repeats. The exponential phase is 
reached on the day 3 for the U87MG, day 2 for the 1321N1, day 2 for the SVGp12 and on day 2 for hCMEC/D3 
cell lines. The plateau phase is reached from the day 6 for the U87MG cell line, day 8 for the 1321N1 cell line, 
day 6 for SVGp12 and on day 5 for hCMEC/D3 cell lines.  
A 
C 
B 
D 
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The morphology of U87MG, 1321N1 and SVGp12 was observed under a light microscope 
during the study of growth patterns at 10 X magnification. As seen in Figure 3.1, on day 3 
the adherent cell lines showed elongated cell processes (Figure 3.2A). 
 
 
 
 
Figure 3.2 Light microscopy images of cells on day 3 of growth. 
A U87MG, grade IV glioblastoma cell line. B 1321N1, grade II glioma cell line. C SVGp12, foetal glial 
astrocyte cell line. The scale bar represents 20 µm. 
 
 
3.2.2 Growth kinetics and morphology of short-term cultures 
Growth characteristics of short-term cultures derived from primary tissue (HBMEC, HBVP 
and HA) were studied in cells with a passage number between P2 to P10.  The HBMEC 
showed exponential growth between day 3 and day 6 (Figure 3.3A) and had plateaued by day 
9. The HBVP showed an exponential growth phase from day 2 to day 6 (Figure 3.3B). The 
HA showed exponential growth between day 3 to day 7 (Figure 3.3C). A comparison of all 
short-term cultures together (Figure 3.3D) showed that endothelial cells and astrocytes had 
similar growth kinetics with a doubling time of 51.7 h and 52.3 h respectively, whereas 
pericytes showed the fastest growth and highest cell number at day 10, with a doubling time 
of 24.6 h. A growth kinetic experiment was conducted for the BTNW short-term glioma 
cultures, however it was not possible to continue the experiment as growth was so slow, and 
slowed down further with increase in passage number this estimated to be a doubling time of 
9 days. 
A C B 
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Figure 3.3 Growth analysis of primary cultures. 
 A. HBMEC, human brain microvascular endothelial cells. B. HBVP, human brain vascular pericytes. C. HA, 
Human astrocyte. D. Merge of growth curves of all the human primary cultures. The exponential phase is 
reached on the day 3 for the HBMEC, day 2 for the HBVP, and on the day 3 for the HA cell lines while the 
plateau phase is reached from the day 7 for the HBMEC cell line, day 7 for the HBVP cell line and day 7 for 
HA cell lines. The data points are means of three replicates (n=3) and the error bars represent ± standard 
deviation (±SD) of three inter experimental repeats. 
  
A 
C 
B 
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As seen in Figure 3.3A, on day 5 the endothelial cells HBMEC showed closely opposed 
cobblestone or spindle shaped morphology. The astrocytes HA showed fibroblastic 
morphology with many elongated processes arising from each cell (Figure 3.4B). The pericytes 
HBVP were observed as thin cells with elongated processes rising from each cell (Figure 
3.4C). 
 
 
 
 
Figure 3.4 Light microscopy images of cells on day 5 of the exponential phase of growth. 
A. Human brain microvascular endothelial cells (HBMEC). B. Human astrocyte (HA) C. Human brain vascular 
pericyte cells (HBVP). The scale bar represents 50 µm.  
 
3.2.3 Characterisation by immunocytochemistry 
3.2.3.1 Characterisation of cell lines 
The cell lines, U87MG, 1321N1 and SVGp12 were characterised using a panel of antibodies 
raised against human leukocyte antigen (HLA) and glial fibrillary acidic protein (GFAP) to 
confirm expression of antigens specific for cells of glial and human origin. All cell lines 
expressed GFAP and HLA (Figure 3.5), thus characterising the cells as glial and human 
origin. An isotype control was used as a negative control since it has no specificity for a 
target cell yet retains all the non-specific characteristics of the antibodies (Howat et al., 
2014). GFAP staining was found to be located in the cytoplasm as seen in Figure 3.5 (A, E 
& I). HLA staining was found to be cytoplasmic Figure 3.5 (B, F & J).
C B A 
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Figure 3.5 Fluorescence staining of cell lines for GFAP and HLA. 
 A-D. 1321N1 cell lines, E-H. U87MG cell line and I-L. SVGp12 cell line. All cell lines expressed GFAP (green) (A, E, and I) and. HLA (green) (B, F and J) The isotype 
control was a rabbit IgG primary antibody (C, H, and L) and a no antibody control was also used (D, H and L). All cells were counterstained with the nuclear fluorescent 
dye DAPI (blue). The scale bar represents 50 µm. 
Isotype control 
1321N1 
U87MG 
SVGp12 
GFAP HLA Control 
A B C  D 
E  F  G  H 
I  L  K  J 
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3.2.3.2 Characterisation of short term cultures  
In this study the heterogeneous short term cultures derived from glioma patients were 
characterised to determine the predominant cell population. The patient derived short term 
cultures were defined as low passage between P2 to P4, mid-passage between P5 to P8 and 
high passage between P9 to P13. GFAP was used as a marker for glial cells, CD44 as a 
marker for endothelial cells and epithelial membrane antigen (EMA) as a marker for 
meningioma. EMA was included as a negative control for the purpose of confirming the 
diagnosis of the BTNW cultures as being glioma and not meningioma. All characterisation 
was done using a biotinylated secondary antibody detected by DAB staining and all cells 
were counter stained by haematoxylin and eosin.  
The BTNW914 culture at passage 3 showed a heterogeneous cell population and expressed 
both GFAP and CD44, but not EMA (Figure 3.6 A-E). At mid passage 7, the cells showed 
dark brown staining for GFAP, indicating a high level of expression and faint brown stain 
for CD44, whereas no staining was observed for EMA (Figure 3.6 F-J). At passage 12, the 
cells showed faint staining for GFAP and no staining for both CD44 and EMA (Figure 3.6 
K-O). The cells did not show any staining in the isotype or no antibody control at any of the 
passages.  
The BTNW370 at passage 3 showed expression of GFAP, very faint staining for CD44, but 
no staining for EMA indicating that the cells show characteristics of glial cells and 
endothelial cell marker but no expression for meningioma cell marker (Figure 3.7 A-E). At 
passage 7 the cells showed dark brown staining for GFAP and no staining for CD44 or EMA 
(Figure 3.7 F-J). The BTNW370 short term culture showed a loss of expression endothelial 
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cell marker from low passage 3 to mid passage 7. At passage 12, the cells showed faint 
staining for GFAP and no staining for both CD44 and EMA (Figure 3.7 K-O).  
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Figure 3.6 DAB staining of patient derived short term culture BTNW914. 
Cells stained with GFAP, EMA and CD44 at early passage (P3) (A-E), mid passage (P7) (F to J) and late passage number (P12) (K to O). The isotype control was a rabbit 
IgG primary antibody (D, I, and N) and a no antibody control stain (E, J and O). All cells were counterstained with haematoxylin eosin. The expression of GFAP (A, F & 
K) and CD44 (B, G & L) decreases with increase in passage number the highest expression was seen at low passage (A & B respectively). The cells did not show expression 
of EMA (C, H & M). The scale bar represents 50 µm. 
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Figure 3.7 DAB staining of patient derived short term culture BTNW370.  
Cells stained with GFAP, EMA and CD44 at early passage (P3) (A-E), mid passage (P7) (F to J) and late passage number (P12) (K to O). The isotype control was a 
rabbit IgG primary antibody (D, I, and N) and a no antibody control stain (E, J and O). All cells were counterstained with haematoxylin eosin. The expression of GFAP 
(A, F & K) decreases with increase in passage number the highest expression was seen at low passage (A). The cells did not show expression of CD44 (B, G & L) EMA 
(C, H & M).  The scale bar represents 50 µm.
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3.3 Discussion and conclusion 
The study of the growth pattern of cell lines prior to performing experiments is essential to 
determine various growth characteristics which contribute to the experimental planning. The 
growth curve provides information regarding the cell number for seeding and the time at 
which lag phase is reached. Typical cell growth shows three phases: 1) a lag phase, which 
denotes time required by the cell population to recover from subculture, attach and multiply; 
2) the log phase which represents the phase in which the cell numbers begin to proliferate 
exponentially, and 3) a second lag phase or the plateau phase in which the cell culture 
becomes confluent and the growth rate slows down or stops and the curve looks like a plateau 
when plotted on a graph (Mather and Roberts, 1998).  
The early exponential growth phase of cell was therefore selected as the optimal time point 
for all experiments to be conducted since protein expression and function is a key end point 
required to meet the aims of this thesis, as protein expression and function needs be measured 
in healthy dividing cells (Schauble et al., 2012). Various factors such as nutrient level, 
attachment factors and mitogens can influence the exponential phase of growth of cells. The 
cells when in the plateau lag phase undergo senescence which is biological aging; a phase 
between cell maturity and cell death (Vulic and Kolter, 2002). The plateau phase changes the 
cellular, molecular structure and metabolism phenotype, therefore considering drug 
metabolising enzyme, transporter and tight junction protein expression and function is 
essential to this study, investigations in the plateau phase needed to be avoided. For all the 
cell lines investigated, the lag phase was complete by day 3 when seeded at 2 x104 cells/ ml 
on day 0, therefore to ensure cells were in the early exponential growth phase for 
experiments, they were used after 3 days, or alternatively for culture set ups that required 
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longer incubations times (Section 5.2), a lower seeding density was used at day 0, again to 
ensure experiments were conducted during the exponential phase of growth.  The doubling 
times of commercially available cell lines were compared to the literature, and where 
available, were found to be in agreement with published values. U87MG and 1321N1 have 
previously been reported to have a doubling time of 34 h and 22 h respectively, which was 
in close agreement the values presented here of 30.2 h and 24.6 h (Daeke et al., 2000; Kin et 
al., 2012). For the short-term cultures, doubling times were slower compared to the 
immortalised cell lines, which was expected as the cell lines carry a mutation for indefinite 
growth, thereby avoiding senescence. For HBMEC, values were reported in the literature 
between 48 and 72 h, and for HA 48.9 h, which was in agreement of the values determined 
in this study of 51.7 h and 52.3 h. No doubling times were available for comparison for 
SVGp12 and pericytes.   
Confirmation of cell line origin and its characteristics is imperative before using cell lines in 
experiments for reliability in reporting experimental results to other researchers (Lucey et 
al., 2009). Lately, there has been an emphasis on the importance of confirming the origin and 
type of cultured cells used for research. Macleod et al., (1999) described that 45 of 252 human 
cell lines (18 %) supplied by 27 of 93 originators (29 %) were contaminated with different 
cell types due improper culturing practice (MacLeod et al., 1999; Rojas, 2011). The glial 
fibrillary acidic protein (GFAP), is a protein expressed by the astrocytes and is involved in 
the maintenance of structure and functions of the cytoskeleton (Gomes et al., 1999). A 
number of studies have reported that the neural stem cells, astrocytes and astroglial tumours 
express GFAP as a major filament protein (Ignatova et al., 2002; Gomes et al., 1999; Jung et 
al., 2007a), therefore, GFAP can be used as a cell marker for astrocytes and for the 
characterisation of continuous cell lines and short term cultures. All cells of glial origin 
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(U87MG, 1321N1, SVGp12, BTNW and HA) used in the current study were found to express 
GFAP in the cytoplasm and therefore were considered appropriate to use in the culture model.   
The human leukocyte antigen (HLA), is a protein expressed by cells of human origin. It is 
used as a marker for cells to characterise their origin species and helps in prediction of cross 
contamination between cell lines of different species (Braun et al., 2000). All cells utilised 
in this thesis were found to express HLA and were therefore confirmed as species appropriate 
for the study. Interestingly, HLA is normally found to be expressed as a cell surface antigen, 
however in the cell lines, the staining appeared to be cytoplasmic. 
The culturing of patient derived cells could serve as a patient-specific approach to optimise 
an individually-designed cancer therapy (Hass and Bertram, 2009). To utilise short-term 
cultures as tools for cancer research, it is essential to characterise the properties and cell type 
since these tumours are most likely to be heterogeneous (Rojas, 2011). For glioma short term 
cultures, GFAP, CD44 and EMA can used to characterise the cell population in the culture. 
CD44 is cell surface marker for endothelial cells; it modulates the proliferation and apoptosis 
of microvascular endothelial cells (Tsuneki and Madri, 2014). Epithelial membrane antigen 
(EMA) is a widely used marker to identify meningioma cells (Theaker et al., 1986). EMA 
normally acts as barrier to apical surface of the membrane of epithelial cells, playing a 
protective and regulatory role. In low grade meningioma, the cells show overexpression. 
EMA which is supposed to play an important role during invasion and metastasis due to 
reduced cell adhesion (Langner et al., 2003). Culturing cells from primary tumours for use 
in studying cancer cells can be difficult to establish because of the slow growing nature 
(Wenger et al., 2004). For this reason, it is often recommended to use low passage numbers 
less than P10 (Esquenet et al., 1997) as often at passage numbers greater than this cells 
become quiescent and start to dedifferentiate. The most important factor contributing to the 
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morphology and characteristics of the cell is the passage number (Hughes et al., 2007). There 
is no straight method for determining the passage number or age of the adherent cells; the 
stocks of these cell lines which are maintained in laboratories may also differ (Esquenet et 
al., 1997). The impact of a passage number of the cells on any given cell line is complex and 
dependent on several factors including the tissue and species of origin, the culture conditions, 
and the application for which the cells are used (Hughes et al., 2007; Wenger et al., 2004; 
Vierck and Dodson, 2000). To determine the effects of passage number on cell phenotype, 
the aforementioned phenotypic markers GFAP, CD44 and EMA were investigated at defined 
time points of low passage (P3), mid-passage (P7) and high-passage (P12). 
The absence of expression of EMA in BTNW914 and BTNW370 at low, mid or high passage 
number indicated that the short term culture was derived from biopsy of a glioma patient and 
not meningioma patient. The expression of GFAP at low and mid passage number was high, 
compared to the expression at high passage, indicating that by passage 12, the cells were 
beginning to lose the glial phenotype. The expression of CD44, endothelial cell marker 
showed a decrease in the expression from low to high passage number. As the passage 
number increased, the short term culture BTNW914 showed a decrease in characteristic 
properties. The short term culture derived from patient biopsies showed a decrease in the 
expression of antigens, GFAP and HLA with increase in passage number. These results 
confirmed that for all future experiments the short-term patient derived glioma cultures 
should only be used up until P7, as after this, the cells showed reduced phenotypic expression 
of characteristic markers.  
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In summary, the characterisation confirmed the origin and type of cell to be used for the 
experiments. The growth patterns of the cells provided information about proliferation rate 
of the cells and doubling time of the cell population. The growth curves were used to 
determine the seeding densities of the cells in future experiments. The characterisation data 
confirms the suitability of the cell lines and the short term cultures to be used in the 
development of a physiologically relevant BBB model.  
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CHAPTER 4 
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 Characterisation of drug metabolising 
enzymes and transporters expression and 
activity. 
4.1 Introduction 
The poor prognosis of glioma is largely attributed to the lack of effective treatment regimes, 
and the major hurdle for treatment is the poor bioavailability of the drug at the site of the 
tumour. There has been an emerging understanding  that poor bio-availability can be due to 
transporters effluxing the drug out of the cells (Begley, 2004), and the presence of drug 
metabolising enzymes (DMEs), which serves as a metabolic barrier decreasing 
bioavailability at the tumour site (Nebert et al., 2013; Löscher and Potschka, 2005).  
In this chapter, we studied the expression profiles of the efflux transporters, ABCB1 and 
ABCG2, and the drug metabolising enzymes, CYP3A4 and CYP2D6, in cell lines, primary 
cultures and short term cultures. The aim of these experiments was to fully characterise the 
optimal experimental conditions required to give the highest possible protein expression and 
activity levels comparable to those observed in vivo and to determine which cell lines were 
most suitable to be taken forward to the next stage of BBB model validation in Chapter 5. 
The expression of these proteins was studied under standard and altered culturing conditions 
including: human serum or foetal bovine serum (FBS), culturing cells in the presence of 
different extracellular matrices such as fibronectin, poly-L-lysine and MaxGel and protein 
expression and activity profiles in cell lines, primary cultures and short term cultures. 
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4.2 Results 
The expression of the efflux transporters and DMEs was assessed by extracting protein from 
cultured cells. Various different protein extraction protocols were used to optimise the 
extraction methods yielding maximum protein concentration required to study expression of 
proteins of interest. 
 
4.2.1 Protein linearity experiment 
Protein was extracted by method I from the U87MG, 1321N1 and SVGp12 cells in the 
exponential growth phase (day 3 to day 7), which was determined by their respective growth 
curves (see Section 3.2.2).  The extracted protein was quantified by Bradford assay in a 96 
well plate and the absorbance was read at 595 nm wavelength. The day on which the 
maximum protein yield was reached was selected to study the protein expression profiles in 
the cell lines. As seen in Figure 4.1, the concentration of protein showed a linear increase 
with respect to time up to day 5 in 1312N1 cell line and up to day 6 in U87MG and SVGp12 
cell lines. The concentration of extracted proteins started to plateau on day 7 for all the three 
cell lines at concentration of 2.16 mg/ml in 1321N1, 2.06 mg/ml in U87MG and 1.51 mg/ml 
in SVGp12. The protein concentration and cell number showed a linear relationship (data not 
shown). 
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Figure 4.1 Concentration of protein extracted with respect to time in the exponential growth phase of cell lines. 
The data points are means of three replicates (n=3) and the error bars represent ± standard deviation (±SD) of 
three inter repeats of an experiment. 
 
4.2.2 Protein extraction method optimisation 
From the previous experiment, it was concluded that cells in exponential growth phase gave 
the highest protein concentration. It was essential to lyse cells and to solubilise and extract 
protein in the intact (non-degraded) form, so that immunoreactivity was retained to study 
protein expression by immunoblotting. Different methods for protein extraction (see Section 
2.3.2.1- 2.3.2.4) were used to maximise the protein yield. The total protein content extracted 
included both intracellular and surface proteins. The concentration of the protein from cell 
samples was extrapolated from a standard linear plot of absorbance versus known bovine 
serum albumin (BSA) concentration at 612 nm to determined using the Bradford assay.   
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The extraction of protein by Method I, which involved scraping U87MG, 1321N1 and 
SVGp12 cells from the flask followed by cell lysis (see Section 2.3.2.1) (Figure 4.2). The 
concentration of U87MG, 1321N1 and SVGp12 was 1.02 mg/ml, 1.37 mg/ml and 0.84 mg/ml 
respectively.  
 
Figure 4.2 Standard linear plot of BSA (mg/mL) vs. absorbance at 612 nm. 
This plot was used to calculate protein concentration after method I extraction protocol (see Section 2.3.2.1). 
The absorbance values were interpolated to determine the unknown protein concentration. These data points 
are representative of three replicates (n=3) and the error bars represent mean ± standard deviation (±SD) of 
three inter-experimental repeats. 
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The extraction of protein by Method II involved trypsinising cells from the flask followed by 
cell lysis (see Section 2.3.2.2). As seen in Figure 4.3, the concentration of U87MG, 1321N1 
and SVGp12 was 1.06 mg/ml, 1.40 mg/ml and 0.704 mg/ml respectively. 
 
 
 
Figure 4.3 Standard linear plot of BSA (mg/mL) vs. absorbance at 612 nm. 
This plot was used to calculate protein concentration after method II extraction protocol (see Section 2.3.2.2). 
The absorbance values were interpolated to determine the unknown protein concentration. These data points 
are representative of three replicates (n=3) and the error bars represent mean ± standard deviation (±SD) of 
three inter-experimental repeats. 
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The extraction of protein by Method III involved spinning U87MG, 1321N1 and SVGp12 
cells at a lower speed following lysis using RIPA buffer (see Section 2.3.2.3). As seen in 
Figure 4.4, the concentration of U87MG, 1321N1 and SVGp12 was 0.83 mg/ml, 0.67 mg/ml 
and 0.40 mg/ml respectively. 
 
 
 
Figure 4.4 Standard linear plot of BSA (mg/mL) vs. absorbance at 612 nm. 
This plot was used to calculate protein concentration after method III extraction protocol (see Section 2.3.2.3). 
The absorbance values were interpolated to determine the unknown protein concentration. These data points 
are representative of three replicates (n=3) and the error bars represent mean ± standard deviation (±SD) of 
three inter-experimental repeats. 
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The extraction of protein by Method IV involved sonication of U87MG, 1321N1 and 
SVGp12 cells to facilitate lysis (see Section 2.3.2.4). As seen in Figure 4.5, the concentration 
of U87MG, 1321N1 and SVGp12 was 0.45 mg/ml, 0.27 mg/ml and 0.4 mg/ml respectively. 
 
 
Figure 4.5 Standard linear plot of BSA (mg/mL) vs. absorbance at 612 nm. 
This plot was used to calculate protein concentration after method IV extraction protocol (see Section 2.3.2.4). 
The absorbance values were interpolated to determine the unknown protein concentration. These data points 
are representative of three replicates (n=3) and the error bars represent mean ± standard deviation (±SD) of 
three inter-experimental repeats. 
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 A summary of highest protein yielded from each protocol is shown in Table 4.1. SVGp12 
and 1321N1 showed maximum yields of protein of 0.84 mg/ml and 1.37 mg/ml respectively 
using method I for extraction, which involves scraping of cells from culture dishes. U87MG 
showed maximum recovery of protein of 1.4 mg/ml for method II which involved 
trypsinising cells from culture dishes and showed concentration of 1.37 mg/ml with method 
I (scraping cells). Method III and method IV both showed low concentration of protein, 
hence, it was concluded that method I yields the optimal yield of protein most cells and was 
therefore used for all the subsequent experiments. Method I was preferable to method II 
because it involved scraping cells on ice which minimised protein degradation. 
Table 4.1 Summary of the protein concentration of cell lines using different extraction protocol. 
Protocol used Method I Method II Method III Method IV 
Protein 
extracted 
(mg/ml) 
U87MG 1.02 1.06 0.83 0.45 
1321N1 1.37 1.4 0.67 0.27 
SVGp12 0.84 0.70 0.4 0.43 
 
The optimised extraction protocol method I was also used to extract proteins from all short 
term cultures derived from primary cells.   
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4.2.3 Protein expression profile for different cell lines 
4.2.3.1 Protein expression profile in standard tissue culture conditions 
The extracted proteins were studied for the expression of the drug metabolising enzymes, 
CYP3A4 and CYP2D6, and the efflux transporters, ABCB1 and ABCG2. Protein was 
extracted from cancerous cell line (U87MG, 1321N1), glial cells (SVGp12, HA), endothelial 
cells (hCMEC/D3, HBMEC), pericytes (HBVP) and patient derived short term cultures 
(BTNW914 and BTNW370), grown in T75 flasks as a monolayer. All the Western blots 
shown in this Chapter were normalised by quantifying the protein concentration by Bradford 
assay and loading each well with an equal amount of protein. In addition, the expression of 
β-actin was used as the loading control for all Westerns by normalising densitometry 
measurements for proteins of interest relative to β-actin. All of the densitometry results from 
Western immunoblots were compared relative to per cent expression of CYP in the 
bactosomes or relative to per cent expression of rat liver lysate (RLL) for the transporter. 
Bactosomes were used as the positive control as they contain overexpressed human 
cytochrome P450 gene in a bacterial membrane. All positive controls were defined as 100 % 
and expression was shown relative to this. 
As seen in Figure 4.6, all the cultures showed the expression of the CYP3A4. The highest 
expression confirmed by densitometry analysis was seen in HBMEC short-term cultures (106 
%) and the lowest expression was observed for SVGp12 (9 %), and the short term glioma 
culturesBTNW914 (22 %) and BTNW370 (19 %) (Figure 4.7). In the immortalised cell lines, 
the highest expression was shown by the 1321N1 cell line (64 %).  
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Figure 4.6 Western blots showing expression of CYP3A4 (57 kDa).  
Expression was studied in immortalised cell lines and short term cultures. β-actin was used as the loading 
control. Each well was loaded with 20 µg of protein. 
  
 
 
Figure 4.7 Densitometry analysis of the blots showing expression of CYP3A4. 
The data is plotted per cent relative to the expression of the enzyme in positive control human CYP3A4 
bactosomes. These data points are representative of three replicates (n=3) and the error bars represent mean ± 
standard deviation (±SD) of three inter-experimental repeats. * p < 0.05 was considered to be statistically 
significant. 
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The expression of CYP2D6 enzyme in all of the different immortalised and short term 
cultures (Figure 4.8) was determined by Western blot. All of the results were reported relative 
to per cent expression of rat liver lysate (RLL) (defined as 100 %). All the cultures showed 
expression of the CYP2D6. The highest expression was seen in HBMEC primary cultures 
(117 %) and the lowest expression was observed in SVGp12 (16 %) and the, short term 
cultures BTNW914 (59 %) and BTNW370 (61 %). From the cell lines, the highest expression 
was shown by the 1321N1 cell line (56 %) (Figure 4.9).  
 
 
 
 
 
 
 
 
 
Figure 4.8 Western blots showing expression of CYP2D6 (57 kDa).  
Expression was studied in immortalised cell lines and short term cultures. β-actin was used as the loading 
control. Each well was loaded with 20 µg of protein. 
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Figure 4.9 Densitometry analysis of the blots showing expression of CYP2D6. 
The data is plotted per cent relative to the expression of the positive control CYP2D6 in bactosomes. These data 
points are representative of three replicates (n=3) and the error bars represent mean ± standard deviation (±SD) 
of three inter-experimental repeats. * p < 0.05 was considered to be statistically significant. 
 
The expression of ABCB1 efflux transporters in all immortalised and short term cultures 
(Figure 4.10) was determined by Western immunoblotting and expression was semi-
quantified by densitometry. All of the results were reported relative to per cent expression of 
rat liver lysate (RLL) (defined as 100 %) which was used as the positive control since the 
liver shows high expression of the ABCB1 efflux transporter. All of the cultures showed 
expression of the ABCB1 transporter. The highest expression, confirmed by densitometry, 
was seen in HBMEC primary cultures (98 %) and the lowest expression was observed in 
short term cultures BTNW914 (21 %) and BTNW370 (18 %) and the immortalised cell line 
1321N1 (17 %). From the cell lines, the highest expression was shown by the foetal glial 
astrocytes SVGp12 (64 %) (Figure 4.11).  
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Figure 4.10 Western blots showing expression of ABCB1 efflux transporter (170 kDa).  
Expression was studied in immortalised cell lines and short term cultures relative to the positive control rat liver 
lysate (RLL). β-actin was used as the loading control. Each well was loaded with 20 µg of protein. 
 
 
Figure 4.11 Densitometry analysis of the blots showing semi-quantitation of the ABCB1 efflux transporter. 
The data is plotted per cent relative to the expression of the transporter in rat liver lysate. These data points are 
representative of three replicates (n=3) and the error bars represent mean ± standard deviation (±SD) of three 
inter- experimental repeats * p < 0.05 was considered to be statistically significant. 
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The expression of ABCG2 efflux transporter in immortalised and short term cultures (Figure 
4.12) was determined by Western blot. The RLL was used the positive control since the liver 
shows high expression of the ABCG2 efflux transporter. All the cultures showed expression 
of the ABCG2 transporters. The highest expression from the mean of three gels, confirmed 
by densitometry analysis, was seen in HBMEC primary cultures (81 %) and the lowest 
expression was seen in the hCMEC/D3 cell line (38 %). For the cell lines, the highest 
expression was shown by U87MG (57 %) (Figure 4.13).  
 
 
 
 
 
 
 
Figure 4.12 Western blots showing expression of ABCG2 efflux transporter (72 kDa).  
Expression was studied in immortalised cell lines, and short term cultures relative to the positive control rat 
liver lysate (RLL). Each well was loaded with 20 µg of protein. 
 
  
ABCG2 
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Figure 4.13 Densitometry analysis of the blots showing expression of ABCG2 efflux transporter. 
The data is plotted as per cent relative to the expression of the enzyme in rat liver lysate control. These data 
points are representative of three replicates (n=3) and the error bars represent mean ± standard deviation (±SD) 
of three inter-experimental repeats * p < 0.05 was considered to be statistically significant. 
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In summary, the expression of efflux transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 
and CYP2D6 were determined by Western blot in cell lines and short term cultures. The 
short-term cultures that were to be used to construct the in vitro BBB; HBMEC, HBVP and 
HA showed higher expression of ABCB1, ABCG2 and CYP3A4, CYP2D6 compared to the 
immortalised endothelial cell line hCMEC/D3 and the immortalised glial cell line SVGp12. 
When comparing the immortalised glioma cell lines (1321N1 and U87MG) to the short-term 
patient derived glioma cell lines, the results were not as clear. CYP3A4 expression was 
higher in the immortalised glioma cell lines compared to short-term cultures, whereas 
CYP2D6 and ABCB1 was higher in short-term glioma cultures compared to the immortalised 
cell lines. There was no significant difference between cultures for ABCG2.    
4.2.3.2 Effect of altered culture condition on protein expression profile. 
The HA, HBVP and HBMEC short-term cultures showed high expression of the efflux 
transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and CYP2D6 (Section 4.2.3.1), they 
were therefore taken forward to the next stage of the study, to determine whether altering 
experimental condition could enhance the protein expression further. In standard 
experimental conditions the short-term cultures were grown in 10 % FBS without ECM. The 
altered experimental conditions involved culture in 5 % HS without ECM, and in the presence 
of ECM; MaxGel, poly-L-lysine or fibronectin. These optimised conditions were then used 
to develop the in vitro BBB model. This data laid the foundation of developing a 
physiologically relevant model. All data was plotted as per cent protein expression relative 
to expression in standard culturing conditions, which was set at 100 %. 
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As seen in Figure 4.14, the cells cultured in human serum, compared to cells grown under 
standard conditions, showed little difference in the expression of ABCG2, CYP3A4 and 
CYP2D6. The expression was quantified by densitometry to confirm this. The cells cultured 
in fibronectin showed the highest expression  of both efflux transporters; ABCB1 and ABCG2 
and DMEs; CYP3A4 and CYP2D6.  
 
Figure 4.14 Expression of the efflux transporters and drug metabolising enzymes in HA (human astrocyte) in 
different culturing conditions.  
A. Expression of ABCB1 efflux transporter. B. Expression of ABCG2 efflux transporter. C Expression of 
CYP3A4 enzyme. D. Expression of CYP2D6 enzyme. E. Expression of β-actin in all the models, β-actin was 
used as the loading control. Each well was loaded with 10 µg of protein.  
A 
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As seen in Figure 4.15A, the expression of ABCG2 was semi-quantified by densitometry. 
Cells cultured in the presence of fibronectin showed the highest ABCG2 expression, an 
increase to 867% compared to the standard culture conditions whereas poly-L-lysine and 
MaxGel™ showed an expression of 796 % and 209 %, respectively. The cells, cultured in 
human serum, increased the expression of ABCG2 transporter to 187 % compared to 
expression in standard culturing condition. As seen in Figure 4.15 B, the expression of 
ABCB1 increased to 715 % when cultured on fibronectin, compared to the standard culturing 
conditions. The other ECM, poly-L-lysine or MaxGel™, showed an increase of 510 % and 
508 % respectively. The cells cultured in human serum showed an increase to 270 % in the 
expression of ABCB1 when compared to expression in standard culturing condition. 
As seen in Figure 4.15 C, the expression of CYP3A4 was highest when the cells were 
cultured in fibronectin, and the lowest when the cells were cultured in poly-L-lysine. The 
expression of CYP3A4 increased to 114 % in fibronectin and 109 % in MaxGel™ and 
decreased to 73 % in poly-L-lysine when compared to expression in standard culturing 
condition. When the cells were grown in human serum, the expression of CYP3A4 showed 
a slight increase to 104 % when compared to cells cultured in FBS. As seen in Figure 4.15 
D, the CYP2D6 enzyme expression was highest when the cells were cultured with 
fibronectin. The expression increased to 124% in fibronectin and 111 % in poly-L-lysine. 
The expression of CYP3A4 showed a decrease to 57 % in cells which were cultured with 
MaxGel™ as the ECM. The CYP3A4 expression increased to 115 % when the cells were 
grown on to human serum. 
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Figure 4.15 Densitometry analysis of the blots showing expression of efflux transporters and DMEs in HA cells. 
A. Expression of ABCG2, B. Expression of ABCB1, C. Expression of CYP3A4 and D. Expression of CYP2D6. 
The data is plotted as per cent relative to the expression of proteins in standard culturing conditions i (10 % 
FBS and no ECM). The error bars represent mean ± standard deviation (±SD) of three measurements of each 
band. * p < 0.05 was considered to be statistically significant. 
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As seen in Figure 4.17, expression of efflux transporters; ABCB1 and ABCG2 and DMEs; 
CYP3A4 and CYP2D6 in HBVP were assessed in various culturing conditions. The HBVP 
cultured in human serum compared to cells grown in standard culturing conditions (10 % 
FBS, no ECM) did not show a significant difference in the protein expression. The pericytes 
cultured in fibronectin showed the highest expression of both efflux transporters and DMEs. 
This is explained in details with the densitometry analysis which is expressed as per cent 
expression relative to standard culturing conditions (Figure 4.16).  
 
Figure 4.16 Expression of the efflux transporters and drug metabolising enzymes in HBVP (pericyte cells) in 
various culturing conditions.  
A. Expression of ABCB1 efflux transporter. B. Expression of ABCG2 efflux transporter. C; Expression of 
CYP3A4 enzyme. D. Expression of CYP2D6 enzyme. E. Expression of β-actin in all the models, β-actin was 
used as the loading control. Each well was loaded with 10 µg of protein. 
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The protein expression was semi quantified by densitometry, the expression of ABCG2 was 
highest when the cells were cultured in the presence of fibronectin. As seen in Figure 4.17 
A, the expression increased to 281% when compared to the standard culturing conditions. 
MaxGel™ showed an increase to 257 % and poly-L-lysine showed a decrease in expression 
to 67 % in comparison to standard culturing conditions. The cells grown in human serum 
showed a decrease in the expression of ABCG2 to 52 %. As seen in Figure 4.17  B, the 
expression of ABCB1 was highest in cells cultured in the presence of fibronectin. The cells 
grown in fibronectin showed an increase to 194 % compared to the other ECM which showed 
an increase in expression to 222 % in MaxGel and a decrease in expression to 24 % in poly-
L-lysine. The cells, when weaned on to human serum, showed decreased expression of the 
ABCB1 transporter to 37 %. 
As seen in Figure 4.17  C, the CYP3A4 enzyme expression was highest when the cells were 
cultured with fibronectin as the ECM. The expression increased to 244 % in fibronectin, 218 
%in poly-L-lysine and 159 % in MaxGel™. The cells were grown in human serum which 
resulted in no significant change in CYP3A4 expression. As seen in Figure 4.17  D, the 
expression of CYP2D6 was highest when the cells were cultured in fibronectin and the lowest 
was when the cells were cultured in poly-L-lysine. The expression of CYP2D6 increased to 
386 % in fibronectin, 210 % in MaxGel™ and 305 % in poly-L-lysine. When the cells were 
grown in human serum, the expression of CYP3A4 increased to 150 %, compared to cells 
cultured in FBS.   
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Figure 4.17 Densitometry analysis of the blots showing expression of efflux transporters and DMEs in HBVP 
cells. 
A. Expression of ABCG2, B. Expression of ABCB1, C. Expression of CYP3A4 and D. Expression of CYP2D6. 
The data is plotted per cent relative to the expression of proteins in standard culturing conditions 10 % FBS and 
no ECM. The error bars represent mean ± standard deviation (±SD) of three measurements of each band. * p < 
0.05 was considered to be statistically significant. 
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As seen in Figure 4.18, expression of efflux transporters; ABCB1 and ABCG2 and DMEs; 
CYP3A4 and CYP2D6 in HBMEC were assessed in various culturing conditions. The cells 
cultured in human serum as compared to standard culturing conditions did not show 
significant difference in the protein expression. The cells cultured in fibronectin showed the 
highest expression of both efflux transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and 
CYP2D6. This is explained in detail with the densitometry analysis (Figure 4.19).  
 
 
Figure 4.18 Expression of the efflux transporters and drug metabolising enzymes in HBMEC (endothelial cell) 
primary culture in various culturing conditions.  
A. Expression of ABCB1 efflux transporter. B. Expression of ABCG2 efflux transporter. C. Expression of 
CYP3A4 enzyme. D. Expression of CYP2D6 enzyme. E., β-actin was used as the loading control. Each well 
was loaded with 10 µg of protein. 
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As seen in Figure 4.19 A, the expression of ABCG2 increased to 245 % in the presence of 
fibronectin, when compared to the standard culturing conditions. The other ECM used also 
showed an increase in expression, MaxGel™ to 186 % and poly-L-lysine to 212 % compared 
to control. The cells grown in human serum showed an increase in the expression of ABCG2 
to 147 %. As seen in Figure 4.19 B, the expression of ABCB1 was highest in cells cultured 
in the presence of fibronectin, (288 %) when compared to the other ECM which showed an 
increase to 181 % in MaxGel™ and a decrease in expression to 161 % in poly-L-lysine. The 
cells grown in human serum showed an increase the expression of the ABCB1 transporter to 
130 %, compared to the control. 
As seen in Figure 4.19 C, the expression of CYP3A4 was highest when the cells were 
cultured in fibronectin as the ECM. The expression of CYP3A4 increased to 123 % in 
fibronectin, and showed a decrease to 75 % in MaxGel and 89 % in poly-L-lysine. When the 
cells were weaned on to human serum, the expression of CYP3A4 decreased to 57 % 
compared to cells cultured in FBS. As seen in Figure 4.19 D, the CYP2D6 enzyme expression 
was highest when the cells were culture with fibronectin as the ECM. The expression 
increased to 327 % in fibronectin, 260% in poly-L-lysine and 188 % in MaxGel. The cells 
weaned on to human serum showed an increase the expression of CYP2D6 to 141 % when 
compared to control.  
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Figure 4.19 Densitometry analysis of the blots showing expression of efflux transporters and DMEs in HBMEC 
cells. 
A. Expression of ABCG2, B. Expression of ABCB1, C. Expression of CYP3A4 and D. Expression of CYP2D6. 
The data is plotted per cent relative to the expression of proteins in standard culturing conditions i.e. FBS. The 
error bars represent mean ± standard deviation (±SD) of the three measurements of each band. * p < 0.05 was 
considered to be statistically significant. 
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The various culturing conditions were performed to maximise the expression of efflux 
transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and CYP2D6 in primary cultures 
HA, HBVP and HBMEC. As seen in Table 4.2, the short-term cultures showed an increase 
in the expression of efflux transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and 
CYP2D6 when cultured in fibronectin as the ECM. HS was also chosen as the serum for cells 
to be cultured in. Fibronectin and HS would be adapted in to the developing the in vitro BBB 
model to enhance expression of these proteins. It was also essential to determine if the 
culturing had an effect on the activity of the efflux transporters; ABCB1 and ABCG2 and 
DMEs; CYP3A4 and CYP2D6, which was further studied. 
Table 4.2 Summary of the % expression of different protein relative to standard culturing conditions. 
Primary 
culture 
Protein Standard 
Culturing 
Condition 
Altered culturing conditions (% relative to standard 
culturing conditions) 
FBS HS MaxGel Poly-L-
lysine 
Fibronectin 
HA 
 
 
 
ABCG2 100 259.49 508.09 510.11 714.26 
ABCB1 100 186.61 208.77 795.47 866.86 
CYP3A4 100 103.91 100.11 73.25 714.26 
CYP2D6 100 115.06 56.70 110.5 124.07 
HBVP 
 
 
 
ABCG2 100 52.38 257.14 67.95 280.52 
ABCB1 100 3.55 222.12 24.08 193.76 
CYP3A4 100 108.11 158.96 218.44 243.61 
CYP2D6 100 149.54 210.12 304.63 385.55 
HBMEC 
 
 
 
ABCG2 100 146.71 186.97 211.83 244.59 
ABCB1 100 130.52 180.93 161.05 287.37 
CYP3A4 100 57.33 74.85 88.82 122.47 
CYP2D6 100 141.26 187.75 250.23 327.15 
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4.2.4 Activity levels of efflux transporters 
Most of the drugs given for the treatment of glioma such as etoposide, doxorubicin, and 
vinblastine, which permeate through the BBB, are actively effluxed by transporters. This 
leads to poor bio-availability of drugs at the tumour site, therefore it is essential to evaluate 
not only the expression but also the activity of the efflux transporters. After determining the 
expression of protein levels of the efflux transporters, activity levels were also studied in 
standard tissue culture conditions of 10 % FBS, no ECM and then compared to altered 
culturing conditions 5 % HS or the three different types of ECM to determine if the activity 
could be maximised. 
4.2.4.1 Activity of efflux transporters in standard tissue culture 
conditions. 
The cell lines, primary cultures and short term cultures were assessed for the activity of the 
efflux transporters, ABCB1 and ABCG2, using an efflux assay kit.  The cells were loaded 
with fluorescent substrate dyes and incubated at 37 ºC. The cells were washed and measured 
for fluorescence after 60 min to determine the concentration of dye extruded from the cell. 
The control comprised of cells loaded with the dye incubated at 4 ºC, the activity of efflux 
transporters is inhibited at 4 ºC. Approximately 2.5 x 105 cells were used each test to assess 
the activity of ABCB1 and ABCG2. The values obtained were RFU of the substrate dye not 
effluxed out from the cell. The inverse of that was calculated and was plotted % relative to 
control, which did not show any fluorescence since the efflux transporters were inhibited. 
As seen from Figure 4.20 A, the highest activity of ABCB1 transporter was 56.6 % in 
HBMEC cells, the other primary cultures HA and HBVP showed similar activity level 
compared to HBMEC. The cell lines showed lower activity when compared to short term 
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cultures. The lowest activity recorded was 9.4 % in SVGp12 cells. The short term cultures 
BTNW370 and BTNW914 showed relative efflux activity of 22.3 % and 17.2 % respectively. 
The endothelial cell line hCMEC/D3 showed activity levels of 36.8 % which was low in 
comparison to the short-term endothelial culture HBMEC showing 56.69 % activity. The 
activity of ABCB1 was higher in short-term cultures HBVP and HA, compared to the cell 
lines and this was comparable to the expression of ABCB1 studied in Section 4.2.3.1. 
Activity of ABCG2 transporter was observed as seen in Figure 4.20 B, the highest activity of 
ABCG2 was 56.72 % in the HBMEC short-term culture. HBMEC and HA. The cell lines and 
the short term cultures showed similar activity levels of ABCG2 transporter. The lowest 
efflux activity of 18.1 % was observed in the SVGp12 cell line. The activity levels were high 
in primary cultures; HBMEC, HA and HBVP which were used to develop the in vitro BBB 
model. 
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Figure 4.20 Activity of efflux transporters in different cells. 
A: Activity of ABCB1 transporter B: Activity of ABCG2 transporter. The graphs were plotted as percentage 
relative to the control which was 0 % activity of the efflux transporter. The data points are means of three 
replicates (n=3) and the error bars represent ± standard deviation (±SD) of three inter-experimental * p < 0.05 
was considered to be statistically significant. 
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4.2.4.2 Activity of efflux transporters in altered culturing conditions 
Different culturing conditions were assessed with respect to the activity of the efflux 
transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and CYP2D6. In standard culturing 
conditions the primary cultures were grown in 10 % FBS without ECM. The altered culturing 
condition included culture with5 % HS without ECM and in the presence of ECM, MaxGel, 
poly-L-lysine and fibronectin.   
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As seen in Figure 4.21 for the U87MG cell line, the activity of ABCB1 was 14.3 % when 
cultured in standard tissue culture conditions in a monolayer with medium supplemented 
with 10 % FBS relative to the control. The culturing of cells in human serum increased the 
activity increase to 17.6 % but not significantly. The activity of ABCB1 shows a significant 
increased with the addition of ECM. The highest efflux activity was 30.1 %, which was 
observed in cells grown in fibronectin. The other extracellular matrices also showed an 
increase in efflux activity to 22.8 % for poly-L-lysine and 25.1 % for MaxGel™ (Figure 4.21 
A).  
As seen in Figure 4.21 B, the highest activity for ABCG2 was seen in U87MG cells grown 
in fibronectin 47.2 %. Cells grown on the other matrices also showed a significant increase 
in efflux activity when compared to the cells grown in FBS for example poly-L-lysine helped 
increase efflux activity to 40.5 % activity and MaxGel™ to 38.8 %. The cells, when cultured 
in human serum, showed an increase in efflux activity from 24.7 % to 30.1 % (Figure 4.21 
B). 
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Figure 4.21 Activity of efflux transporters in U87MG cells (grade IV glioma). 
A. Activity of ABCB1 transporter B. Activity of ABCG2 transporter. The graphs were plotted as percentage 
relative to the control which was 0 % activity of the efflux transporter. The data points are means of (n=2) 
experiments conducted in triplicate and repeated twice and the error bars represent ± standard deviation (±SD) 
of six measurements from two experimental replicates * p < 0.05 was considered to be statistically significant.  
A 
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As seen in Figure 4.22 for the 1321N1 cell line, the activity of ABCB1 was 18.2 % when 
cultured in standard tissue culture conditions in monolayer with medium supplemented with 
10 % FBS. The culturing of cells in human serum did not significantly alter efflux activity. 
The activity of ABCB1 showed a significant increase with the addition of ECM where in the 
presence of fibronectin, efflux increased to 39.6 %, in the presence of poly-L-lysine and 
MaxGel™ activity increased to 31.2 % and 30.2 % respectively (Figure 4.22 A).  
As seen in Figure 4.22 B, the highest activity of ABCG2 was 43.2 % shown by 1321N1 cells 
grown in fibronectin. Other matrices also showed an increase in the activity where in the 
presence of poly-L-lysine and MaxGel™ activity was 35.5 and 38.1 % respectively. The 
cells, when cultured in human serum, showed an increase in the activity of ABCG2 from 22.2 
% to 26.8 %, but this was not significant (Figure 4.22 B). 
 
 
 
134 
 
 
Figure 4.22 Activity of efflux transporters in 1321N1 cells (grade IV glioma). 
A. Activity of ABCB1 transporter B. Activity of ABCG2 transporter. The graphs were plotted as percentage 
relative to the control which was 0 % activity of the efflux transporter. The data points are means of three 
replicates from two experimental repeats (n=2) and the error bars represent ± standard deviation (±SD) six 
measurements from two experimental replicates. * p < 0.05 was considered to be statistically significant   
A 
B 
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As seen in Figure 4.23 in the SVGp12 cell line, the activity of ABCB1 was 9.2 % when 
cultured in standard tissue culture conditions in monolayer with medium supplemented with  
10 % FBS. The culturing of cells in human serum did not significantly enhances efflux 
activity. The activity of ABCB1 showed a significant increase with the addition of ECM in 
the culturing conditions. The highest activity was 22.2 % which was observed in cells grown 
in fibronectin. The cells in the presence of other extracellular matrices also showed an 
increase in the activity, to 16.1 % in the presence of poly-L-lysine and 16.7 % activity in the 
presence of MaxGel™ (Figure 4.23 A).  
As seen in Figure 4.23 B, the highest activity of ABCG2 was seen in SVGp12 cells grown in 
fibronectin 38.3 %. The other matrices also showed a significant increase in the activity as 
compared to the cells grown in FBS. Cells grown on poly-L-lysine showed 31 % efflux 
activity and on MaxGel™ showed 32.3 % activity. The cells when cultured in human serum 
showed an increase in the activity of ABCG2 from 18.9 % to 23.0 % (Figure 4.23 B). 
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Figure 4.23 Activity of efflux transporters in SVGp12 cells (foetal glial cells) 
A. Activity of ABCB1 transporter B. Activity of ABCG2 transporter. The graphs were plotted as percentage 
relative to the control which was 0 % activity of the efflux transporter. The data points are means of three 
replicates from two experimental repeats and the error bars represent ± standard deviation (±SD) six 
measurements from two experimental replicates. * p < 0.05 was considered to be statistically significant   
A 
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As seen in Figure 4.24 in HBMEC short-term cultures, the activity of ABCB1 was 55.7 % 
when cultured in standard tissue culture conditions in monolayer with medium supplemented 
with 10 % FBS. The culturing of cells in human serum did not make any significant change 
in the activity of transporter. The activity of ABCB1 showed a significant increase with the 
addition of fibronectin in to 78.1 %. The addition of other extracellular matrices did not show 
much increase in the activity when compared to fibronectin. Poly-L-lysine showed an 
increase to 63.4 % and MaxGel™ showed 67.5 % activity of ABCB1 efflux transporter 
(Figure 4.24 A).  
As seen in Figure 4.24 B, the highest efflux activity of ABCG2 was seen in HBMEC cells 
grown in fibronectin 82.3 %. The other matrices also showed a significant increase in the 
activity when compared to the cells grown in FBS, at similar activity levels; 65.3 % in the 
presence of poly-L-lysine and 66 % efflux activity in the presence of MaxGel™. The cells 
when cultured in human serum and FBS showed similar activity levels of ABCG2; 55.1 % 
and 55.9 % respectively (Figure 4.24 B). 
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Figure 4.24 Activity of efflux transporters in HBMEC. 
A. Activity of ABCB1 transporter B. Activity of ABCG2 transporter. The graphs were plotted as percentage 
relative to the control which was 0 % activity of the efflux transporter. The data points are means of three 
replicates from two experimental repeats and the error bars represent ± standard deviation (±SD) of six 
measurements from two experimental replicates. * p < 0.05 was considered to be statistically significant   
A 
B 
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As seen in Figure 4.25 for the HA short-term culture, the activity of ABCB1 was 56.1 % 
when cultured in standard tissue culture conditions in monolayer with medium supplemented 
with 10 % FBS. The culturing of cells in human serum did not make a significant difference 
in the activity of transporter. The activity of ABCB1 showed a significant increase with the 
addition of ECM in the culturing conditions. The highest activity was 70 % which was 
observed in cells grown in fibronectin. In the presence of other extracellular matrices efflux 
activity was 64.5 % for poly-L-lysine and 63.5 % for MaxGel™ showed 63.5 % (Figure 4.25 
A).  
As seen in Figure 4.25 B, the highest activity of ABCG2 was seen in HA cells grown in 
fibronectin 74.9 %. The other matrices also showed a significant increase in the activity as 
compared to the cells grown in FBS. Cells grown on poly-L-lysine showed 69.7 % activity 
and MaxGel™ showed 59.3 % activity. The cells when cultured in human serum showed an 
increase in the activity of ABCG2 from 41.2 % to 45.8 % compared to standard conditions 
(Figure 4.25 B). 
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Figure 4.25 Activity of efflux transporters in HA cells. 
A. Activity of ABCB1 transporter B. Activity of ABCG2 transporter. The graphs were plotted as percentage 
relative to the control which was 0 % activity of the efflux transporter. The data points are means of three 
replicates from two experimental repeats and the error bars represent ± standard deviation (±SD) of six 
measurements from two experimental replicates. * p < 0.05 was considered to be statistically significant   
A 
B 
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As seen in Figure 4.26 for the HBVP cells, the activity of ABCB1 was 47.3 % when cultured 
in standard tissue culture conditions in monolayer with medium supplemented with FBS. The 
culturing of cells in human serum did not make a significant difference to the efflux activity. 
The activity of ABCB1 shows a significant increase with the addition of ECM in the culturing 
conditions. The highest activity was 77.1 % which was observed in cells grown in fibronectin. 
The other extracellular matrices also showed an increase in the activity, cells grown on poly-
L-lysine showed 57.5 % and MaxGel™ showed 62.6 % activity of the ABCB1 efflux 
transporter (Figure 4.26 A).  
As seen in Figure 4.26 B, the highest activity of ABCG2 was seen in HBVP cells grown in 
fibronectin 75.4 %. Cells grown on poly-L-lysine also showed a significant increase in the 
activity to 69.5 %. On the other hand MaxGel™ showed 50.6 % activity of efflux transporter 
which was not as high as the other extracellular matrices used. The cells, when cultured in 
human serum, showed a slight increase in the activity of ABCG2 from 22.1 % to 26.5 %, 
however this was not significant (Figure 4.26 B). 
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Figure 4.26 Activity of efflux transporters in HBVP cells. 
A. Activity of ABCB1 transporter B. Activity of ABCG2 transporter. The graphs were plotted as percentage 
relative to the control which was 0 % activity of the efflux transporter. The data points are means of three 
replicates two experimental repeats and the error bars represent ± standard deviation (±SD) of six measurements 
from two experimental replicates. * p < 0.05 was considered to be statistically significant   
A 
B 
 
 
143 
As seen in Figure 4.27 for the hCMEC/D3 cell line, the activity of ABCB1 was 37.3 % when 
cultured in standard tissue culture conditions in monolayer with medium supplemented with 
FBS. The culturing of cells in human serum increased the activity of transporter to 40.5 % 
which was significant as compared to the activity by the different ECM. The activity of 
ABCB1 shows a significant increase with the addition of ECM in the culturing conditions. 
The highest activity was 62.9 % which was observed in cells grown in fibronectin. The other 
extracellular matrices also showed an increase in the activity, cells grown on poly-L-lysine 
showed 53.4 % and MaxGel™ showed 50.9 % activity of ABCB1 efflux transporter (Figure 
4.27 A).  
As seen in Figure 4.27 B, the highest activity of ABCG2 was seen in hCMEC/D3 cells grown 
in fibronectin 60.3 %. The other matrices also showed a significant increase in the activity 
when compared to the cells grown in FBS. Cells grown on poly-L-lysine showed 46.5 % 
activity and MaxGel™ showed 49.2 % activity of efflux transporter. The cells when cultured 
in human serum did not show a significant increase in the activity of ABCG2 (Figure 4.27 
B). 
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Figure 4.27 Activity of efflux transporters in hCMEC/D3 cells. 
A. Activity of ABCB1 transporter B. Activity of ABCG2 transporter. The graphs were plotted as percentage 
relative to the control which was 0 % activity of the efflux transporter. The data points are means of three 
replicates two experimental repeats and the error bars represent ± standard deviation (±SD) of three six 
measurements from two experimental replicates. . * p < 0.05 was considered to be statistically significant   
A 
B 
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4.2.5 Activity levels of drug metabolising enzymes 
Certain glioma drugs which reach the tumour site are metabolised by the CYP enzymes, 
present at the tumour site, leading poor bio-availability of the drug. It is essential to study 
both expression and the activity of these enzymes in cells to be able to predict therapeutic 
drug concentration at the site of action. The cell lines and short term cultures were assessed 
for the activity of the drug metabolising enzymes CYP3A4 and CYP2D6 using fluorescent 
probes 7-benzyloxy-4-trifluoromethylcoumarin (BFC) and 3-[2-(N,N-diethyl-N-
methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) respectively, by 
measurement of fluorescent metabolite formation. Prior to studying the activity of enzymes, 
the protein and substrate concentration was optimised to ensure that kinetic measurements 
were in the linear region of the reaction and no component was rate limited. 
4.2.5.1  Standard curve of metabolite 
A standard curve was required to derive the concentration of metabolite produced by the 
CYPs of interest. A standard curve of fluorescence versus metabolite concentration for either, 
7-hydroxy-4-trifluoromethylcoumarin (HFC) in Figure 4.28 or 3-[2-(N,N-diethyl-N-
methylammonium) ethyl]-7-hydroxy-4-methylcoumarin (AHMC) in Figure 4.29 was plotted 
and the linear line of best fit was fitted. The fluorescence emission readings/ min from the 
kinetic experiments were converted into rate of metabolite formation per min by dividing by 
the slope of the linear line of best fit from standard curve as described in Section 2.6.3.2.  
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Figure 4.28 Standard plot of concentration of fluorescence verses AHMC metabolite concentration. 
The excitation wavelength was 310 nm and emission wavelength was 410 nm. The data points are means of 
three replicates (n=3) and the error bars represent ± standard deviation (±SD) of three inter repeats of an 
experiment. 
 
Figure 4.29 Standard plot of concentration of fluorescence verses metabolite HFC. 
The excitation wavelength was 390 nm and emission wavelength was 460 nm. The data points are means of 
three replicates (n=3) and the error bars represent ± standard deviation (±SD) of three inter-experimental 
repeats. 
y = 138.2 x 
y = 130.4 x 
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4.2.5.2 Protein linearity optimisation  
When protein concentration and hence enzyme concentration is increased, the rate of 
metabolite formation will increase up to a certain point until the substrate becomes rate 
limited, therefore the rate of metabolite formation will slow. The purpose of the next study 
was to characterise the linear relationship between the protein concentration and metabolism 
at a set substrate concentration (25 µM), and to determine the concentration at which linearity 
of metabolism was lost. A range of protein concentrations between 0.1 mg/ml to 1 mg/ml 
were investigated. The bactosomes were used as a protein source and the activity was 
measured every 30 seconds over 25 min as shown in 
 
Figure 4.30 for CYP3A4 and Figure 4.31 for CYP2D6. The rate of metabolite formation was 
calculated with respect to bactosomes concentration as shown for CYP3A4 and CYP2D6. 
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The optimum protein concentration selected was 1 mg/ml for both CYP3A4 and CYP2D6, 
as this was within the linear region of the reaction. 
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Figure 4.30 Activity of CYP3A4 metabolism of BFC to HFC at different protein concentration in bactosomes. 
Fluorescent HFC metabolite formation following BFC metabolism by CYP3A4. The enzyme blank was used as the negative control. The data points are means of three 
replicates (n=3) and the error bars represent ± standard deviation (±SD) of three inter-experimental repeats. 
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Figure 4.31 Activity of CYP2D6 metabolism of AMMC to AHMC at different protein concentrations of bactosome. 
Fluorescent AHMC metabolite formation following metabolism of AMMC by CYP2D6. The enzyme blank was used as the negative control. The data points are means 
of three replicates (n=3) and the error bars represent ± standard deviation (±SD) of three inter-experimental repeats.   
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4.2.5.3  Substrate linearity optimisation 
When substrate concentration is increased, the rate of metabolite formation will increase up 
to a certain point until the CYP enzyme active site becomes saturated, thereafter the rate of 
metabolite formation will slow. A range of substrate (BFC or AMMC) concentrations 
between 0.1 μM to 150 μM was used to optimise the substrate linearity experiment. The 
bactosomes were used as protein source at a concentration of 1 mg/ml (optimised from the 
previous experiment) and the activity was measured every 30 seconds over 25 min as seen in 
Figure 4.32 A for CYP3A4 and Figure 4.32 B for CYP2D6. The rate of metabolite formation 
was calculated and plotted with respect to substrate concentration as shown for CYP3A4 and 
CYP2D6 in Figure 4.33A and B. It was concluded that 25 μM of substrate concentration 
should be used for all the enzyme kinetic studies, as the reaction was still linear at this point.  
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Figure 4.32 A Activity of CYP3A4 enzyme at different BFC substrate concentration with respect to time  
Fluorescent HFC metabolite formation following BFC metabolism by CYP3D4. The substrate blank was used as the negative control. The data points are means of three 
replicates (n=3) and the error bars represent ± standard deviation (±SD) of three inter-experimental repeats. 
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Figure 4.32 B: Activity of CYP2D6 enzyme at different AMMC substrate concentration  
Fluorescence AHMC metabolite formation following metabolism of AMMC by CYP2D6. The substrate blank was used as the negative control. The data points are means 
of three replicates (n=3) and the error bars represent ± standard deviation (±SD) of three inter-experimental repeats. 
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Figure 4.33 Michaelis Menton plot determining the rate of metabolism A CYP3A4 B CYP2D6  
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4.2.5.4 CYP activity measurements in cell lines 
The cell lines and short term cultures were grown in monolayer under standard conditions to 
an optimum cell number, yielding total protein concentration of 1 mg/ml in each well. The 
cells were incubated with the substrates (BFC or AMMC) at the optimum concentration of 
25 μM. The fluorescence of the metabolite (HFC/AHMC) formed in the wells was measured 
every 10 min up to 120 min at 37 ºC [Adapted from (Donato et al., 2004)]. As seen in Figure 
4.34 and Figure 4.35, the fluorescent metabolite was measured and plotted against time and 
the rate of enzyme activity at 25 µM substrate was determined. 
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Figure 4.34 Activity CYP3A4 metabolism of 25 µM BFC to HFC in 1 mg/ mL cell lines and short term cultures. 
The metabolite HFC formation was measured at excitation wavelength 410 nm and emission wavelength 510 nm. The data points are means of three replicates (n=3) and 
the error bars represent ± standard deviation (±SD) of three inter-experimental.  
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Figure 4.35 Activity CYP2D6 metabolism of 25 µM AMMC to AHMC in 1 mg/ml cell lines and short term cultures. 
The metabolite AHMC formation was measured at excitation wavelength was 390 nm and emission wavelength was 460 nm. The data points are means of three replicates 
(n=3) and the error bars represent ± standard deviation (±SD) of three inter-experimental repeats. 
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After calculation of the rate of metabolism in each cell culture at 25 µM (Table 4.3), the rate 
of metabolite formation was compared to relative metabolism in bactosomes at the same 
substrate and protein concentration (
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Figure 4.30 and 
 
Figure 4.31). 
Table 4.3 Rate of CYP3A4 and CYP2D6 enzyme at 25 µM substrate concentration in cell lines, primary and 
short term cultures. 
 CYP3A4 CYP2D6 
Cell line/ primary cultures Rate at 25 µM [S] (µM HFC 
/ min/ mg protein) 
Rate at 25 µM [S] (µM HFC 
/ min/ mg protein) 
1321N1 0.065 0.018 
U87MG 0.019 0.019 
SVGp12 0.017 0.016 
HBMEC 0.286 0.156 
HBVP 0.227 0.229 
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HA 0.249 0.231 
hCMEC/D3 0.197 0.193 
BTNW914 0.189 0.188 
BTNW370 0.201 0.204 
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4.3 Discussion and conclusion 
Over the last four decades, patients with glioma have shown poor prognosis when compared 
to patients with other cancer types such as colon cancer (Rachet et al., 2009). The poor 
prognosis is largely due to ineffective treatment caused by poor bioavailability of the glioma 
therapeutics at the tumour site, which can be partly attributed to the efflux transporters and 
DMEs enzymes located at the site of tumour that play a crucial role in the drug disposition 
and metabolism (Parkinson et al., 2006). In the current study, expression and activity of the 
efflux transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and CYP2D6 in glioma cell 
lines, short term cultures of endothelial cells, astrocytes and pericytes were determined in 
standard and altered tissue culturing conditions. It is well documented in hepatocyte studies 
that in vitro protein expression and activity of drug metabolising enzymes and transporters is 
lower than that observed in vivo, leading to under prediction of the extent drug metabolism 
(Baxter et al., 2014; Galetin, 2014). To predict the drug disposition and metabolism, it is 
essential to use models that have expression and activity as close as possible in comparison 
to in vivo (Kuteykin-Teplyakov et al., 2010). To ensure a physiologically relevant in vitro 
model is developed, experimental conditions were optimised to give the highest protein 
expression and activity levels.  
The most critical step in protein analysis is the extraction of proteins and sample preparation 
(Chatterjee et al., 2012), therefore the protein extraction protocol was optimised by trialling 
different techniques. From the Bradford assay, it was concluded that the lysing after scraping 
the cells from the culture dish on ice and trypsinisation of the cells both gave the highest 
protein yield. According to Huang et al., (2010) trypsinisation of cells causes damage to the 
cell membrane, this could be relevant, since the current study involved looking at 
transmembrane transporter proteins (Huang et al., 2010). To avoid, protein degradation, 
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scraping of cells from culture dishes was selected as the most appropriate and efficient 
protein extraction protocol.  
There has been an extensive use of immortalised cell lines in biological experiments due to 
ease of use, reproducibility, faster growing properties and cheap cost. These cells are easy to 
maintain and can be cultured with desired properties using specific growth conditions. These 
cells are however prone to genotypic and phenotypic drifting which leads to the cells 
developing a phenotype different from the cells in vivo (Pan et al., 2009; Stacey, 2001), 
resulting in misrepresentation of the tissue specific functions, leading to spurious results 
(Masters, 2000). The short-term cultures derived from primary cells in tissue explant, closely 
represent the properties of the tissue in vivo. These cells only grow up to a certain passage 
number before dedifferentiating and require specialised culturing conditions (Calatozzolo et 
al., 2005). The first protein expression study performed here confirmed that neither 
phenotypic drift or dedifferentiation had occurred as all of the CYPs and transporters were 
detectable in all of the cell lines used. Comparing immortalised and short-term cultures in 
the study here, it was found that under standard conditions short-term human astrocytes 
cultures and short term endothelial cells (HBMEC) had a higher expression of the CYPs and 
transporters compared to the immortalised counterparts SVGp12 and hCMED/D3 
respectively. When comparing the glioma short term cultures (BTNW914 and BTNW370) 
with the immortalised glioma cell lines (U87MG and 1321N1), it was not so clear. CYP3A4 
and ABCB1 showed higher expression and CYP2D6 and ABCG2 showed lower expression 
in the short-term cultures. Most of the papers have measured the expression in the form of 
mRNA levels. Lee et al., (2007) reported the expression, localization and activity levels of 
efflux transporters ABCG2 in brain endothelial cells of human and rat and glial cells. He 
observed that the expression and activity of ABCG2 was higher in human endothelial cells 
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as compared to rat endothelial cells (Lee et al., 2007). This was in unison if our findings of 
HBMEC (human endothelial cells) showing high expression of ABCG2. Vrigintino et al.  
(2002), showed that expression of ABCB1 in human endothelial cells was observed in the 
luminal membrane and the mRNA was detected in the cortex region (Virgintino et al., 2002). 
There are limited reports in the literature about transporter and CYP protein expression in 
cells at the BBB and glioma. The expression of CYP has been described in the isolated rat 
brain and microvessels but as of now no data has been reported on the expression of CYP in 
the human BBB. Ghersi-Egea et al., (1994) hypothesized that CYP enzymes are located 
primarily at blood-brain interfaces, where they form an enzymatic barrier. He reported the 
expression of CYP in isolated rat brain (Ghersi-Egea et al., 1994). Dauchy et al. (2008), 
showed the activity of various different types of CYP in the microvessel of the brain.  
No data was found in the literature for comparison on the expression and activity of CYP3A4, 
CYP2D6, ABCB1 and ABCG2 at the BBB in vivo. HBMEC, HA and HBVP showed higher 
expression of both the efflux transporters and the CYP enzymes compared to cell lines, thus 
these cells were short-listed as the component of the BBB model to be designed and were 
taken forward into the next study which was optimisation of experimental conditions to 
enhance protein expression. 
When comparing protein expression in the cells grown in FBS to those grown in human 
serum, no significance difference was observed in any protein expression in HA, HBVP and 
HBMEC cultures. When ECM was added into the culture, an improvement was observed in 
all proteins expressed for all cell lines, most significantly and consistently for cells grown on 
fibronectin. The extracellular matrix (ECM), has been shown to play a complex and dynamic 
role in cellular functions such as structure, motility and proliferation. The addition of 
extracellular matrix (ECM) to the cells increased the cell adhesion and cell-cell 
communication (Ruoslahti, 1996). Numerous papers have attested the ability of ECM to 
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communicate both spatial and temporal information to the adhering cells (Rubenstein and 
Kaufman, 2008; Behonick and Werb, 2003; Ulrich et al., 2009; Schlie-Wolter et al., 2013; 
Ishihara et al., 2008). Wolter et al. (2013), have shown that ECM affects cell adhesion 
dynamics, the formation of focal adhesion complexes, cell morphology, proliferation and 
intercellular communication. They also showed that when endothelial cells were cultured in 
fibronectin, it enhanced the cells attachment dynamics such as adhesion kinetic and force, 
formation of focal adhesion complexes, morphology, proliferation, and intercellular 
communication (Schlie-Wolter et al., 2013). All the culture showed a change in the protein 
expression levels indicating that the culturing environment has an   influence on the cell 
growth (Freshney, 2000). 
The activity of efflux transporters in the cell lines indicated that primary cultures have a 
higher activity for efflux transporters as compared to cell lines. Veringa et al. (2013), reported 
the activity of ABCB1 and ABCG2 in glioma cultures. According to them, both the efflux 
transporters are functional and active at the BBB (Veringa et al., 2013). It is essential to 
incorporate these components while designing an in vitro model. The activity was determined 
in various different culturing condition, cells cultured on fibronectin showed the highest 
activity. Anderson et al. (2002), reported the upregulated activity of ABCB1 in rat endothelial 
cells is upregulated post radiation. No data in literature was found for comparing the activity 
of cells in altered culturing conditions. From the current results it was observed that the 
primary cells when cultured in 5 % human serum and in the presence of fibronectin as the 
ECM showed the highest activity for the efflux transporters ABCB1 and ABCG2. 
The activity of CYP3A4 and CYP2D6 was studied in all the cell lines and primary cultures. 
The activity was higher in primary cultures, the highest activity was observed in HBMEC 
primary culture. Donato et al. (2004), observed activity of various CYP isoforms on 
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hepatocytes and developed a robust activity measuring assay (Donato et al., 2004). Rodriguez 
et al. (2002) reported a panel of CYP expression and activity for hepatocytes and hepatoma 
cell line. He also emphasised the point of loss expression or lower expression of CYP in cell 
lines. This supported our findings that the cell lines showed a low activity for CYP as 
compared to the primary culture. No data was found which utilised altered culturing 
conditions to increase the expression and activity to a maximal level. The data showed that 
the HBMEC primary culture showed the highest expression and activity for both the CYP 
enzymes; CYP3A4 and CYP2D6. 
Despite the numerous models designed for the BBB, there has been no published BBB model 
having all components derived from human such as cells, ECM, serum that has been 
characterised for the expression and activity of CYP3A4, CYP2D6, ABCB1 and ABCG2 
Translating these findings here in to the design of the in vitro BBB model, fibronectin was 
chosen as the ECM to grow cells on, and short-term cultures HA, HBMEC and HBVP were 
chosen as the most suitable cell lines.  
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CHAPTER 5 
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 Development of the blood brain barrier 
model. 
5.1 Introduction 
The blood brain barrier (BBB) is a regulatory interface which restricts the transport of 
substances between the circulation and the central nervous system (Shawahna et al., 2012). 
It is a complex system comprising of different cellular components such as endothelial cells, 
pericytes and astrocytes. Drug permeability across the BBB is an obstacle, challenging the 
development and success rate of neuropharmaceutical candidates (Poller et al., 2008). In vitro 
models are invaluable tools for studying the BBB phenotype, signalling pathways and drug 
penetration into the brain. Many in vitro BBB models have been designed to study the 
underlying mechanism involved in the transport of therapeutics across the BBB. It has often 
been claimed that these in vitro models closely reflect the human BBB in terms of phenotype, 
restricted paracellular permeability, and functional transporters and enzymes (Lacombe et 
al., 2011). Most in vitro models, however, use components from non-human species, which 
differ considerably in terms of intercellular tightness, active transport and metabolic activities 
(Chu et al., 2013). These differences make it difficult to predict how a neuropharmaceutical 
candidate may permeate the brain and hence there is a need to develop an in vitro BBB model 
with components of human origin.  
The endothelial cells form a compact layer ensheathing the blood capillaries and the presence 
of membrane proteins form TJs which exhibit high trans endothelial resistance. Trans-
endothelial electrical resistance (TEER) is a key BBB characteristic, which provides the 
measurement of membrane potential, resistance and hence integrity of the BBB (Weksler et 
al., 2013). The expression profile of efflux transporters largely determines permeability 
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properties and hence the study of expression profiles and functionality of efflux transporters 
and enzymes is an important requirement for the quality of the in vitro models (Wilhelm et 
al., 2011b).  
In this chapter, different co- and tri-culture models were designed and cultured mimicking 
the BBB in vivo using short term cell cultures of human origin. The designed models have 
been grown in different culture conditions to maximise the expression of tight junction 
proteins, endothelial resistance and determine the protein expression profiles of DMEs and 
efflux transporters. The aim of this study was to design a physiologically relevant and fully 
characterised BBB model that could be utilised to study the drug disposition in glioma in 
downstream experiments (Chapter 6). 
 
5.2 Results 
5.2.1  Validation of the TEER Instrumentation 
Various co- and tri- culture models were set up as described in Section 2.8 on polycarbonate 
inserts to measure the TEER and expression of occludin and claudin.  The first experiments 
were concerned with validating the EVOM instrument against the ECIS and CellZscope 
instruments for measuring TEER and secondly, deciding which endothelial cell line to 
include in the model, either the immortalised hCMEC/D3 or the short-term culture HBMEC 
The immortalised endothelial cell line hCMEC/D3 was used in all validation experiments 
concerning TEER measurements due to ease of use.  
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5.2.1.1 TEER measurements of designed BBB models using EVOM  
5.2.1.1.1 Assay validation for reproducibility 
To assess the reproducibility of the TEER values made using the EVOM instrument, five 
measurements within each well were taken (Figure 5.1), to assess variability in permeability 
across the insert, then each culture was set up in triplicate and mean TEER taken across the 
three wells to give an indication of intra-assay variability (Figure 5.2). Finally, the 
experiment was repeated on three different occasions and the mean TEER was calculated to 
give an indication of inter-assay variability (Figure 5.3); which is the data reported in the 
results throughout the chapter.  
 
 
Figure 5.1 Mean of five measurements of TEER within each well 
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Figure 5.2 Mean of three measurements of TEER for intra-replicates of an experiment.  
 
Figure 5.3 Mean of three measurements of TEER for inter-replicates of an experiment.  
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The hCMEC/D3 is a cell line generated from primary human brain capillary endothelial cells 
via a lentiviral vector system (Urich et al., 2012). The mono-, co- and tri- culture models of 
the hCMEC/D3 human brain capillary endothelial cells with astrocytes (SC-1800) and/ or 
pericytes (HBVP) were analysed for TEER values over 7 consecutive days. All the models 
showed a steady increase in TEER values up to day 4, thereafter the tri-culture showed a 
decrease in the TEER values. The TEER of 317 Ω/cm2 was recorded by the hCMEC/D3 
monolayer (Figure 5.4A).The co-culture of hCMEC/D3 and SC-1800 out of contact showed 
a peak TEER value of 292 Ω/cm2 which decreased after day 4. The co-culture of hCMEC/D3 
and SC-1800 in contact showed a peak TEER value of 326 Ω/cm2 which decreased after day 
5. The addition of pericytes to endothelial cell and astrocytes to form a tri-culture, increased 
the TEER values (Figure 5.4D and E) compared to the other models. The highest TEER 
recorded was 385 Ω/cm2, which was measured in the tri-culture model of hCMEC/D3, 
SC1800 in contact and HBVP out of contact (Figure 5.4E).  
The merged graph of the TEER values with respect to time for different co- and tri- cultures 
of hCMEC/D3 is shown in Figure 5.5. The co-culture of hCMEC/D3 and SC-1800 in contact 
and monoculture of hCMEC/D3 showed a decrease in TEER after day 5 whereas the co-
culture of hCMEC/D3 and SC-1800 out of contact showed a decrease after day 4.  
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Figure 5.4 Effect of co- and tri cultivation on the induction of TEER in hCMEC/D3 monolayers of in vitro BBB 
models measured by the EVOM probe.  
A. hCMEC/D3 monoculture. B. hCMEC/D3 and SC-1800 (in-contact) co-culture. C. hCMEC/D3 and SC1800 
(out of contact) co-culture. D. hCMEC/D3, SC1800 (in-contact) and HBVP (in-contact) tri-culture. E. 
hCMEC/D3, SC1800 (in-contact) and HBVP (out of contact) tri-culture. TEER readings with respect to time 
for different culture models up to Day 7, the readings showed an increase up to day 4 and began to decline from 
day 4 onwards. The data points are means of three replicates (n=3) and the error bars represent ± standard 
deviation (±SD) of three inter-experimental repeats. 
A 
E 
D 
C 
B 
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Figure 5.5 Comparison between TEER values measured by EVOM for all of the hCMEC/D3 co- and tri- culture models. 
All the models showed an increase up to day 4, the tri-cultures showed a drop in the TEER values after this point, whereas other model showed a drop in TEER values 
after day 5. The data points are means of three replicates (n=3) and the error bars represent ± standard deviation (±SD) of three inter-experimental repeats.
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The models were also studied for the expression of tight junction proteins occludin and 
claudin-5 (Figure 5.6 A & B). All of the Western blots presented in this Chapter were 
normalised by quantifying the protein concentration by Bradford assay and loading each well 
with equal amount of protein. β-actin was used as the loading control, and protein expression 
was normalised against β-actin expression for densitometry analysis. The tri-culture model 
comprising of the hCMEC/D3, SC-1800 (in contact) and HBVP (out of contact) (Lane 5) 
showed the highest expression of both occludin and claudin-5 (Figure 5.6 A & B), which was 
also confirmed by the highest densitometry reading of 775 % for occludin and 1434 % for 
claudin-5 relative to the mono-culture control (Figure 5.7 A and B) .All the models showed 
an increase in the expression of claudin-5 compared to the hCMEC/D3 mono-culture (Lane 
1) suggesting that co- and tri- culturing of cells improved the level of protein expression. 
Whereas the expression of occludin was more variable and the expression was 52 % in the 
hCMEC/D3 and SC-1800 (in contact) co-culture relative to the hCMEC/D3 mono-culture 
control (Figure 5.6 A and B). 
 
 
 
 
 
 
 
Figure 5.6 Western blots for TJs proteins expression in hCMEC/D3 mono-, co- and tri- cultures. 
A. Western blot for claudin-5 protein (23 kDa). B. Western blot of for occludin protein (65 kDa). Each well 
was loaded with 10 µg protein. β-actin protein (42 kDa) was used as the loading control. 
A 
B 
LANE: 
1) hCMEC/D3 monoculture.  
2) hCMEC/D3 and SC-1800 (in-
contact) co-culture.  
3) hCMEC/D3 and SC1800 (out of 
contact) co-culture.  
4) hCMEC/D3, SC1800 (in-contact) 
and HBVP (in-contact) tri-culture.  
5) hCMEC/D3, SC1800 (in-contact) 
and HBVP (out of contact) tri-
culture. 
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Figure 5.7 Densitometry analysis of TJs proteins expression in hCMEC/D3 mono-, co- and tri- cultures. 
A. Densitometry for occludin expression (65 kDa). B. Densitometry for claudin-5 expression (23 kDa). 1) 
hCMEC/D3 monoculture. 2) hCMEC/D3 and SC-1800 (in-contact) co-culture. 3) hCMEC/D3 and SC1800 (out 
of contact) co-culture. 4) hCMEC/D3, SC1800 (in-contact) and HBVP (in-contact) tri-culture. 5) hCMEC/D3, 
SC1800 (in-contact) and HBVP (out of contact) tri-culture. The error bars represent ± standard deviation (±SD) 
of three measurement of each protein band. * p < 0.05 was considered to be statistically significant.  
A 
B 
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5.2.1.2 TEER measurements of designed BBB models using ECIS  
The ECIS instrument measured the TEER in real-time two dimensionally across cells seeded 
as monolayers, via an electrode at the base of the array (Section 2.8.2). In this experiment, 
the hCMEC/D3 was used as a representative endothelial cell line to set up co- and tri-culture 
models on the ECIS. The cells were seeded on the ECIS array which was coated with 5 µg 
of fibronectin and the TEER reading was recorded for up to 160 h. One well on the ECIS 
array was kept blank which was seeded with growth medium to determine the background 
TEER values. The cells were supplied with their respective culture media as described in 
Section 2.8. 
TEER values for the hCMEC/D3 monoculture were measured on the ECIS array. For this 
model the TEER values steadily increased before peaking at 80-100 h followed by a steady 
decrease in the values. The maximum value of TEER in hCMEC/D3 monoculture was 558 
Ω/cm2 (Figure 5.8). 
 
Figure 5.8 TEER measurements of endothelial (hCMEC/D3) monoculture in 2D ECIS model.  
The graph is an average of the data from two separate experiments. 
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The hCMEC/D3 cells were grown in co-cultures as a monolayer with either astrocytes (SC-
1800) or pericytes (HBVP). The astrocyte co-culture showed a higher TEER compared to the 
pericyte co-culture. The highest TEER value for the astrocyte co-culture was 750 Ω/cm2 at 
80 h, after which it dropped sharply (Figure 5.9). The highest TEER value for the pericyte 
co-culture was 475 Ω/cm2, the TEER values showed a sharp decrease after 100 h (Figure 
5.10). 
 
Figure 5.9 TEER measurements of endothelial cells (hCMEC/D3) and astrocytes (SC-1800) co-culture in 2D 
ECIS model. 
The graph is an average of the data from two separate experiments. 
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Figure 5.10 TEER measurements of endothelial cells (hCMEC/D3) and pericytes (HBVP) co-culture in 2D 
ECIS model. The graph is an average of the data from two separate experiments. 
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The TEER measurement in mono- and co-cultures on ECIS showed a similar trend to the 
TEER measurements obtained by the EVOM probe, where culturing two cell types together 
increased the TEER values. As seen in Figure 5.11, TEER values showed an increase and a 
small peak at 475 Ω/cm2 at 5 h followed by a drop, then a steady increase to 760 Ω/cm2, at 
80 h, after which a sharp decrease was observed. 
 
Figure 5.11 TEER measurements of endothelial cells (hCMEC/D3), astrocytes (SC1800) and pericytes (HBVP) 
tri-culture in 2D ECIS model.  
The graph is an average of the data from two separate experiments.  
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The merged graph in Figure 5.12 compares the TEER values with respect to time for all the 
models, where the lowest TEER value of 475 Ω/cm2 was shown by the endothelial cells and 
pericytes co-culture. The highest values of 760 Ω/cm2 at 82 h was shown by endothelial cells, 
astrocyte and pericytes tri-culture. The co-culture of endothelial cells and astrocytes showed 
similar values to the tri-culture model, the TEER value of the co-culture was 750 Ω/cm2 at 
80 h.  
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Figure 5.12 Comparison of TEER measured for co- and tri- culture 2D models set up on the ECIS array.  
The highest TEER values shown by the tri-culture model at 83 h. The graph is an average of the data from two separate experiments. 
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The models were also studied for the expression of tight junction proteins occludin and 
claudin-5 (Figure 5.13 A & B). The tri-culture model (Lane 4), showed the highest expression 
of both occludin and claudin-5, compared to all of the other models confirmed by 
densitometry to be 1161 % and 758 % increase relative to the hCMEC/D3 monolayer control 
(Figure 5.14 A & B). The co-culture of endothelial cells with astrocytes (Lane 2), showed 
higher expression of occludin compared to co-culture of endothelial cells with pericytes (EP) 
(Lane 3), confirmed by densitometry to 100 % and 52.6 %, whereas claudin was more 
variable and showed lower expression in the co-culture of endothelial cells with astrocytes, 
compared to the co-culture of pericytes (Figure 5.14 A &B) The lowest expression of 
occludin and claudin-5 was seen by the hCMEC/D3 mono-culture (Lane 1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 Western blots for TJs proteins expression in hCMEC/D3 mono-, co- and tri- cultures setup on the 
ECIS array. 
A. Western blot of occludin protein (65 kDa) expression in different BBB models B. Western blot of claudin-5 
protein (23 kDa) expression in different BBB models. For the Western blots, each well was loaded with 10 µg 
protein. β-actin protein (42 kDa) was used as the loading control. 
 
 
LANES: 
1) hCMEC/D3 monoculture.  
2) hCMEC/D3 and SC-1800 co-
culture.  
3) hCMEC/D3 and HBVP co-
culture.  
4) hCMEC/D3, SC1800 and 
HBVP tri-culture.  
 
 
A 
B 
      1              2                3               4 
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Figure 5.14 Densitometry analysis of TJs proteins expression in hCMEC/D3 mono-, co- and tri- cultures setup 
on the ECIS array. 
A. Densitometry for occluding expression (65 kDa). B. Densitometry for claudin-5 expression (23 kDa). 1) 
hCMEC/D3 monoculture. 2) hCMEC/D3 and SC-1800 co-culture. 3) hCMEC/D3 and HBVP) co-culture. 4) 
hCMEC/D3, SC1800 and HBVP tri-culture. The error bars represent ± standard deviation (±SD) of three 
measurements of each protein band. * p < 0.05 was considered to be statistically significant. 
  
B 
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184 
5.2.1.3 TEER measurements of BBB models using Cellzscope 
The next stage was to compare the Cellzscope instrument for measuring TEER in the in vitro 
BBB models (as described in Section 2.8.3) to the EVOM probe. The Cellzscope was used 
to measure the TEER values of the 3D mono-, co- and tri- culture models for up to 90 h in 
real-time. In this measuring system an additional parameter was measured which is the 
capacitance of the cells. Capacitance provides additional information about the cell layer 
properties: in particular it is indicative of the expression of microvilli and other membrane 
extrusions. The cells showing low capacitance are indicative of cell attachment to the insert 
and integrated cell layer properties.  
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The hCMEC/D3 monoculture was seeded on insert and the TEER was recorded, the highest 
value recorded was 7 Ω.cm2 at 70 h (Figure 5.15 A). The corresponding capacitance stabilises 
after 50 h, the cells form a compact monolayer after 50 h (Figure 5.15 B). Initially on setting 
up model, the mono-culture showed a high capacitance and an unstable TEER up to 40 h of 
measurement. The readings showed a steady increase in TEER up to 70 h which subsequently 
dropped after reaching the peak value. 
 
Figure 5.15 A. TEER measurements B. Capacitance of endothelial (hCMEC/D3) monoculture in 3D model.  
The graph is an average of data from two separate experiments.  
A 
B 
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The co-culture of endothelial cells and the astrocytes peaked at 60 h, the astrocytes in the co-
culture were seeded in contact with the insert on the basolateral side. As seen in Figure 5.16, 
TEER values showed an increase within 5 h of seeding the cells, a small peak at 38 Ω.cm2 
was observed which dropped down temporaily and then TEER showed a steady increase up 
to 57 h. The highest value recorded was 45 Ω.cm2 at 57 h (Figure 5.16 A), the corresponding 
capacitance value indicated that the cells formed a compact monolayer between 50 -60 h. 
After 60 h, the cells began to detach which was indicated by the increase in the capacitance 
(Figure 5.16 B). 
 
Figure 5.16 A: TEER measurements B: Capacitance of endothelial cells (hCMEC/D3) and astrocytes (SC-1800) 
co-culture in 3D model. 
The graph is an average of data from two separate experiments. 
A 
B 
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The co-culture of endothelial cells and the pericytes peaked at 60 h, the pericytes in the co-
culture were seeded in contact with the insert on the basolateral side. As seen in Figure 5.17, 
TEER values showed an exponential increase within 5 h of seeding the cells, a peak at 8 
Ω.cm2 was observed which dropped transiently and then the TEER showed a steady increase 
up to 59 Ω.cm2. The highest TEER value recorded was 12.5 Ω.cm2 (Figure 5.17 A), the 
correspnding capacitance value indicated that the cells formed a compact monolayer between 
50 -70 h. After 80 h, the cells begin to detach which was indicated by the increase in the 
capacitance (Figure 5.17 B). 
 
Figure 5.17 A. TEER measurements and B. Capacitance of endothelial cells (hCMEC/D3) and pericytes 
(HBVP) co-culture in 3D model. 
The graph is an average of data from two separate experiments. 
A 
B 
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The TEER values in tri-culture of endothelial cells, astrocytes and the pericytes peaked 
between 65 h, the astrocytes and pericytes in the co-culture were seeded in contact of the 
insert on the basolateral side. As seen in Figure 5.18, TEER values showed an increase within 
5 h of seeding the cells, a peak TEER at 12 Ω.cm2 was observed which dropped down and 
then the  TEER showed a steady increase up to 65 h. The highest TEER value recorded was 
22 Ω.cm2 (Figure 5.18 A), the correspnding capacitance value indicated that the cells formed 
a compact monolayer after 40 h. The cells remained in a compact monolayer, which was 
indicated by a stable capacitance value (Figure 5.18 B). 
 
Figure 5.18 A. TEER measurements and B. Capacitance of endothelial cells (hCMEC/D3), astrocytes (SC1800) 
and pericytes (HBVP) tri-culture in 3D model. 
The graph is an average of data from two separate experiments. 
A 
B 
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The merged graph in Figure 5.19 compared the TEER values of all the different models, 
where the highest TEER was shown by endothelial and astrocyte co-culture and the lowest 
value was shown by the endothelial mono-culture. The TEER of all the models began to 
decrease after 70 h. Unlike the models set up and measured using EVOM and ECIS the tri-
culture model did not show the highest TEER readings. The overall TEER values given by 
the Cellzscope were much lower than the TEER values given by model measured using 
EVOM and ECIS. The tri-culture measured by Cellzscope gave a TEER of 22 Ω.cm2 whereas 
ECIS gave 258 Ω/cm2 and EVOM gave 760 Ω/cm2. The unit of measuremnt and algorithms 
used to calculate TEER in the three system was different in all instruments, both ECIS and 
EVOM measured resistance in Ω/cm2 whereas CellZscope measured resistance in Ω.cm2. 
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Figure 5.19 Comparison of all the TEER measurements in different co- and tri- culture 3D models set up on the Cellzscope.   
The highest TEER value was recorded in an EA co-culture model at 58 h. All the models showed a decrease in the TEER after 65 h. The graph is an average of data from 
two separate experiments. 
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The models were also studied for the expression of tight junction proteins occludin and 
claudin-5 (Figure 5.20 A & B). The tri-culture model, hCMEC/D3, SC1800 (in-contact) and 
HBVP (in-contact) tri-culture (Lane 4) showed the highest expression of both occludin and 
claudin-5 as compared to all the models, confirmed by densitometry to be an 201 % and 371 
% increase relative to the hCMEC/D3 monoculture (Figure 5.21 A & B). The co-culture of 
astrocyte, hCMEC/D3 and SC-1800 (in-contact) (Lane 2) showed a higher expression of both 
occludin and claudin, confirmed by densitometry to be 146 % and 309 % respectively, which 
when compared to the pericyte co-culture hCMEC/D3 and HBVP (in-contact) (Lane 3) was 
only 78 % occludin and no expression of claudin-5 (Figure 5.21 A & B).  
 
 
 
 
 
 
 
 
 
Figure 5.20 Western blots for TJs protein expression in hCMEC/D3 mono-, co- and tri- cultures set up on 
Cellzscope. 
A. Western blot for occludin protein expression (65 kDa). B. Western blot for claudin-5 protein expression (23 
kDa). Each well was loaded with 10 µg protein. β-actin protein (42 kDa) was used as the loading control. 
 
LANES: 
1) hCMEC/D3 monoculture.  
2) hCMEC/D3 and SC-1800 (in-
contact) co-culture.  
3) hCMEC/D3 and HBVP (in-
contact) co-culture.  
4) hCMEC/D3, SC1800 (in-contact) 
and HBVP (in-contact) tri-culture.  
 
A 
B 
      1              2                3               4 
Claudin-5 
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Figure 5.21 Densitometry analysis of TJs proteins expression in hCMEC/D3 mono-, co- and tri- cultures set up 
on Cellzscope. 
A. Densitometry for expression of occludin (65 kDa). B. Densitometry for expression of claudin-5 (23 kDa). 1) 
hCMEC/D3 monoculture. 2) hCMEC/D3 and SC-1800 (in-contact) co-culture. 3)  hCMEC/D3 and HBVP (in-
contact) co-culture. 4) hCMEC/D3, SC1800 (in-contact) and HBVP (in-contact) tri-culture. The error bars 
represent ± standard deviation (±SD) of three measurements of each protein band. * p < 0.05 was considered to 
be statistically significant. 
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5.2.2 Optimising experimental conditions 
5.2.2.1 Short-term endothelial cells: mono-, co- and tri- cultures 
The HBMEC endothelial cells mono-, co- (with astrocytes) and tri- (with astrocytes and 
pericytes) culture models were assessed for TEER values over 15 consecutive days using the 
EVOM instrument. All of the models showed a steady increase in TEER values up to day 10 
(Figure 5.22). The lowest TEER values 100 Ω/cm2 were recorded in the monolayer culture 
of HBMEC (Figure 5.22 A) and co-culture model comprising of HBMEC and HBVP cells 
out of contact (Figure 5.22 B). The models where endothelial cells were in contact with 
pericytes and astrocytes, continued to demonstrate increased resistance until day 13 (Figure 
5.22 C & E). In models where endothelial cells were out of contact with pericytes and 
astrocytes (Figure 5.22 B & D), the TEER values started to fluctuate and decrease after day 
10. The highest TEER value of 258 Ω/cm2 was recorded for the tri-culture comprising of the 
HBMEC on the insert, HBVP cells in contact with the insert and the HA cells out of contact 
at the bottom of the well (Figure 5.22 F).  
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Figure 5.22 Effect of co- and tri cultivation on the induction of TEER in HMBEC monolayers of in vitro BBB 
models.  
A. HBMEC monoculture. B. HBMEC and HBVP (out of contact) co-culture. C. HBMEC and HBVP (in-
contact) co-culture. D. HBMEC and HA (out of contact) co-culture E. HBMEC and HA (in-contact) co-culture 
F. HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture. TEER readings for different culture models 
up to Day 15. The data points are means of three experimental repeats (n=3) and the error bars represent ± 
standard deviation (±SD), where each experiment was conducted in triplicate and each culture was measured 
five times (n=15).  
A 
E F 
D 
C 
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The TEER readings of all the HBMEC co- and tri-models were plotted together on a line 
graph to compare the trend TEER values of different models with respect to time (Figure 
5.23). The highest TEER was of 258 Ω/cm2 was shown by the tri-culture model having 
HBMEC, HA (in-contact) and HBVP (out of contact). All models showed a drop in the TEER 
values after day 13. 
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Figure 5.23 Comparison of TEER values between all the HBMEC co- and tri- culture models. 
There was a steady increase in the TEER values for all models up to day 6. After day 6 the tri-culture model showed an large increase in the TEER values compared to 
other models. The data points are means of three experimental repeats (n=3) and the error bars represent ± standard deviation (±SD), where each experiment was conducted 
in triplicate and each culture was measured five times (n=15). * p < 0.05 was considered to be statistically significant. 
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As seen in Figure 5.24, the tri-culture model in lane 6, comprising of the HBMEC, HA (in-
contact) and HBVP (out of contact) showed highest expression of both occludin and claudin-
5, confirmed by densitometry as 867 % and 136 % relative to the HBMEC monoculture (Lane 
1) (Figure 5.24 A & B). The co-culture of HBMEC and HBVP out of contact (Lane 2) showed 
the lowest expression of occludin and the HBMEC and HBVP in contact (Lane 3), had the 
lowest expression of claudin, confirmed by densitometry to be 93 % and 17 % respectively 
(Figure 5.25 A & B).  
 
 
 
 
 
 
 
Figure 5.24 Western blots for TJs proteins expression in HBMEC mono-, co- and tri- cultures. 
A. Western blot for occludin protein (65 kDa). B. Western blot for claudin-5 protein (23 kDa). Each well was 
loaded with 10 µg protein. β-actin protein (42 kDa) was used as the loading control. 
 
 
A 
B 
 LANES: 
1) HBMEC monoculture. 
2) HBMEC and HBVP (out of 
contact) co-culture.  
3) HBMEC and HBVP (in-contact) 
co-culture.  
4) HBMEC and HA (out of contact) 
co-culture. 
5) HBMEC and HA (in-contact) co-
culture. 
6) HBMEC, HA (in-contact) and 
HBVP (out of contact) tri-culture. 
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Figure 5.25 Densitometry analysis of TJs proteins expression in HBMEC mono-, co- and tri- cultures. 
A. Densitometry analysis for occludin (65 kDa). B. Densitometry analysis for claudin-5 (23 kDa). 1) HBMEC 
monoculture. 2) HBMEC and HBVP (out of contact) co-culture. 3) HBMEC and HBVP (in-contact) co-culture. 
4) HBMEC and HA (out of contact) co-culture. 5) HBMEC and HA (in-contact) co-culture. 6) HBMEC, HA 
(in-contact) and HBVP (out of contact) tri-culture. The error bars represent mean ± standard deviation (±SD) 
of three measurements of each protein band quantified. * p < 0.05 was considered to be statistically significant. 
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5.2.2.2 Comparison of culture models in FBS and human serum 
The main aim was to develop an in vitro BBB model having components of human origin to 
avoid any species variability. All of the cultures investigated in the thesis had been grown in 
human serum (HS), however to determine the effects of HS compared to foetal bovine serum 
(FBS) on the properties of the BBB and to allow comparison to studies in the literature, a 
small subset of experiments were conducted comparing the two conditions. The primary cells 
were weaned from FBS to human serum, in order to determine the effect of human serum on 
the TEER values. The co- (HBMEC and HA) and tri- culture (HBMEC, HA and pericyte) 
models giving the highest TEER values in Figure 5.19 were selected for the study, as the 
high TEER and TJ protein expression suggested that the BBB formed was intact under these 
conditions. TEER values were taken between day 1 to day 15 using the EVOM instrument.  
All of the culture models showed a similar trend for the TEER values (Figure 5.26 A-D) and 
no significant difference was seen in the TEER values when the cells were cultured in FBS 
or human serum. The tri-culture model grown in FBS showed highest TEER value of 258 
Ω/cm2 on day 12. The tri-culture model grown in human serum showed highest TEER value 
of 259 Ω/cm2 on day 13. A similar trend was seen with the co-culture models, the maximum 
TEER value of the model grown in FBS was 211 Ω/cm2 on day 12 and the model grown in 
human serum was 208 Ω/cm2 on day 13. . 
As seen in Figure 5.27, a scatter plot comparing the TEER values with respect to time for 
both the models cultured in FBS and human serum showed no difference. 
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Figure 5.26 Effect of foetal calf serum and human serum on the induction of TEER in HBMEC co- and tri-
culture in vitro BBB models.  
A.: HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture model cultured in foetal bovine serum. B. 
HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture model cultured in human serum. C. HBMEC 
and HA (in-contact) co-culture model cultured in foetal bovine serum. D. HBMEC and HA (in-contact) co-
culture model cultured in human serum. TEER readings for different culture models up to Day 15. The data 
points are means of three replicates (n=3) and the error bars represent ± standard deviation (±SD) of three inter- 
experimental replicates. 
A 
B 
D 
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Figure 5.27 Comparison between TEER values obtained from HBMEC co- and tri-cultures of in vitro BBB models grown in foetal calf serum and human serum in. 
All models traced a similar pattern of TEER values showing no significant difference in the readings. The data points are means of three replicates (n=3) and the error bars 
represent ± standard deviation (±SD) of three inter–experimental repeats. * p < 0.05 was considered to be statistically significant. 
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The models were studied for the expression of the tight junction proteins, occludin and 
claudin-5 (Figure 5.28 A & B). The tight junction proteins occludin and claudin-5 showed 
similar expression in models grown in human serum or FBS. The expression of occludin was 
225 A.U. in HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture model cultured 
in human serum as compared to other models which gave an average value of 255 A.U. As 
seen in Figure 5.29 B, expression of claudin was seen to be similar in all the co-cultures and 
tri-culture models grown in FBS and HS. The expression of claudin-5 was 239 A.U. in 
HBMEC, HA (in-contact) co- culture model cultured in human serum as compared to other 
models which gave an average value of 248 A.U 
 
 
 
 
 
 
 
 
 
 
Figure 5.28 Western blots for TJs protein expression in HBMEC co- and tri-cultures of in vitro BBB models 
grown in foetal calf serum and human serum. 
A. Western blot of different models for occludin protein (65 kDa) B. Western blot of different models for 
(claudin-5 protein (23 kDa). Each well was loaded with 10 µg protein. β-actin protein (42 kDa) was used as the 
loading control.  
LANES: 
1) HBMEC, HA (in-contact) and 
HBVP (out of contact) tri-culture. 
2) HBMEC, HA (in-contact) and 
HBVP (out of contact) tri-culture in 
human serum. 
3) HBMEC and HA (in-contact) co-
culture. 
4) HBMEC and HA (in-contact) co-
culture in human serum. 
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Figure 5.29 Densitometry analysis of TJs proteins expression in HBMEC co- and tri-cultures of in vitro BBB 
models grown in foetal calf serum and human serum. 
A. Densitometry for expression of culture models for occludin (65 kDa). B. Densitometry for expression of 
culture models for claudin-5 (23 kDa). 1) HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture 
model cultured in foetal bovine serum. 2) HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture 
model cultured in human serum. 3) HBMEC and HA (in-contact) co-culture model cultured in foetal bovine 
serum. 4) HBMEC and HA (in-contact) co-culture model cultured in human serum. The error bars represent ± 
standard deviation (±SD) of three measurement of each protein band. * p < 0.05 was considered to be 
statistically significant. 
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5.2.2.3 Comparison of models grown on static polycarbonate, Alvetex 
insert and perfused Alvetex insert. 
In vivo the cells grow in a three dimensional environment and are under a constant shear 
stress (5-50 dyne/cm3) due to the surrounding blood flow. In this study, we took the culture 
models which gave us the highest TEER value and TJ protein expression; which was the tri-
culture model and the co-culture models comprising of the endothelial cells and the astrocytes 
(in contact) (Section 5.2.1.1), and cultured them in a three-dimensional polycarbonate 
scaffold (Alvetex insert), with perfusion of media, to apply shear stress, thus trying to mimic 
the conditions in vivo. 
The inserts were connected to a perfusion plate which was maintained at flow pressure of 20 
dyne/cm2. These perfused models were compared to the static models also set up using the 
Alvetex scaffold. The perfusion of tri-culture model increased the maximum TEER value 
from 456 Ω/cm2 to 723 Ω/cm2 (Figure 5.30 A & B). The perfusion of co-culture model 
increased the TEER value from 421 Ω/cm2 to 647 Ω/cm2 (Figure 5.30 C & D). The tri-culture 
model, HBMEC, HA (in-contact) and HBVP (out of contact) showed a higher TEER value 
than the co-culture model, HBMEC and HA (in-contact) (Figure 5.30 A & C).  
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Figure 5.30 Comparison of TEER values between co- and tri-culture models of HBMEC in Alvetex scaffold 
with and without perfusion (sheer flow).  
A. Co-culture of HBMEC and HA in static conditions. B. Co-culture of HBMEC and HA in perfused conditions 
C. Tri-culture model of HBMEC, HA and HBVP in static conditions. D. Tri-culture model of HBMEC, HA 
and HBVP in perfused conditions. The data points are means of three replicates (n=3) and the error bars 
represent ± standard deviation (±SD) of three inter-experimental repeats. 
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The merged graph of the TEER values with respect to time for different co- and tri- cultures 
models cultured in static polycarbonate inserts, static Alvetex scaffolds and perfused Alvetex 
scaffolds is shown in Figure 5.31. The tri-culture and co-culture models when grown in the 
3D Alvetex scaffold showed an increase in the TEER values as compared to the tri-culture 
on polycarbonate inserts. The Alvetex model when perfused with a flow of media showed a 
further increase in the TEER values. The TEER value of tri-culture model was 258 Ω/cm2 in 
polycarbonate insert model which increased to 440 Ω/cm2 in static alvetex insert which 
further increased to 710 Ω/cm2 in the perfused Alvetex inserts. It can be concluded that the 
cultures grown in 3D scaffolds showed a higher TEER values compared to 2D inserts. The 
introduction of flow by perfusing the scaffolds enhanced the TEER expression. 
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Figure 5.31 Comparison of TEER measurements in co- and tri- cultures of HBMEC with perfused alvetex scaffold, static alvetex scaffold and static polycarbonate insert 
of BBB models.  
The data points were means of three replicates (n=3) and the error bars represent ± standard deviation (±SD) of three inter-experimental repeats. * p < 0.05 was considered 
to be statistically significant. 
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The models were also studied for the expression of tight junction proteins occludin and 
claudin-5 (Figure 5.32 A & B). The tight junction proteins occludin and claudin-5 showed 
the lowest expression in co-cultures on static polycarbonate inserts (Lane 1) and highest 
expression in tri-cultures on perfused Alvetex inserts (Lane 6), confirmed by densitometry to 
be 716 % and 307 % for occludin and claudin respectively (Figure 5.33 A & B). The co-
culture of HBMEC and HA (in-contact) (Lanes 1, 3 and 5) grown in different inserts showed 
lower expression of occludin and claudin when compared to the tri-culture HBMEC, HA (in-
contact) and HBVP (out of contact) grown on different inserts (Lanes 2, 4 and 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.32 Western blots for TJs proteins expression in HBMEC tri-cultures set up on different inserts. 
A. Western blot for claudin-5 protein (23 kDa). B. Western blot for occludin protein (65 kDa). Each well was 
loaded with 10 µg protein. β-actin protein (42 kDa) was used as the loading control. 
 
1) HBMEC and HA (in-contact) co-culture static polycarbonate insert. 
2) HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture static polycarbonate insert. 
3) HBMEC and HA (in-contact) co-culture on static alvetex scaffold. 
4) HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture on static alvetex scaffold. 
5) HBMEC and HA (in-contact) co-culture on perfused alvetex scaffold. 
6) HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture on perfused alvetex scaffold. 
 
 
 A 
B 
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Figure 5.33 Densitometry analysis of TJs proteins expression in HBMEC tri-cultures set up on different inserts. 
A. Densitometry for expression of occludin (65 kDa). B. Densitometry for claudin-5 expression (23 kDa). 1) 
HBMEC, HA (in-contact) co-culture on static polycarbonate insert. 2) HBMEC, HA (in-contact) and HBVP 
(out of contact) on tri-culture static polycarbonate insert. 3) HBMEC, HA (in-contact) co-culture on static 
Alvetex scaffold. 4) HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture on static Alvetex scaffold. 
5) HBMEC, HA (in-contact) co-culture on perfused alvetex scaffold. 6) HBMEC, HA (in-contact) and HBVP 
(out of contact) tri-culture on perfused Alvetex scaffold. The error bars represent ± standard deviation (±SD) 
of three measurements of each protein band. * p < 0.05 was considered to be statistically significant. 
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5.2.2.4 Effect of location of pericyte in co- and tri- culture models 
The tri-culture of endothelial cells, astrocyte and pericyte showed a high TEER value when 
compared to co-culture of endothelial cells and astrocytes. In the following study cultures of 
endothelial cells, astrocytes and pericytes were grown in various formations with: 1) 
pericytes in contact with the HBMEC and HA on the insert or 2) HBMEC and HA co-
cultured on the insert with pericytes out of contact or 3) HBMEC and HA co-cultured on the 
insert in the presence of pericyte conditioned media and all were compared to the control 4) 
co-culture of HBMEC and HA (in-contact). This was conducted to see if the location of the 
cells in the tri-culture affected the TEER values and the expression of TJs proteins and also 
to determine whether factors secreted into pericyte conditioned media stimulated the other 
cells leading to increase in TEER values.  
All the three models show similar readings of TEER up to day 6, after which the tri-culture 
model comprising of HBMEC, HA (in-contact) and HBVP (out of contact) showed the 
highest TEER value of 259 Ω/cm2 on day 13 (Figure 5.34 B). The HBMEC, HA (in-contact) 
and HBVP (in-contact) tri-culture showed a peak TEER value of 210 Ω/cm2 on day 12 
(Figure 5.34 A). The co-culture of HBMEC, HA (in-contact) grown in pericyte conditioned 
media showed maximum peak TEER value of 208 Ω/cm2 on day 13. As seen in Figure 5.35, 
showing the merge of the TEER measurements with respect to time for all models, the 
HBMEC and HA (in-contact) co-culture supplemented with pericyte conditioned media did 
not show any significant difference in the TEER values when compared to the control 
HBMEC and HA (in-contact). All the models showed a decline in the TEER values after day 
13. 
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Figure 5.34 Effect of location of pericyte on the induction of TEER in tri- or co-culture in vitro BBB models.  
A. HBMEC, HA (in-contact) and HBVP (in-contact) tri-culture. B. HBMEC, HA (in-contact) and HBVP (out 
of contact) tri-culture. C. HBMEC, HA (in-contact) co-culture with HBVP conditioned medium. D. HBMEC, 
HA (in-contact) co-culture [control]. The data points are means of three replicates (n=3) and the error bars 
represent ± standard deviation (±SD) of three inter-experimental repeats.  
A B 
D C 
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Figure 5.35 Comparison of TEER values between HBMEC and HA (in-contact) co-culture with different location of pericyte. 
Tri-culture models of pericyte seeded either in or out of contact showed higher TEER values after day 6 in comparison to the control and the co-culture with pericyte 
conditioned medium. The data points are means of three replicates (n=3) and the error bars represent ± standard deviation (±SD) of three inter-experimental repeats. * p < 
0.05 was considered to be statistically significant. 
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The models were studied for the expression of the tight junction proteins, occludin and 
claudin-5 (Figure 5.36 A & B). Tri-culture models with pericytes out of contact (Lane 3) or 
in contact with the transwell insert (Lane 4) showed a higher expression of tight junction 
proteins occludin and claudin-5 when compared to co-culture with pericyte conditioned 
medium (Lane 2) and co-culture alone (Lane 1).  Densitometry measurements confirmed 
these findings indicating a highest value of 169 % for occludin (Lane 4) and 136 % for 
claudin (Lane 4) (Figure 5.37). 
 
 
 
 
 
 
 
 
 
Figure 5.36 Western blots of TJs proteins expression in HBMEC co- and tri-cultures with different location of 
HBVP. 
A. Western blot of different models for occludin protein (65 kDa). B. Western blot of different models for 
claudin-5 protein (23 kDa). Each well was loaded with 10 µg protein. β-actin protein (42 kDa) was used as the 
loading control.  
LANES: 
1) HBMEC and HA (in-contact) 
co-culture. 
2). HBMEC, HA (in-contact) 
and HBVP (in-contact) tri-
culture 
3) HBMEC, HA (in-contact) and 
HBVP (out of contact) tri-culture 
4) HBMEC, HA (in-contact) co-
culture with pericyte conditioned 
medium 
A 
B 
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Figure 5.37 Densitometry of TJs proteins expression in HBMEC co-, tri-cultures with different location of 
HBVP. 
A. Densitometry for occluding expression (65 kDa). B. Densitometry for claudin-5 expression (23 kDa). 1) 
HBMEC and HA (in-contact) co-culture. 2) HBMEC, HA (in-contact) co-culture with pericyte conditioned 
medium 3) HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture. 4) HBMEC, HA (in-contact) and 
HBVP (in-contact) tri-culture. The error bars represent ± standard deviation (±SD) of three measurements of 
each protein band. * p < 0.05 was considered to be statistically significant. 
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5.2.3 Expression and activity of proteins in designed in vitro BBB 
models. 
5.2.3.1 Expression and activity of efflux transporters ABCB1 and ABCG2 
in HBMEC models 
The efflux transporters located at the BBB play an important role in the disposition of drug 
administered for the treatment of glioma. It was therefore essential to characterise the 
expression and activity of the efflux transporters in designed in vitro BBB models to 
construct a physiologically relevant model. The expression and activity of efflux transporters 
ABCB1 and ABCG2 were studied in all the HBMEC mono-, co- and tri-culture BBB models. 
 As seen in Figure 5.38A, expression of ABCB1 efflux transporter was higher in models 
comprising of endothelial cells and astrocytes (Lane 4 and 5) compared to all of the other 
models comprising of endothelial cells and pericytes (Lane 2 and 3). The tri-culture of 
HBMEC, HA (in-contact) and HBVP (out of contact) (Lane 6) and co-cultures of HBMEC 
and HA showed similar expression of ABCB1 efflux transporters. The HBMEC monoculture 
showed the lowest expression of ABCB1 transporters (Lane 1). 
All models showed expression of ABCG2 efflux transporters (Figure 5.38 B), the lowest 
expression was seen in co-culture model of HBMEC and pericyte (out of contact) (Figure 
5.38 A) (Lane 2). The HBMEC mono-culture (Lane 1) showed expression higher when 
compared to the co-culture models (Lane 2,3,4,5), but the expression of ABCG2 efflux 
transporter was higher in tri-culture model (Lane 6) compared to all the other designed BBB 
models. The expression was semi quantified by densitometry as seen in Figure 5.39 which 
showed similar trend of results. 
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Figure 5.38 Expression of efflux transporters in different in vitro BBB models. 
A. Expression of ABCB1. B. Expression of ABCG2. β-actin was used as the loading control. Each well was 
loaded with 10 µg of protein.  
  
A 
B 
 LANES: 
1) HBMEC monoculture. 
2) HBMEC and HBVP (out of contact) co-culture.  
3) HBMEC and HBVP (in-contact) co-culture.  
4) HBMEC and HA (out of contact) co-culture. 
5) HBMEC and HA (in-contact) co-culture. 
6) HBMEC, HA (in-contact) and HBVP (out of contact) tri-culture. 
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Figure 5.39 Densitometry of efflux transporters in different in vitro BBB models. A. ABCB1. B. ABCG2 
* p < 0.05 was considered to be statistically significant 
  
A 
B 
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The activity of the efflux transporter ABCB1 was assessed in different BBB models set up 
using HBMEC mono-, co-, and tri-cultures (Figure 5.40). The activity of ABCB1 transporter 
was highest in the tri-culture model compared to all the other models. The co-cultures of 
astrocytes showed a similar activity in both in-contact and out of contact model which was 
also observed in the expression of the ABCB1. All the models showed a higher activity 
compared to the mono-culture suggesting co- and tri- culture enhances the activity of ABCB1. 
The co-culture of endothelial cells with pericytes, when grown in contact showed an increase 
in the activity of ABCB1 compared to pericytes grown out of contact co-culture. The highest 
activity was shown by the tri-culture which was comparable to the expression of the ABCB1, 
as the tri-culture showed a high expression of ABCB1. 
 
Figure 5.40 Activity of ABCB1 efflux transporter in different in vitro BBB models. 
Activity of ABCB1 in the different model designed, highest activity was observed in tri-culture model HBMEC, 
HA (in-contact) and HBVP (out of contact). The efflux activity was measured by using substrate rhodamine123, 
the data was plotted relative to control. The dye loaded cells at 4 ºC which inhibits the activity of the efflux 
transporter was the control. The data points are means of three replicates (n=3) and the error bars represent ± 
standard deviation (±SD) of three inter-experimental repeats. * p < 0.05 was considered to be statistically 
significant 
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The activity of ABCG2 transporter was assessed in all the different types of BBB model 
derived from HBMEC mono-, co- and tri-culture set-up. The highest activity of ABCG2 
transporter was recorded in the tri-culture model as compared to all the other models which 
is similar to the expression of ABCG2, where the highest expression was shown by the tri-
culture model. The co-cultures of astrocytes showed a similar activity in astrocyte in-contact 
as compared to astrocytes grown out of contact (Figure 5.41). As seen in the activity of 
ABCB1, all the models showed a higher activity as compared to the mono-culture suggesting 
co- and tri- culture enhances the activity of the ABCG2 efflux transporter. The co-culture of 
endothelial cells with the pericytes grown in contact also showed an increase in the activity 
of ABCG2 compared to pericytes grown in out of contact co-culture (Figure 5.38). The co-
culture of endothelial cells with the pericytes showed the lowest expression and activity of 
ABCG2. 
 
Figure 5.41 Activity of ABCG2 efflux transporter in different in vitro BBB models. 
Activity of ABCB1 in the different model designed, highest activity was observed in tri-culture model HBMEC, 
HA (in-contact) and HBVP (out of contact). The efflux activity was measured by using substrate rhodamine123, 
the data was plotted relative to control. The dye loaded cells at 4 ºC which inhibits the activity of the efflux 
transporter was the controlThe data points are means of three replicates (n=3) and the error bars represent ± 
standard deviation (±SD) of three inter experimental repeats. * p < 0.05 was considered to be statistically 
significant.  
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5.2.3.2 Expression and activity of drug metabolising enzymes CYP3A4 
and CYP2D6 in HBMEC models. 
The drug metabolising enzymes are responsible for the metabolism of certain drugs 
administered for the treatment of glioma. The metabolism leads to poor bio-availability of 
the drug at the tumour site. It is essential to evaluate the expression of these enzymes in the 
in vitro BBB models to construct a physiological relevant model. The expression and activity 
of drug metabolising enzymes CYP3A4 and CYP2D6 was studied in all the HBMEC mono-
, co- and tri-culture BBB models by Western blotting. 
Both astrocyte in-contact co-culture and tri-culture models both showed similar levels of 
expression of the CYP3A4 and CYP2D6. The lowest expression of both the enzymes was 
observed in the pericyte in-contact and pericyte out of contact model (Figure 5.42). CYP2D6 
was lowest in HBMEC monoculture whereas CYP3A4 expression was lowest in pericyte co-
culture. The CYP2D6 enzyme showed highest expression in the astrocyte co-cultures and the 
tri-culture. The expression of CYP3A4 was highest in the tri-culture model. This was 
confirmed by the densitometry analysis (Figure 5.43).   
 
 
 
 
 
Figure 5.42 Expression of drug metabolising enzymes in different in vitro BBB models. 
A Expression of CYP2D6 enzyme. B. Expression of CYP3A4 enzyme. β-actin was used as the loading control. 
Each well was loaded with 10 µg of protein. 1) HBMEC monoculture. 2) HBMEC and HBVP (in-contact). 3) 
HBMEC and HBVP (out of contact). 4) HBMEC and HA (out of contact). 5) HBMEC and HA (in-contact). 6) 
HBMEC, HA (in-contact) and HBVP (out of contact).  
A 
B 
      1                 2                 3                   4                 5                  6 
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Figure 5.43 Densitometry of drug metabolising enzymes in different in vitro BBB models. 
A CYP2D6 enzyme. B. CYP3A4 enzyme. 1) HBMEC monoculture. 2) HBMEC and HBVP (in-contact). 3) 
HBMEC and HBVP (out of contact). 4) HBMEC and HA (out of contact). 5) HBMEC and HA (in-contact). 6) 
HBMEC, HA (in-contact) and HBVP (out of contact).* p < 0.05 was considered to be statistically significant 
   
A 
B 
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The fluorescence metabolite formation was measured with respect to time for up to 60 min 
after addition of the probe substrate BFC or AMMC for CYP3A4 and CYP2D6, as seen in 
Figure 5.44 and Figure 5.45  respectively.  
 
 
223 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.44 Measurement of fluorescent HFC formation by CYP3A4 with respect to time in different in vitro BBB models. 
Fluorescent HFC metabolite formation following BFC metabolism by CYP3A4. The enzyme blank was used as the negative control. The substrate blank included the cells 
with buffer and NADPH. Each model had equal number of cells to measure the activity. The data points are means of three replicates (n=3) and the error bars represent ± 
standard deviation (±SD) of three inter-experimental.
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Figure 5.45 Measurement of AMHC formation by CYP2D6 in different in vitro BBB models. 
Fluorescent AHMC metabolite formation following AMMC metabolism by CYP3A4. The enzyme blank was used as the negative control. The substrate blank included 
the cells with buffer and NADPH. Each model had equal number of cells to measure the activity. The data points are means of three replicates (n=3) and the error bars 
represent ± standard deviation (±SD) of three inter-experimental repeats. 
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After calculation of the rate of metabolism in each model at 25 µM of substrate concentration 
(Table 5.1), the rate of metabolite formation was compared to relative metabolism in 
bactosomes at the same substrate and protein concentration. 
Table 5.1 Rate of enzyme activity at 25 µM [S] 
 CYP3A4 CYP2D6 
Models Rate at 25 µM [S] (µM HFC 
/ min/ mg protein) 
Rate at 25 µM [S] (µM HFC 
/ min/ mg protein) 
HBMEC monoculture. 0.365 0.359 
HBMEC and HBVP (out of 
contact) co-culture.  
0.389 0.377 
 HBMEC and HBVP (in-
contact) co-culture.  
0.419 0.416 
HBMEC and HA (out of 
contact) co-culture. 
0.434 0.421 
HBMEC and HA (in-
contact) co-culture. 
0.459 0.437 
HBMEC, HA (in-contact) 
and HBVP (out of contact) 
tri-culture. 
0.483 0.479 
 
5.2.4 Comparison of expression and activity of proteins between 
Alvetex perfusion and transwell tri-culture model 
The main aim of the project was to develop a 3D BBB model, therefore it was essential to 
study the efflux transporters and DMEs components of the BBB in the Alvetex scaffolds. 
Previous TEER data had shown that models grown on a 3D scaffold formed a stronger barrier 
(Figure 5.31) compared to 2D transwell insert models. Also, expression and activity levels 
of efflux transporters and DMEs was highest in tri-cultures compared to the other models, 
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therefore expression and activity of transporters and DMEs in the Alvetex scaffold was only 
compared against the most successful models to date. 
5.2.4.1 Expression and activity of efflux transporters ABCB1 and 
ABCG2. 
The expression and activity of the Alvetex perfusion model for efflux transporters ABCB1 
and ABCG2 was compared with the transwell tri-culture model. Western blots were 
undertaken to assess the expression of efflux transporters in the tri-culture transwell and tri-
culture Alvetex models. As seen in Figure 5.41 A & B, Alvetex perfusion model showed a 
higher expression of both the efflux transporters compared to the transwell tri-culture model. 
The expression of ABCG2 was higher than ABCB1 in both the Alvetex perfused model and 
the transwell tri-culture model. β-actin was used to normalise the data and to confirm that 
each well was loaded with equal amount of protein. These results can be confirmed by 
densitometry analysis (Figure 5.46 C and D)  
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Figure 5.46 Expression and activity of efflux transporter in both tri-culture in vitro BBB models. 
A. Expression of ABCB1 transporter. B. Expression of ABCG2 transporter. β-actin was used as the loading 
control. Each well was loaded with 10 µg of protein. C. Densitometry of ABCB1 transporter. D. Densitometry 
of ABCG2 transporter  The data points are means of three replicates (n=3) and the error bars represent ± standard 
deviation (±SD) of three inter-experimental repeats. 
 
 
 
 
 
 
 
 
A B 
C D 
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As seen in Figure 5.47, the activity of efflux transporter ABCB1 did not show significant 
higher activity in Alvetex perfusion model when compared to transwell tri-culture model, 
whereas the activity of ABCG2 transporter showed significantly higher activity compared to 
the transwell tri-culture model. 
 
 
Figure 5.47 Activity of ABCB1 and ABCG2 in the different designed tri-culture models.  
The data points are means of three replicates (n=3) and the error bars represent ± standard deviation (±SD) of 
three inter-experimental repeats.  
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5.2.4.2 Expression and activity of drug metabolising enzymes CYP3A4 
and CYP2D6. 
The expression and activity of the Alvetex perfusion model for drug metabolising enzymes 
CYP3A4 and CYP2D6 was compared with the transwell tri-culture model. The tri-culture 
model showed high TEER and high activity compared to all the designed in vitro BBB model. 
The Western blots were undertaken to assess the proteins levels of the drug metabolising 
enzymes in both the tri-culture set ups.  
As seen in Figure 5.48 A & B, the alvetex perfusion model showed a higher expression of 
both the drug metabolising enzymes CYP3A4 and CYP2D6 compared to the transwell tri-
culture model. β- actin was used to normalise the data and to confirm that each well was 
loaded with equal amount of protein. The densitometry showed the higher expression of 
CYP3A4 in alvetex tri-culture was 158.27 A.U. as compared to 93.68 A.U in transwell tri-
culture. The densitometry showed the higher expression of CYP3A4 in alvetex tri-culture 
was 138.68 A.U. as compared to 63.68 A.U in transwell tri-culture (Figure 5.48 C & D).  
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Figure 5.48 Expression and activity of drug metabolising enzyme in both tri-culture in vitro BBB models. 
A. Expression of CYP3A4 enzyme. B. Expression of CYP2D6 enzyme. β-actin was used as the loading control. 
Each well was loaded with 10 µg of protein. C. Densitometry of CYP3A4 enzyme. D. Densitometry of CYP2D6 
enzyme The data points are means of three replicates (n=3) and the error bars represent ± standard deviation 
(±SD) of three inter experimental repeats 
 
The models were studied for the activity levels of the drug metabolising enzymes (Figure 
5.49). The 25 μM fluorescent metabolite was incubated with the fluorescence was read up to 
60 min. The fluorescence of cultures and was measured, the alvetex scaffold showed a higher 
fluorescence of the metabolite formed as compared to the tri-culture model on transwell 
insert. The data was used to calculate the rate of enzyme at 25 μM of substrate concentration. 
 
A 
C 
B 
D 
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Figure 5.49 Activity of CYP3A4 and CYP2D6 in the different designed tri-culture models.  
The data points are means of three replicates (n=3) and the error bars represent ± standard deviation (±SD) of 
three inter experimental repeats. 
 
After calculation of the rate of metabolism in each model at 25 µM of substrate concentration 
(Table 5.2) the rate of metabolite formation was compared to relative metabolism in 
bactosomes at the same substrate and protein concentration. 
Table 5.2 Rate of enzyme activity at 25 µM [S] 
 CYP3A4 CYP2D6 
Models Rate at 25 µM [S] (µM HFC 
/ min/1mg/ml protein) 
Rate at 25 µM [S] (µM HFC 
/ min/1mg/ml protein) 
Tri-culture in tranwell insert 0.483 0.479 
Tri-culture on alvetex insert 0.621 0.598 
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5.3 Discussion and conclusion 
The BBB is a highly organised interface, as such in vivo complexity is difficult to attain in 
vitro. There has been an on-going search for an in vitro BBB model which is simple, 
reproducible and closely mimics the in vivo barrier both functionally and anatomically 
(Gaillard et al., 2001). The in vitro model in comparison to in vivo will need to have high 
throughput capacity, low cost, help in identification of early signs of cell toxicity and reduce 
the number of animal usage. As yet, no simple in vitro model has been able to mimic the 
functional abilities of BBB in vivo (Obermeier et al., 2013). Each in vitro model should be 
optimised and characterised for a well-defined purpose (Bicker et al., 2014; Erben et al., 
1995). For the purpose of predicting drug disposition when treating CNS disease such as 
glioma, it is essential, that the in vitro BBB model possesses relevant characteristics, such as 
the full complement of drug metabolising enzymes and transporters and a functional barrier. 
To date, no BBB model has been adopted by the pharmaceutical industry as the “gold 
standard”, which makes the development of a reliable model an important task (Patabendige 
et al., 2013). Until then, it has been proposed that combined approaches should be applied 
for the development of a BBB model which can be used to rationalise and optimise the 
evaluation of drug penetration in CNS drug delivery (Lundquist and Renftel, 2002; 
Shawahna et al., 2012).  The aim of this chapter was therefore to 1) study functional integrity 
of the BBB using TEER measurements and detection of TJ proteins, 2) measure expression 
and activity of key transporters and DMEs important for glioma drug disposition, utilising a 
range of different mono-, co- and tri-culture systems, in different experimental conditions 
(serum, 2D, 3D, cell conformation (in or out of contact with the insert) static, perfusion) as 
well as reviewing different instruments for TEER determination. 
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Reproducibility of TEER measurements across the insert were checked, and confirmed to 
have a coefficient of variance (CV) value of < 15 %, which was considered to be acceptable 
(Li and Chow, 2005). Initial problems caused due to un-uniform monolayer of cells due to 
clusters of cells forming on the insert were overcome by optimising the cell seeding density 
and optimising the concentration extracellular matrix (data not shown), and this was 
supported by reproducibly measurements observed across the insert Thereafter the intra-
assay (triplicate measurements across three models on one plate) and inter experimental 
repeats (different plates set up on three separate occasions) gave CV values < 15 % 
confirming good reproducibility of TEER measurements by EVOM. 
The EVOM instrument for TEER measurements was also validated against two other 
instruments. Firstly, for the 2D ECIS array, the cells were seeded on top of each other in 
layers and the resistance was measured at the base of the set up. A disadvantage of the ECIS, 
is that the array does not have compartments to perform any permeability assays or screening 
for novel compounds, unlike the EVOM probe which can be used across transwell inserts/ 
scaffolds. The advantage of using the ECIS was that it gave a real time measurement of the 
TEER, unlike the EVOM probe that measured TEER at discrete time points. Interestingly, a 
small peak was observed in all cultures at 5 h, which was attributed to cell adherence. Such 
details were lost with the EVOM probe which only provided TEER measurements every 24 
h Although the model was a two dimensional measurement of resistance, the pattern of TEER 
with respect to time in ECIS was comparable to the pattern observed by EVOM in the 
hCMEC/D3 mono-, and tri- cultures, where the highest reading TEER was seen in the tri-
culture followed by co-culture at approximately 3.5 days, compared to the EVOM that 
showed a TEER peak at 4 days in the tri-culture model. Semi-quantitation of Western blots 
for occludin and claudin supported the TEER measurements, also indicating the highest 
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expression in the tri-culture and lowest expression in the monoculture matched the highest 
and lowest TEER values. .  
The designed in vitro BBB models were set up on transwell inserts and measured using 
Cellzscope. The advantage of using Cellzscope was that it measured TEER in real time and 
did not require the manual insertion of probe which might disrupt the barrier forming cells 
(Benson et al., 2013). The values of the TEER were very low when compared to the TEER 
values measured using the EVOM. The TEER was also measured in Ω.cm2 as opposed to 
Ω/cm2 in the other two measuring systems (EVOM, ECIS). Due to lack of information from 
the company about the algorithm used to calculate the Cellzscope TEER, a direct comparison 
of values to EVOM was not possible, The tri-culture model measured by Cellzscope gave a 
peak TEER of 22 Ω.cm2 and co-culture gave a TEER of 45 Ω.cm2 at 2.4-2.7 days, however 
the TEER data was not supported by Western blot densitometry analysis, which revealed 
lowest occludin and claudin expression in the same co-culture model. Again, a small peak 
was observed at 5 h in all models, which also coincided with a decrease in capacitance, so 
was again attributed to cell adherence.   
The most important characteristic of an in vitro BBB model is a high TEER value (Wilhelm 
et al., 2011b). When comparing all three instruments for measuring TEER, and subtracting 
the background blanks from EVOM (already done), ECIS and CellZscope (data not shown), 
EVOM gave the highest TEER values. In addition, the EVOM model appeared to maintain 
a barrier for longer, whereas TEER declined quickly in the ECIS and Cellzscope models. 
EVOM and ECIS were thought to give reliable TEER values, as these were supported by the 
Western blot analysis of TJ protein expression, however, Cellzscope was deemed unreliable. 
It was decided the EVOM probe should be used so transwell and 3D models could be 
 
 
235 
measured, however it was highlighted that a disadvantage of the EVOM was a lack of real-
time TEER measurements. 
The next validation step was to compare the immortalised human endothelial cell line 
(hCMEC/D3) against the short-term human endothelial cell line (HCMEC). In the current 
study, different co- and tri- cultures were set up using two different endothelial cell lines, 
The cell lines both showed an increase in the TEER values in co- and tri- cultures compared 
to their monocultures. The hCMEC/d3 in tri-culture showed the highest peak TEER of 385 
Ω/cm2 at day 4, whereas the HBMEC in tri-culture had a lower TEER at 258 Ω/cm2. Both of 
the cell lines in tri-culture showed the highest TJ protein expression compared to the other 
models. The developed BBB model required a steady plateau phase in the TEER values 
which can be used to test the permeability of novel therapeutics, including NPs. The co- and 
tri-cultures of immortalised hCMEC/D3 did not establish a steady plateau phase, whereas the 
model designed using short-term HBMEC cell cultures did. In the literature it was reported 
that best results are obtained with models based on primary endothelial cells; the major 
limitation of the models using immortalised endothelial cell lines was the relatively high 
paracellular permeability (Roux and Couraud, 2005). A model with high paracellular 
permeability cannot to be used for screening of novel drugs or NPs, therefore, the model 
cannot be used commercially and defeats the purpose of designing an in vitro BBB model. 
The HBMEC primary culture are highly purified version of brain cells and were found to 
have unmatched value for basic and translational research (Naik and Cucullo, 2012). The 
complex TJs between these endothelial cells are primarily responsible for the barrier function 
and provide a high electrical resistance of about 2000 Ω/cm2 in vivo (Crone and Olesen, 
1982). It is known that complexity of TJs is higher in brain capillaries than in other vessels, 
their development and regulation is highly complex but they form an essential component 
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for maintaining a healthy micro environment in the CNS (Lai and Kuo, 2005). Compared to 
the in vivo TEER values, the in vitro model was still a long way off achieving physiologically 
relevant resistance. Taking, the results and literature into consideration, the short-term 
HBMEC cultures were chosen as the most suitable for the model. 
Cells harvested from human origin are frequently utilised for the development and 
optimisation of in vitro BBB models. These primary cultures provide the closest phenotypic 
resemblance to the cells in vivo (Lundquist and Renftel, 2002), it therefore follows that all 
components in the culture such as serum and ECM should also be of human origin, however 
this is often not the case. One of the aims here was to ensure that all the components used to 
develop the BBB model were kept similar to in vivo as possible. A small study was conducted 
where cells that had been initially cultured in 10 % foetal bovine serum (FBS) were weaned 
on to 5 % human serum. Interestingly, there was no significant difference in the TEER values 
or expression of TJs proteins occludin and claudin-5 in cells of the model grown in (FBS) or 
human serum. Serum is added to culture media to promote cell proliferation and maintain in 
vivo like conditions. Harvey et al. (2002), suggested that the serum inhibits the formation of 
TJs and lowering the level of serum in culture promotes formations TJs and tightens the 
barrier. Serum has many components that could affect tight junctions, including proteins, 
lipids, hormones, and growth factors. Chang et al., (1997) showed that the clotting factors 
present in the serum do not affect the TJs by measuring the TEER. They suggested that the 
growth factors such as fibroblast growth factors, vascular endothelial growth factor, and 
hepatocyte growth factor-scatter factor are likely to have a role in causing a gradual decline 
in the TEER caused by decrease in TJs formation (Chang et al., 1997). Since the presence of 
5 % serum did not appear to inhibit barrier formation it was decided to continue using serum 
of human origin to avoid any inter-species variability (Harvey et al., 2002).  
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The final part of the model validation involved investigations of various cell confirmations 
(mono-, di- and tri-) in or out of contact with the insert (2D) or scaffold (3D) and static or 
perfused environments. It has been demonstrated by several groups that co- and tri-
cultivation of pericytes and/or astrocytes with endothelial cells show an increase in the TEER 
resistance when compared to the mono-cultivation of endothelial cells (Hatherell et al., 2011; 
Nakagawa et al., 2007a; Deli et al., 2005). Nakagawa et al., describes that co-culture of 
pericytes with endothelial cells gave a high TEER value of 388 Ω/ cm2 using EVOM and low 
permeability (Nakagawa et al., 2007a; Nakagawa et al., 2009b). On the other hand, Hatherell 
et al. (2011), showed that the co-culture of endothelial cells with the astrocytes seeded on the 
basolateral side of the insert gave a high TEER value of 240 Ω/ cm2 using EVOM. The 
presence of astrocytes and/or pericytes elevates the TEER values. In the data reported here, 
the co-cultures of endothelial cells and astrocytes/ or pericytes both showed a higher TEER 
value when compared to endothelial mono-culture. This supported the findings of Goldstein 
et al. (2008), who stated that the co-culturing of endothelial cells with astrocytes/ pericytes 
increased the complexity and formation of the TJs (Goldstein, 1988). Comparing the two co-
culture models of astrocytes and endothelial cells in the study here, the in-contact model 
showed a higher TEER value when compared to out of contact model. The astrocytes in 
contact with the endothelial cells were separated by a 8 µm membrane, the short lived factors 
secreted by astrocytes are able to penetrate the 8 µm barrier which helped modulate the BBB 
properties by improving cell-cell signalling resulting in an increase in the TEER (Cohen-
Kashi Malina et al., 2009; Abbott et al., 2006b). It is also known that these astrocyte derived 
soluble factors secreted in the culture medium are responsible for the induction of the BBB 
phenotype on the endothelial cells (Rubin et al., 1991; Haseloff et al., 2005).  The 8 µm pore 
size of the polycarbonate membrane used restricts the migration of astrocytes across the 
surface of the insert, but does not restrict the astrocytic foot processes. These astrocyte foot 
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processes penetrate through the pore of the filter and interact with the endothelial cells seeded 
which leads tightening of the barrier (Patabendige et al., 2013). The synergetic effect of the 
cell-cell interaction leads to induction of the BBB properties thus explaining the higher TEER 
values observed with the tri-culture model (Nakagawa et al., 2007a). Thus, the presence of 
both pericytes and astrocytes enhances the tight junction formation and increases the 
tightness of the barrier as seen in the study here and confirmed in the literature (Nakagawa 
et al., 2009a).  
The endothelial cells hold a unique position among biomechanically responsive cells in vivo, 
these cells are subjected to interaction with other cells and are relatively under high shear 
stress due to constant blood flow which gives the BBB its integrity and function. 
Consequently, endothelial cells are an important component of models to study the effect of 
shear stress on cell function (Shawahna et al., 2012; Davies, 1989). Siddharthan et al., have 
described a model in which the endothelial cells are co-cultured with astrocytes and subjected 
to flow. Cells subjected to shear stress or flow show an increased expression of the tight 
junction proteins occludin and claudin and decreased permeability when compared to cells 
in static cultivation (Siddharthan et al., 2007).  
Similar results were observed when the co- and tri- cultures in this study,  cultures that were 
grown on a perfused Alvetex scaffold gave the highest TEER values,. The initial TEER 
values of the models were similar, after day 3 the model with shear stress showed an increase 
in the TEER. The highest value of TEER in a perfused model was 710 Ω/cm2 whereas the 
highest TEER value of a static model was 250 Ω/cm2. Cucullo et al. (2008), have reported 
similar results in his study where the dynamic model with pulsatile flow showed a TEER of 
1000 Ω/cm2 and the static model showed a TEER of 70 Ω/cm2. Several reports have 
suggested that application of shear stress induces morphological and functional changes in 
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endothelial cells (Siddharthan et al., 2007; Krizanac-Bengez et al., 2003; Cucullo et al., 
2008). 
As seen in the current study, the presence of pericyte in the co-culture model of endothelial 
cells and astrocyte enhanced the TEER values of the models. The pericyte were cultured by 
three different methods, in-contact, out of contact and conditioned media. All the models 
showed a similar TEER pattern and expression of TJs proteins higher than the control which 
was the co-culture of endothelial cells and astrocytes. Pericytes are normally associated with 
three major roles i) CNS microvasculature-contractility ii) regulation of endothelial cell 
activity and iii) macrophage activity (Lai and Kuo, 2005). These roles involve participation 
in different cell signalling components which either interact with the pericyte or are produced 
by the pericyte. The cell signalling agents include neuromodulators, vasoactive peptides, 
metabolic factors, growth factors and cytokines. The pericyte have shown to regulate the 
endothelial cell growth and proliferation by secreting TGF-β-1 (Rucker et al., 2000). The 
TGF-β-1 enhances the expression of contractile proteins such as actin, thus strengthening the 
barrier, hence explaining why conditioned media alone was enough to improve TEER 
(Bandopadhyay et al., 2001). 
To date no in vitro BBB model developed has been assessed for the expression and activity 
levels of the efflux transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and CYP2D6. To 
improve activity and expression levels it is necessary to mimic the in vivo microenvironment 
of the cells. Extensive work has been done in xenobiotic drug metabolism and disposition in 
in vitro liver models, therefore the aim was to translate this work to in vitro BBB models 
(Godoy et al., 2013; Baxter et al., 2014). The efflux transporters and DMEs both play a 
crucial role in drug disposition and metabolism in glioma. In the presence of a brain tumour, 
the BBB has often been reported to be compromised (On et al., 2013), increasing the 
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possibility that chemotherapeutic agents may be able to enter the CNS, however, the efflux 
transporters and drug metabolising enzymes will still be functional leading to poor bio-
availability of the drug. It is essential therefore, to develop therapeutics which can not only 
overcome the physical barrier but also the transport barrier and the metabolic barrier at the 
tumour site, thus enabling treatment of the tumour. In the current study the expression and 
activity levels of all the proposed models were studied for the efflux transporters; ABCB1 
and ABCG2 and DMEs; CYP3A4 and CYP2D6 activity. The tri-culture model showed the 
highest expression and activity compared to the other designed models. As compared to 
mono-culture which showed 32 % activity for ABCB1, the tri-culture showed 68 % activity. 
The activity of ABCG2 was also higher in tri-culture, 69 % as compared to the mono-culture 
showing 20 % activity. These expression and activity levels of the efflux transporters; 
ABCB1 and ABCG2 and DMEs; CYP3A4 and CYP2D6 established the physiologically 
relevant characteristic of the designed BBB model. In liver, the efflux transporters and 
enzymes are studied by modelling in vitro for the purposes of drug toxicology and safety 
pharmacology, making this model possibly more predictive of drug toxicity compared with 
existing models (Baxter et al., 2014; Godoy et al., 2013).  
In summary, the BBB model was developed by utilising multiple cell types in optimised 
culture conditions giving the highest expression of efflux transporters; ABCB1 and ABCG2 
and DMEs; CYP3A4 and CYP2D6. The model was also optimised for a high expression of 
TJs proteins and high TEER values. On comparison of the various models studied, the tri-
culture model of astrocytes (in contact) and pericytes (out of contact) of HBMEC 
monoculture model gave the highest resistance and high expression of tight junction proteins, 
occludin and claudin-5. The modelled barrier was translated to a 3D scaffold and induced 
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with shear stress by perfusing the scaffold. This model was further tested by permeability 
assays and NPs and aptamers to assess its functionality as an in vitro BBB model. 
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CHAPTER 6 
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 Functionality of the tri-culture as an in 
vitro BBB model 
6.1 Introduction 
There has been an emerging need to develop short term in vitro models and computational 
tools that can predict the efficacy and toxicity of therapeutics and NPs on the body (Hanada 
et al., 2013; Masserini, 2013). The urgent need to develop a model for screening of CNS 
targeted therapeutics has led to development of various in vitro BBB models. These models 
allow screening of designed novel therapeutics and delivery systems including NPs and 
aptamers. 
The major strategy in treating the glioma is to circumvent the BBB, in recent years 
nanobiotechnology has been suggested as a promising strategy to overcome the BBB. It 
provides efficient tools for diagnosis, delivery mechanism and increases the chances of 
developing curative treatment for glioma. Papers have suggested improved transportation of 
glioma drugs such as temozolomide (Modi et al., 2009) and doxorubicin (Ulbrich et al., 
2009) compared to conventional systemic delivery. Nanoparticles are small in size and are 
able to flow easily through the blood capillaries due to appropriate surface functionalisation 
thereby rendering NPs as biological entities (Tian et al., 2012; Oberdorster et al., 2009). 
These developing neuro-therapeutics have to be screened for their toxicity, safety and long 
term effect on the body (Ragnaill et al., 2011; Lu et al., 2006). Methods for the toxicity 
testing of NPs are the same as the techniques used in modern drug development, however, 
the toxic mechanism of NPs can be more diverse than that of drug compounds (Lee et al., 
2009). NPs can be used to encapsulate drugs and slowly release drugs at the site which 
prevents the drug from being effluxed and metabolised by the enzymes. Until recently most 
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of the screening of the NPs has been done on two dimensional models which comprise of 
cells cultured in dishes, the use of 3D BBB models forms a bridge between 2D models and 
in vivo models (Masserini, 2013; Oberdorster et al., 2009; Tian et al., 2012). 
In the study here, it has previously been shown that the tri-culture model of HBMEC, HA 
(in-contact) and HBVP (out of contact) and co-culture of HBMEC and HA (in-contact) 
constructed on polycarbonate membrane gave higher TEER values, higher expression of TJs 
proteins and higher expression and activity of efflux transporters (ABCB1 and ABCG2) and 
DMEs (CYP3A4 and CYP2D6). In this chapter, the tri-culture model and co-culture model 
were characterised for their permeability using dextran tagged with FITC. The flux of 
fluorescence of FITC-dextran molecules from the apical side to the basolateral side of the 
insert was measured. The model showing lowest permeability and hence improved and more 
physiologically relevant barrier properties was then used to screen the effects of various lipid 
NPs and aptamers on the TEER values (measured by EVOM) of the modelled in vitro BBB 
with respect to time. Nanoparticles had been designed by Prof Singh and Dr Wan for delivery 
of chemotherapeutic agents (NP loaded with: docetaxel, aciatic acid or curcumin either with 
or without transferrin (delivery tag) or rhodamine (for fluorescent detection of the NP)) and 
an aptamer called SA43 had previously been shown to be an effective glioma targeting 
molecule (unpublished data Shraddha Aptekar, PhD thesis). 
 
6.2 Results 
6.2.1 FITC-Dextran permeability assay 
The permeability of the model was tested using dextran (10,000 Da), which was tagged to 
FITC. The permeability was determined at 1 mg/ml of FITC-dextran which was adapted as 
 
 
245 
described in Simoneau et al., 2012. The paracellular permeability of model 1), the tri-culture 
model [HBMEC, HA (in-contact) and HBVP (out of contact)], and model 2), the co-culture 
model [HBMEC and HA (in-contact)] was studied. The fluorescence of media containing 
FITC-dextran collected from the basolateral side of models were compared to the 
fluorescence of 100 µl stock of 1 mg/ml FITC-dextran stock loaded in the apical side of the 
model was determined in a 96-well plate using a plate reader. The fluorescence was sampled 
from the apical side of the well at time 0 h, 1 h, 2 h and 3 h, for measurement of apparent 
permeability. As seen in Figure 6.1, the level of fluorescence increased with respect to time 
demonstrating flux of FITC-dextran cross the barrier. The fluorescence levels were higher in 
model 2, suggesting the paracellular permeability of the tri-culture model was lower than that 
of the co-culture model. At 1 h, the permeability of tri-culture is 7.61 % relative to the 
fluorescence of the FITC-dextran stock which is lower than 28.30 % shown by co-culture 
model. A similar trend was seen at 2 h and 3 h, the permeability shown by tri-culture was 
11.69 % and 19.86 % respectively and co-culture was 35.42 % and 76.28 %.  
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Figure 6.1: Permeability of FITC-dextran across different models at time intervals 1 h, 2 h and 3 h  
relative to the control of FITC-dextran stock on the apical side which was defined as 100 %. * p < 0.05 was 
considered to be statistically significant. The data points are means of three replicates (n=3) and the error bars 
represent ± standard deviation (±SD) of three inter repeats of an experiment. 
 
6.2.1.1 Apparent permeability (Papp) of the designed models 
The linear relationship of FITC-dextran concentration versus relative fluorescence unit 
(RFU) was plotted to quantify concentration of FITC-dextran, to enable further calculation 
of the apparent permeability co-efficient Papp value for both models by using the formula 
described in Section 2.9.2.   
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Figure 6.2: Standard plot of fluorescence versus concentration of FITC-dextran measured at excitation 
wavelength 492 nm and emission wavelength 518 nm. The data points are means of three replicates (n=3). 
 
The Papp values of the in vitro BBB models are shown in Table 6.1Error! Reference source 
not found.. The apparent permeability of tri-culture was lower at 6.18 ± 1.38 x 10-5 cm. min-
1 compared to 15.08 ± 1.40 x 10-5 cm. min-1 obtained for the co-culture model.  
Table 6.1 Apparent permeability value of the in vitro BBB models  
 
Model Papp values  
(cm. min-1) 
Tri-culture [HBMEC, HA (in-
contact) and HBVP (out of 
contact)] 
6.18 ± 1.35 x 10-5 
Co-culture [HBMEC and HA 
(in-contact)] 
15.08 ± 1.40 x 10-6 
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6.2.2 Screening of nanoparticles and aptamer 
SA43 Aptamer and lipid nanoparticles containing docetaxel, curcumin and asiatic acid were 
screened on the tri-culture in vitro BBB model to determine their permeability across the 
barrier. As the NPs contained known toxic drugs and the cytotoxicity properties of the 
aptamer were unknown, it was necessary to determine the optimum concentration to be used 
in the tri-culture model by investigating the cytotoxicity of the NPs on endothelial cells.  
Presence of a cytotoxic response would cause a breakdown in the barrier leading to the 
generation of false data. Cell viability screening following exposure to aptamer and NPs was 
done using the MTS assay and the percentage of viable cells was determined (see Section 
2.9.3). 
6.2.2.1 Toxicity screening of nanoparticles and aptamer by MTS 
The toxicity screening of the NPs determined the concentration of the NPs to be used for the 
cellular uptake studies. All percentage viability was expressed relative to the vehicle control 
for the aptamer/ NP. As seen in Figure 6.3, the percentage cell viability of docetaxel loaded 
lipid NPs decreased with time, showing lowest percentage of 67.04 % of viable cells on day 
3 at a concentration of 0.1 µg/ml. The docetaxel lipid nanoparticle tagged with rhodamine 
(Figure 6.3 A) showed similar results as compared to docetaxel lipid nanoparticle tagged 
with rhodamine and transferrin ligand. The transferrin ligand tagged NPs showed a decrease 
in per cent viable cells with time, showing 64.24 % viable cell at 72 h at a concentration of 
0.1 µg/ml.  (Figure 6.3 B). The concentration of 0.1 µg/ml was used for screening in the 
models  
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Figure 6.3: Percentage cell viability of endothelial cells relative to vehicle control after treatment with three 
different concentrations of docetaxel loaded lipid nanoparticle at time points 24 h, 48 h and 72 h determine by 
the MTS assay.  
A. docetaxel loaded lipid nanoparticle tagged with fluorescent rhodamine123. B. docetaxel loaded lipid 
nanoparticle tagged with fluorescent rhodamine123 and the ligand transferrin. The vehicle control used in the 
experiment was 5 % dextrose. The data points are means of three replicated (n=3) and the error bars represent 
± standard deviation (±SD).  
A 
B 
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As seen in Figure 6.4, the asiatic acid lipid NPs (A) and empty asiatic acid lipid NPs (B) 
showed that percentage cell viability decreased with time, with lowest percentage of viable 
cells at 72 h. At 24 h, all of the different concentration 1.2 µg/ml, 0.12 µg/ml and 0.012 µg/ml 
of the asiatic acid loaded lipid nanoparticle showed similar percentage of cell viability, 
however, the cell viability decreased at 48 h and 72 h (Figure 6.4 A). After 72 h, 68.68 % of 
viable cells were observed with 1.2 µg/ ml of asiatic acid loaded lipid nanoparticle. In Figure 
6.4 B, empty lipid nanoparticles were tested showed a higher percentage of of viable cells 
(83.49 %) at 24 h when compared to asiatic acid loaded nanoparticle. The percentage of 
viable cells decreased with time for all NP except for the cells incubated with empty asiatic 
acid nanoparticle which did not show any difference in the cell viability (Figure 6.4), where 
at 24 h, 48 h and 72 h, the per cent viability was 84 %, 83% and 87 % at 1.2 µg/ml, 0.12 
µg/ml and 0.012 µg/ml respectively. The concentration of 0.12 µg/ml was used for screening 
in the models 
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Figure 6.4: Percentage cell viability of endothelial cells relative to vehicle control after treatment with three 
different concentrations of lipid nanoparticle at time points 24 h, 48 h and 72 h as measured by the MTS assay.  
A. asiatic acid loaded lipid nanoparticle. B. empty asiatic acid lipid nanoparticle. The vehicle control used in 
the experiment was 0.1 % DMSO. The data points are means of three replicates (n=3) and the error bars 
represent ± standard deviation (±SD).  
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As seen in Figure 6.5 following exposure of curcumin loaded NP, the percentage cell viability 
decreased with time, showing lowest percentage of 70 % viable cells at 72 h at a 
concentration of 2.87 µg/ ml (Figure 6.5 A). At 24h and 48 h these NPs showed cell viability 
of 98 % and 83 % at 2.87 µg/ ml. As seen in Figure 6.5 B, the SA43 aptamer did not show 
any change in the percentage cell viability up to 48 h. At 72 h, there was a decrease in the 
cell viability from 98 % to 92 % at a concentration of 100 nM. The concentration of 0.1 µg/ml 
of curcumin lipid NPs and 10 nM of SA43 aptamer was used for screening in the models 
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Figure 6.5: Percentage cell viability of endothelial cells relative to vehicle control after treatment with three 
different concentrations of NPs and SA43 aptamer at time points 24 h, 48 h and 72 h as measured by the MTS 
assay. 
A. curcumin loaded lipid nanoparticle, 0.1 % ethanol was used as vehicle control. B. SA43 aptamer, 200 µl of 
culture media was used as vehicle control. The data points are means of three replicates (n=3) and the error bars 
represent ± standard deviation (±SD). 
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6.2.2.2 Permeability of nanoparticles and aptamers 
After validating the models for passive diffusion using the FITC-dextran, the aptamer SA43 
(cy3 tagged) was tested for its permeability across the in vitro BBB tri-culture model. The 
concentration of the aptamer used for screening was determined by the MTS assay (see 
Section 2.9.3). The permeability of the aptamers was significantly lower when compared 
FITC-dextran and a similar trend was seen at all time intervals. 
 
Figure 6.6: Permeability of aptamers SA43 (10nM) and FITC-dextran across different in vitro BBB tri-culture 
model [HBMEC, HA (in contact) and HBVP (out of contact)] at time intervals 1 h, 2 h & 3 h. 
The data points are means of three replicates (n=3) and the error bars represent ± standard deviation (±SD) of 
three inter repeats of an experiment. 
The Papp value for all the NPs was determined as seen in Table 6.2. 
 Table 6.2 Papp of the NPs and SA43 aptamer 
Molecule Papp 
SA43 Aptamer 4.32 ± 3.90 x 10-6 cm/ min 
Docetaxel loaded lipid nanoparticle with ligand transferrin  5.76 ± 7.83 x 10-6 cm/ min 
Docetaxel loaded lipid nanoparticle  7.94 ± 6.72 x 10-6 cm/ min 
Curcumin loaded lipid nanoparticle 5.88 ± 9.31 x 10-6 cm/ min 
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6.2.2.3 Cellular uptake of nanoparticles and aptamers 
It is essential to develop NPs which are permeable across the BBB and are able to deliver 
drugs to the tumour site. The NPs can pass through the BBB by paracellular transport via 
opening of the tight junctions which can be assessed by measuring the TEER values across 
the barrier. A sharp drop in the TEER values is indicative of the TJs opening, if the TEER 
stabilises and come back to the initial value it indicates that the opening of the TJs was 
transient and did not damage the barrier 
The NPs and aptamer were tested for their permeability across the BBB, the measurements 
of TEER was done over a time course of 24 h. The drop in TEER indicated the transient 
opening of TJs, therefore concluding that the NPs were permeable across the designed in 
vitro BBB model.  As seen in Figure 6.7 A, the docetaxel loaded lipid nanoparticle showed 
a decrease in TEER values from 292 Ω/cm2 to 168 Ω/cm2 at 1.5 h whereas when tagged with 
transferrin as a targeting ligand for delivery, the nanoparticle showed a decrease in TEER 
from 294 Ω/cm2 to 157 Ω/cm2 at 0.5 h (Figure 6.7 B). In both instances the TEER values 
gradually increased and stabilised. Asiatic acid loaded lipid nanoparticle and empty 
nanoparticle both did not show any change in the TEER values (Figure 6.7 C and D). The 
SA43 aptamer showed a decrease in the TEER values at 1 hr, which gradually increased and 
stabilised at 6 h (Figure 6.7 F). The curcumin loaded lipid nanoparticle has previously been 
shown to cross the BBB in vivo, and therefore was used as a positive control (Kakkar et al., 
2013). It showed a drop in the TEER value at 0.5 h and the TEER values gradually increased 
and stabilised by 6 h (Figure 6.7 E). Evans Blue Dye (EBD) was used as negative control 
which is known not to cross the BBB in vivo (Bing et al., 2014). EBD did not show any 
change in the TEER values and TEER remained constant at 290 ± 10 Ω/cm2 (Figure 6.7 G). 
Cells only, were used as a control to make sure that the barrier was intact at all time during 
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the measurement and the measures of TEER were true values and not artefacts of a leaky 
barrier.  
 
Figure 6.7 Time course TEER measurement of tri-culture BBB model to study the effect of NPs on the 
resistance of the barrier.  
A. Docetaxel loaded lipid nanoparticle tagged with rhodamine (0.1 µg/ml) B. Docetaxel loaded lipid 
nanoparticle tagged with rhodamine and transferrin ligand  (0.1 µg/ml) C. Empty asiatic acid lipid nanoparticle 
(0.12 µg/ml) D. Asiatic acid loaded lipid nanoparticle (0.12 µg/ml) E. Curcumin loaded lipid nanoparticle 
(0.287 µg/ml) F. SA43 aptamer (10 nM) G. Evans blue (negative control) (1 µg/ml) H. Cells only (control).  
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6.3 Discussion and conclusion 
An in vitro model is needed to predict permeability and concentration of therapeutic drug 
reaching the site of action for drug-loaded NPs and targeted delivery molecules which can 
be used as potential therapeutics for glioma. It is essential to fully characterised the models 
before it is used to screen these novel molecules. The highly selective nature of BBB is a 
hurdle to the delivery of drugs to CNS tumours, therefore it is essential to study the 
permeability of drugs and NPs across the BBB. The designed in vitro model was 
characterised to determine the permeability of FITC-dextran, NPs and aptamers across the 
formed BBB. Macromolecules, conjugated to fluorescent probes, are frequently used to 
evaluate the permeability of barrier across semi-permeable membranes (Yuan and Rigor, 
2011). Dextran is a complex branched hydrophillic glucan molecule which comprises of 
chains of varying length of polysaccharide ranging between 3 to 2000 kDa, it is a 
biocompatible and biodegradable molecule largely used to study the concentration gradient 
of diffusible molecules and subsequent characterisation of gradient slopes (He et al., 2011). 
The dextran tagged to fluorescent molecules such as FITC or rhodamine can be used to study 
the permeability of different models (Yuan and Rigor, 2011). These validated models can 
then be used to commercially screen novel compounds and delivery systems, such as the NPs 
and aptamers, to study the permeability across the in vitro BBB model. In the current study, 
the co and tri-culture models were tested for their permeability using FITC tagged dextran 
since these two models showed high resistance (TEER values) indicating that the barrier 
formed was intact. The tri-culture model showed lower permeability of dextran as compared 
to the co-culture. The permeability is an important factor for validating a BBB model due to 
the highly selective nature of the BBB in vivo. The permeability data was used to calculate 
the Papp values for the two designed models. The Papp values showed that the tri-culture model 
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had significantly lower permeability, 6.08 ± 1.40 x 10-6 cm/ min when compared to the co-
culture model 15.08 ± 1.40 x 10-6 cm/ min. An in vitro BBB model should ideally have a low 
apparent permeability, this makes the model useful in screening and determining the 
permeability of novel drugs, NPs. From the above Papp value, it was concluded the tri-culture 
model was a more intact and rigid model and hence it can be used to screen compounds to 
determine permeability across the designed barrier. According to the literature, compounds 
can be typically classed as low permeability with a Papp < 60 x10
-6 cm/ min or high 
permeability with a Papp >  60 x10
-6 cm/ min, which confirmed that FITC-dextran in the tri 
and co-culture was still classified as a low permeability molecule, as expected (Di et al., 
2003). In the literature the Papp for 20 kDa dextran in the endothelial monoculture was 
reported to be 600 x10-6 cm/ min (Ma et al., 2008). 
To ensure that the permeability and uptake experiments of nanoparticles and aptamers were 
made across an intact and viable BBB, the effects of low, mid and high concentrations of 
NPs and aptamers were assessed with respect to time, using the MTS assay on endothelial 
cells and the concentrations that were found to be least cytotoxic following 24 h exposure 
were used for the permeability and cellular uptake studies. Evans blue was used as a negative 
control, and no permeability was observed either before or after application of NPs or 
aptamers, proving the barrier had remained intact. 
Numerous diseases such as glioma, inflammatory diseases, diabetes and microbial infections 
can cause the disruption of the BBB. The disruption of the BBB in most circumstances is 
considered as harmful to the patient since it can lead to influx of leukocytes, potential active 
neurotoxins and water from the blood (Zlokovic, 2008). This disruption is associated with 
changes in the endothelial phenotype, decrease in the expression of tight junction proteins 
and remodelling of the junctional complex (Liebner et al., 2008). It is essential to understand 
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the significance of opening of TJs in permeability across the BBB since the ability to 
modulate of the opening of tight junction enables prevention of adverse effects caused due 
to the BBB disruption and the transport of therapeutics to the brain for the effective treatment 
of neurological disorders (Zlokovic, 2008; Weidenfeller et al., 2005). 
Therapeutics for glioma are limited due to the inability of the drugs to reach the tumour site 
across the BBB. Recently interest in research into methods of disrupting the BBB have been 
revisited, such as transient opening of the paracellular pathway, however opening would need 
to be short in duration and specific to the chemotherapeutic that needs to be delivered 
(Stamatovic et al., 2008). Several methods have been devised for the transient opening of the 
BBB for the delivery chemotherapeutics to glioma and other neuroectodermal tumours 
(Stamatovic et al., 2008). An intra-arterial injection of mannitol arabinose, lactamide, saline, 
urea and several radiographic contrast agents were used to reversibly disrupt the BBB 
(Bellavance et al., 2008). These agents are hyperosmolar in nature and cause shrinkage of 
the endothelial cells, thus opening of tight junction. In the current study, the cellular uptake 
of the NPs and aptamers across the BBB model via the paracellular permeability was assayed 
by transient decrease and recovery of TEER, thought to be an indicator of TJs opening. The 
docetaxel loaded nanoparticle with and without the transferrin ligand and the SA43 aptamer 
showed a sharp drop in the TEER values as compared to the positive control curcumin loaded 
NPs. The TEER value of the tri-culture dropped within 1 h from 295 Ω/cm2 to 160 Ω/cm2 on 
addition of the aptamer, docetaxel lipid NPs with transferrin ligand and curcumin loaded 
NPs. The TEER value of the docetaxel loaded NPs dropped to 160 Ω/cm2 from 290 Ω/cm2 
after 1.5 h of incubation with the NP. This indicated the transient opening of the tight junction 
for the paracellular transport of the NPs and aptamer. In a previous study by Kakkar et al. 
(2013), curcumin loaded lipid NPs. have shown to cross the BBB in vivo and these NPs 
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exhibited similar properties in vitro (Kakkar et al., 2013). Both the docetaxel loaded NPs, 
aptamer showed similar TEER values of the curcumin loaded NPs. The data confirms that 
both the docetaxel loaded nanoparticles and the SA43 aptamer are permeable through the 
designed BBB model.  
The NPs and the aptamer when introduced in the tri-culture BBB model caused a change in 
the TEER values which indicated that they interact with the TJs proteins in the endothelial 
barrier causing them to open transiently. The endothelial barrier comprises of actin-myosin 
interactions, the junction proteins that contribute to its restrictive properties (Stamatovic et 
al., 2008). The increase in the paracellular permeability is due to the loss of adhesive 
properties of the junction proteins and the reorganisation of the actin cytoskeleton that cause 
formation of minute inter-endothelial gaps in the barrier (Bazzoni, 2006; Garcia and 
Schaphorst, 1995; Kago et al., 2006). These minute gaps are formed due to change in the 
adhesive properties of phosphoproteins such as tight junction and gap junction proteins. The 
alteration in phosphorylation state of these junction proteins causes a change in their 
interactions, alter transmembrane protein localisation and induces redistribution (Kago et al., 
2006; Kroll and Neuwelt, 1998). The phosphorylation causes a redistribution of the junction 
proteins which disturbs the adhesive contact between the endothelial cells. This is clearly 
observed by the sharp drop in the TEER values across the barrier and low permeability co-
efficient of tracer molecules such as FITC-dextran or fluorescent NPs (Stamatovic et al., 
2006; Stamatovic et al., 2003; Ye et al., 2014). The TJs comprises of membrane proteins 
occludin, claudin, JAM-A and intracellular proteins ZO-1. All these proteins together interact 
to maintain the cell polarity, paracellular permeability and signal transduction at the BBB 
(Bazzoni, 2006) (Lohmann et al., 2004; Haorah et al., 2007).  
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Proposed mechanisms for transient TJ opening have focussed on phosphorylation status. The 
exact phosphorylation site of occludin is still unknown, however, numerous papers have been 
published in the aim of identifying the target site for phosphorylation (Ma et al., 2007; 
Hartsock and Nelson, 2008; Raleigh et al., 2011; Liebner et al., 2000). Raleigh et al., 
explained the occludin S408 on phosphorylation enhances the interaction between tight 
junction proteins and releases the ZO-1 and causes a flux of negatively charged ions 
promoting the paracellular cation flux by claudin-1 and claudin-2 based pores. On the other 
hand on dephosphorylation stabilises the interactions between ZO-1 and occludin thus 
reducing the paracellular flux of ions and preventing pore assembly or opening of the 
junctions between the endothelial cells (Raleigh et al., 2011). Stamatovic et al. (2006), 
suggested that VEGF and CCL2 induce Ser/Thr phosphorylation and cause redistribution of 
TJ protein occludin and ZO-1 and Tyr-phosphorylation causes reorganisation of the TJ 
complex in murine brain endothelial cells (Stamatovic et al., 2006). There is still no clear 
evidence on how the redistribution occurs, Smythe et al., suggested that polymerisation of 
the actin filament, actin and myosin association and generation of intraendothelial contractile 
forces leads to pulling in of the endothelial cells that causes the redistribution of 
transmembrane proteins (Smythe and Ayscough, 2006; van Hinsbergh and van Nieuw 
Amerongen, 2002). 
The regulation of permeability by the paracellular transport comprises of interactions 
between components of endothelial cells and agonist activated signalling pathway. Protein 
kinase C (PKC) is an important regulator of the TJ and TJ-mediated permeability (Stamatovic 
et al., 2008). PKC is a family of serine/threonine kinases which involve controlling function 
of other proteins by phosphorylation of the hydroxyl groups of serine, threonine amino acid 
residues. Proteins of these families are involved in the regulation of various cell cycles, 
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apoptosis, and migration (Willis et al., 2010). Signalling molecules, such as Rho kinase, that 
are involved in the regulation of BBB permeability can also be used as targets for transient 
opening of the BBB. The molecules involved in the signalling pathways play an important 
role in the paracellular permeability of the endothelial barrier. Rho kinase is a part of the 
PKC signalling pathway, it is mainly involved in the regulation of shape and movement of 
the cell by acting on the cytoskeleton. Others signalling molecules involved disassembly of 
the TJs include endothelin-1 and PKC isoenzymes (α, βI, βII, γ, δ, ε, ζ, η, λ, μ and ι) 
(Stamatovic et al., 2008).   
In the current study, lipid NPs and asiatic acid loaded lipid NPs did not show any change in 
the TEER values suggesting that these NPs did not cause a transient opening of the tight 
junction, it cannot be confirmed that the NPs did not cross the BBB, there are alternate routes 
which can be used by the NPs to move across the barrier, and unfortunately there was no 
fluorescent tag on the asiatic acid NPs to assay the flux across the BBB. The transport of NPs 
across the BBB can also occur through transcellular lipophilic pathway, since the NPs are 
made of lipids. These can also be transported by transport proteins or receptors located on 
the cell membrane. The NPs can bind to the receptors located on the cell surface which then 
engulf the NPs and transport it across the endothelial layer by transcytosis (Abbott et al., 
1992; Abbott et al., 2006a; Abbott, 2002). All of these transcellular methods do not affect 
the TJs assembly between the cells and hence the TEER values remain the same. (Simionescu 
et al., 1975; Kroll and Neuwelt, 1998; Haluska and Anthony, 2004).  
In conclusion, the tri-culture model was utilised to test novel NPs and aptamers for their 
permeability across the BBB. In future, the mechanism involved in the transfer of 
nanoparticles across has to be studied in much more detail to understand the transient opening 
of the barrier induced by the NPs and aptamer.   
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 Developing a brain tumour barrier 
model 
7.1 Introduction 
Major components of the blood brain barrier (BBB) include the endothelial cells, which are 
interconnected by tight junctions (TJs) and dynamically interact with the astrocytes, pericytes 
and neurons, forming the neurovascular unit. The BBB maintains homeostasis and protects 
the brain from xenobiotics and controls the level of neuroactive mediators (Pardridge, 2003; 
Abbott et al., 2012; Zlokovic, 2008). The highly selective nature of the BBB restricts the 
delivery of drugs administered for neurological disorders making treatment difficult. 
Glioblastoma multiforme (GBM) is an example of disorder where the BBB causes treatment 
issues. A patient suffering from GBM, a malignant form of glioma shows a median survival 
of 12 -15 month despite of optimal treatment and standard care (Inda et al., 2014). patients 
with GBM exhibit poor prognosis due to the highly invasive nature of cells, however it is 
still not clear how the GBM disrupts the BBB while invading to other sites of the normal 
brain tissue (Vartanian et al., 2014). Even after tumour resection, the GBM cells remain in 
the peritumoural tissue often causing relapse of GBM. 
In this chapter the effect of GBM cells on the newly constructed, optimised and characterised 
tri-culture in vitro BBB model, developed in chapter 5, was studied. The GBM cells; short 
term cultures of BTNW370 and BTNW914 were added to the tri-culture in the form of 
spheroids and the effect on the TEER was studied. The GBM spheroids were seeded on the 
basolateral side of the insert in the setup of the tri-culture model of human microvascular 
endothelial cells (HBMEC), human astrocytes (HA) (in-contact) and human brain vascular 
pericytes (HBVP) (out of contact) as described in Section 2.8. These models were also used 
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to assess the permeability and disposition of nanoparticles (NPs) including docetaxel loaded 
lipid NPs tagged with rhodamine123 with and without transferrin ligand and curcumin loaded 
lipid NPs across the BBB and to the glioma. 
7.2 Results 
7.2.1 TEER measurements 
The TEER measurements of the different brain tumour barrier (BTB) models were conducted 
to study the influence of the GBM cell spheroid on the resistance across the formed BBB. 
Since the GBM cells are highly invasive in nature they are expected to show disruption the 
intact barrier, a phenomenon that has been documented in vivo (Inoue et al., 2010). The tri-
culture model of HBMEC, HA (in-contact) and HBVP (out of contact) was set up and the 
TEER measurement were taken on day 1. GBM cells in the form of spheroids; BTNW370 
and BTNW914 were seeded in the tri-culture set-up on the basolateral side overlaid on the 
pericytes. The TEER readings of these models were taken each day up to day 15 with the tri-
culture model alone used as a control. The measurement was taken 5 times on each insert 
with three intra experimental replicates. 
As seen in Figure 7.1, TEER readings of all the tri-culture models were plotted together on a 
scatter plot to compare the TEER values of the different models. The scatter plot compares 
the trend of TEER measurements for each model over the 15 days. The tri-culture models 
with the GBM spheroids showed a sharp increase in the TEER values up to day 5, after which 
the TEER dropped when compared to tri-culture model (control) which showed a steady 
increase in the TEER values. The tri-culture model with GBM spheroids (basolateral side) 
showed an increase up to day 6. The TEER values on day 6 was 116 Ω/cm2 which dropped 
after day 6 and continued to decrease up to day 12 to 34 Ω/cm2. On day 13, the model showed 
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a slight increase to 47 Ω/cm2 and decreased until day 15. The tri-culture model (control) 
showed a steady increase in TEER up to day 12 giving a maximum TEER value of 265 
Ω/cm2. 
 
Figure 7.1 Comparison of TEER values in tri-culture model with GBM spheroids (basolateral side) compared 
to tri-culture alone without GBM. 
There was a steady increase in the TEER values for all models up to day 5. After day 6 the tri-culture model 
with GBM spheroids showed a decrease in the TEER values as compared to tri-culture model. The data points 
are means of three replicates (n=3) and the error bars represent ± standard deviation (±SD). 
 
7.2.2 Expression of Efflux transporters and DMEs in GBM spheroids. 
The tumour shows the presence of efflux transporters and DME expression which will 
contribute an additional barrier causing drugs efflux and metabolism out of the tumour which 
leads to further reduction in bioavailability. The expression of efflux transporter; ABCB1 and 
ABCG2 and DMEs; CYP3A4 and CYP2D6 in GBM spheroids was compared with the same 
GBM cells grown in monolayer was studied by Western blots. As seen in Figure 7.2A & B, 
GBM spheroids showed a higher expression of both the efflux transporters compared to the 
monolayer. The expression of ABCB1 was 124.91 A.U. and ABCG2 was 99.88 A.U. when 
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compared to monolayer which had a densitometry value of 28.66 A.U. and 48.63 A.U. 
respectively, as seen in the densitometry graph (Figure 7.2 E). β-actin was used to normalise 
the data and to confirm that each well was loaded with equal amount of protein. In Figure 
7.2C & D, the expression of CYP3A4 and CYP2D6 was higher in GBM spheroids when 
compared to monolayer. This was confirmed by densitometry which showed expression of 
CYP3A4 was 151.59 A.U. and CYP2D6 was 148.27 A.U.  (Figure 7.2E). 
 
 
Figure 7.2 Comparison of expression between GBM spheroids and monolayer. 
A. Expression of ABCB1 transporter. B. Expression of ABCG2 transporter. C Expression of CYP3A4 D 
Expression of CYP2D6. β-actin was used as the loading control. E. Densitometry of the expression of efflux 
transporter; ABCB1 and ABCG2 and DMEs; CYP3A4 and CYP2D6 Each well was loaded with 10 µg of 
protein. 
A 
B A 
C D 
B 
D C 
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7.2.3 Testing of NPs in the developed BTB model 
The drugs administered for the treatment of glioma often have CNS bioavailability at the 
tumour even though the BBB is leaky at the site of tumour (On et al., 2013). This may be 
due to the activity of efflux transporter at the tumour site. Transporter functional status plays 
an important role in the disposition of the glioma therapeutics. It is essential to study the role 
of these efflux transporters and take into account their role while designing a model for 
prediction of drug efficacy for glioma. 
The tri-culture GBM models were tested to determine the uptake of NPs by the GBM 
spheroids. To determine the role of the efflux transporters, NP uptake was done in the 
presence and absence of an efflux transporter inhibitor. Vinblastine was used as the inhibitor 
of efflux transporter. The docetaxel loaded lipid NPs tagged with rhodamine123 with and 
without transferrin ligand and curcumin loaded lipid NPs were incubated in the tri-culture 
GBM models on the apical side of the insert. The NPs were also incubated in tri-culture GBM 
models in the apical side of the insert with an inhibitor for efflux transporters. The inhibitor 
was seeded along with the NPs. At different time points the fluorescence of the spheroids 
were read under the plate reader for their fluorescence to determine the uptake of NPs by the 
GBM. The fluorescence was plotted % fluorescence relative to the stock of NPs. 
As seen in Figure 7.3, the fluorescence of the GBM spheroids due to accumulation of NPs 
were read at different time intervals on tri-culture models with GBM spheroids on the 
basolateral side. All the GBM spheroids show an increase in fluorescence with time. The 
fluorescence of NPs was higher in GBM spheroids with the inhibitor. The docetaxel loaded 
lipid NPs with and without inhibitor at 0.5 h showed a very low fluorescence due 
accumulation of NPs, 3.47 % and 4.39 % respectively as compared to the other NPs. The NP 
accumulation shows an increase with respect to time and at 3 hrs the fluorescence reaches 
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62.71 % and 35.69 % with and without inhibitor respectively (Figure 7.3A). The docetaxel 
loaded lipid NPs with transferrin ligand showed highest accumulation of NPs at time 0.5 h 
was 33.91 % and 17.77 % with and without inhibitor respectively. The fluorescence due to 
NP within cells shows an increase with time and at 3 h the accumulation reaches 77.69 % 
and 53.79 % with and without inhibitor respectively (Figure 7.3B). The GBM spheroids 
showed fluorescence due to accumulation of curcumin loaded lipid NPs with transferrin 
ligand NPs at time 0.5 h was 29.71 % and 15.76 % with and without inhibitor respectively. 
The accumulation shows an increase with time and at 3 h the accumulation reaches 74.06 % 
and 52.35 % with and without inhibitor respectively (Figure 7.3C).   
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Figure 7.3 NPs uptake by spheroids on tri-culture with GBM (basolateral side). 
A 0. 33 µg/ml Docetaxel loaded lipid nanoparticle tagged to rhodamine123 B 0.33 µg/ml Docetaxel loaded 
lipid nanoparticle tagged to rhodamine123 with transferrin ligand C 2.87 µg/ml curcumin loaded lipid 
nanoparticle. Stock concentration was the concentration of NPs seeded on the apical side of the insert at time 0 
h. Data is representative of a single experiment. 
stock 
stock 
stock 
C 
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7.3 Discussion and conclusion  
The BBB is a highly selective barrier and regulated by many components which include the 
tight junction proteins, efflux transporters, cytoskeletal components. The barrier function is 
regulated in response to any change in the microenvironment such as tumours, inflammatory 
processes. Nir et al., demonstrated in tumour conditions the capillary endothelial cells are 
disturbed due to the pressure exerted by the tumour bulk (Nir et al., 1989). This makes the 
BBB leaky which provides a passage for the glioma therapeutics to reach the tumour site. 
The functional efflux transporter serves as the transport barrier, which is responsible for the 
disposition of these glioma drugs at the tumour site.  
In this study, the GBM spheroids were added to the tri-culture model, which represents a 
functional, characterised BBB model (Chapter 5). These GBM spheroids were derived from 
tumour biopsies from glioma patients. The GBM cells were seeded at the bottom of the 
culture overlaid on the pericytes or on the apical side overlaid on the endothelial cells. The 
TEER measurement in the control showed a steady increase up to day 12 which begins to 
plateau, this is due to the formation of TJs. The TEER measurement of the models, unlike 
the tri-culture on its own, showed a peak in the first few days of culturing and then show a 
drop after day 6. The increase in TEER may be due to the expression of the protein, 
transforming growth factor (TGF). It had been shown that the GBM cells increased secretion 
of TGF which is a cell growth mediator and plays an important role in proliferation and 
differentiation of cells (Joseph et al., 2013; Golestaneh and Mishra, 2005). We can assume 
that TGF secreted by the GBM cells causes the TEER increase due to cell proliferation, the 
increase in cell proliferation leads to increase in cell-cell communication that increases the 
TJs proteins. These observations suggest the possible involvement of TGF in blood-tumour 
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barrier and BBB impairment in GBM. No data was found in the literature with respect to this 
study so no comparison could be made with other findings. 
GBM cells also show overexpression of vascular endothelial growth factor (VEGF), which 
is an angiogenesis factor. VEGF has been linked with increasing the paracellular permeability 
in a BBB model (Miao et al., 2014). Increase in paracellular permeability leads to access NPs 
permeating into the basolateral side thus. Both these factors have not been studied in a brain 
tumour barrier model before and this could be pivotal in understanding the role of these 
soluble factors which influence the endothelial cells and basement membrane at the BBB 
making it leaky (Figure 7.4). 
 
 
Figure 7.4 BBB structure in vivo. a) normal BBB model b) BBB model when leaky. 
 
In glioma, the drugs delivered are able to pass through the leaky BBB, however the drugs are 
effluxed out of the tumour due the efflux transporters at the tumour site. Another study was 
conducted to elucidate the role of efflux transporters located at the tumour site involved 
 
 
273 
testing the uptake of NPs by GBM spheroids. From chapter 6, it was concluded that the NPs 
were permeable across the robust BBB tri-culture model. The NPs were uptaken by the GBM 
both in the presence and absence of inhibitor. In glioma, as mentioned before the BBB is 
leaky and the drug disposition is carried out by the efflux transporters. From the data, we can 
observe that the GBM spheroids with the inhibitor show high accumulation as compared to 
GBM cells without the inhibitor due to the high fluorescence of the NPs from the model 
without the inhibitor. This indicated that the efflux transporters are effluxing the drugs 
actively out of the cells in the spheroid, however no data was found to compare the findings  
In conclusion, this BTB model show very promising role in prediction of drug disposition 
for glioma. This model currently needs extensive characterisation and protein expression 
studies to establish it as a fully functional BTB model.  
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 Discussion 
8.1 General discussion 
For the last four decades patients with glioma have not shown any improvement in the median 
survival rate when compared to patients with other cancer types such as colon cancer (Rachet 
et al., 2009). Glioma are the most common primary malignant brain tumours in adults and 
comprise of 81 % of the malignant brain tumours (Ostrom et al., 2014). There have been 
numerous drugs designed to treatment glioma, however, these have not shown a significant 
improvement in patient survival. The major hurdle in the treatment of glioma is the blood 
brain barrier which comprises of a physical barrier made up of tight junction proteins and a 
metabolic barrier consisting of efflux transporters and drug metabolising enzymes (DMEs) 
that limit the penetration and efficacy of various CNS drugs (Hitchcock, 2008). At molecular 
level, the function of the barrier at the brain and blood junction mainly involves the efflux 
transporters localised in the luminal membrane of brain capillary endothelial cells which 
restrict the brain uptake and extrusion of xenobiotics (Loscher and Potschka, 2005b; Dean et 
al., 2001). The localised enzymes present at the junction are responsible for metabolising the 
drugs, therefore leading to poor bioavailability.  
There has been an emergence of cell based in vitro models as potential tools to study the in 
vivo mechanisms at the BBB. These models are cost effective, versatile and require a simple 
working environment compared to the in vivo systems (Cecchelli et al., 2014). To date, all 
the research in the BBB field has been focussed on developing a robust in vitro BBB model 
which focuses on the physical barrier and that shows a high expression of tight junction 
proteins and TEER which makes the model highly selective, however the importance of the 
metabolic BBB has often been overlooked. Screening of novel anti-cancer drugs on these 
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models characterised for just the physical barrier only provide us with information about the 
permeability of the drug. There is an urgent need to develop a model which is physiologically 
relevant and focusses on the physical, transport and metabolic barrier present at the blood 
and brain junctions and more importantly a model that is designed with a goal to delivering 
chemotherapeutics to CNS tumours. The proposed model should take into consideration the 
role of efflux transporters and metabolic enzymes in drug disposition.  
The main aim of the project was to design an all human, fully characterised and 
physiologically relevant in vitro BBB model for the prediction of permeability of drugs 
across the blood brain barrier to glioma. To date, numerous models have been designed and 
patented with the desire to construct a fully functional in vitro BBB model which can be used 
to predict efficacy of drugs for neurological disorders, such as those listed in Table 1.5, but 
as yet no model has been reported to be optimised for metabolic function, including 
expression and activity of efflux transporters and DMEs. 
The primary background work before developing the model was to characterise the cell lines 
which were to be used to construct the model and study the growth characteristics. The 
growth curves were used to determine cell population doubling time and exponential growth 
phase. In the past decade there has been an emerging understanding, about cellular cross-
contamination, misidentified cell lines, and the use of cultures at high-passage levels 
contributing to the generation of erroneous and misleading results (Hughes et al., 2007). 
Numerous reviews and research articles have been published mentioning the significance of 
experimental variance between different passage numbers and the need for use of verified, 
tested and characterised cell lines at low or defined passage number (Rojas, 2011; Apps et 
al., 2009; Lucey et al., 2009; Wenger et al., 2004; Hughes et al., 2007; Tsujino et al., 1997; 
Halfter et al., 1998; Grippo et al., 2001). 
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In the current study, the three cell lines, U87MG (grade IV, glioblastoma), 1321N1 (grade 
IV, malignant astrocytoma) and SVGp12 (foetal glial astrocyte) were characterised for their 
origin and type showing positive staining for both HLA and GFAP. The short term glioma 
cultures derived from patient biopsies were characterised for their phenotype using 
antibodies raised against CD44 antigen, EMA antigen and GFAP antigen and it was 
concluded that with the increase in passage number the cells began to lose their characteristic 
phenotype. These findings were supported by Wenger et al. (2004), he reported difference in 
the phenotype of MCF-7 cell line at two different passage numbers and  reiterate the necessity 
for periodically evaluating cells to confirm their origin (Wenger et al., 2004). 
After characterisation of cell line phenotype, the next crucial step in the study was to 
determine the expression of efflux transporters and DMEs and to maximise their expression 
by altering culture conditions. Pan et al. (2009), reported that Hepa1 cells derived from liver 
cells were deficient in mitochondria which led to metabolic pathway, drastically up-
regulating cell cycle-associated functions and largely shutting down drug metabolizing 
enzymes (Pan et al., 2009). It was therefore essential to choose cells which were true to the 
proposed phenotype. Efflux transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and 
CYP2D6 were chosen to be studied. The expression was studied in cell lines (hCMEC/D3, 
U87MG, 1321N1 & SVGp12) and short-term cultures (HBMEC, HBVP, HA, BTNW914 & 
BTNW370). The expression of the efflux transporters; ABCB1 and ABCG2 and DMEs; 
CYP3A4 and CYP2D6 was higher in short term cultures leading to selection of these cells 
to construct the in vitro BBB model. The expression and activity of proteins was higher in 
short-term cells compared to immortalised cell lines which has also been previously reported 
by Alge et al. (2006), who compared the protein expression profiles of short-term versus 
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immortalised human retinal pigment epithelial (RPE) cell line and found that expression of 
proteins was higher in short-term cultures (Alge et al., 2006).  
This then lead to optimising of culturing conditions to enhance the expression and activity of 
the DME and transporter proteins. It has been reported by numerous papers that culturing 
conditions can largely affect the protein expression and activity of cells in culture (Kumar et 
al., 2008; Kumar et al., 2014; Marini et al., 2014). The conditions were altered, bearing in 
mind that all the culturing elements were from human origin so that the model developed 
should be a true representative of human BBB and should not show any elements of inter 
species variability. Due to inter species variability, such as altered DME and transporter 
phenotype, the permeability and effects of the novel therapeutics could be misinterpreted, 
therefore, considerable effort has been put into developing models of human origin (Lacombe 
et al., 2011; Wilhelm and Krizbai, 2014). The cells were cultured in 5 % human serum, with 
and without extracellular matrices (MaxGel, poly-L-lysine & fibronectin). The extracellular 
matrices improves cell attachment and expression of proteins due to improved cell-cell 
communication (Kavanagh et al., 2006; Schlie-Wolter et al., 2013). The short-term cultures 
showed higher expression and activity of the proteins of interest when cultured in the 
presence of fibronectin. Singh et al.,(2010) reported the role of fibronectin in protein 
processing and secretion, binding to cell surface receptors, self-association, and fibril growth 
which enhances the expression and activity of proteins in the cells (Singh et al., 2010). To 
conclude, the short-term cultures grown in 5 % human serum and fibronectin as the ECM 
were selected to translate in the in vitro BBB model. 
To date, all of the models designed for BBB in the literature have focussed on the TEER 
expression across the barrier and the expression of TJs proteins. The TEER value in vivo is 
>1000 Ω/cm2, however various BBB models have been developed to give TEER values 
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ranging between 20 – 700 Ω/cm2.  There are numerous instruments which have been 
developed to measure the resistance across the in vitro BBB. In the current study three 
measuring systems EVOM, ECIS and CellZscope were compared, thus validating the EVOM 
instrument as giving reproducible trends in TEER. Naik et al., (2012) reviewed the EVOM 
instrument and highlight that the resistance is measured in AC current which unlike the DC 
source used by ECIS and CellZscope is not harmful to the cell layer and does not damage the 
electrode (Naik and Cucullo, 2012). The EVOM is also the most widely used equipment for 
measuring TEER, cost-effective and does not involve any complex calculation to determine 
the TEER across the barrier. The designing of an in vitro BBB model required utilising cells 
in different formations; mono-, co- and tri- culture, to maximise the TEER values and assess 
the expression of efflux transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and 
CYP2D6.  
Eigenmann et al., (2013) studied properties of different endothelial cells in monoculture for 
in vitro drug disposition studies, and similar to the findings reported here, human 
microvascular endothelial cells (HBMEC) proved to be the most suitable for modelling in 
vitro BBB models (Eigenmann et al., 2013).  Monoculture models are often used in the 
studies reported in the literature as they are cost effective, simple to establish and have a high 
throughput screening capacity. The mono-culture of HBMEC established here, gave a TEER 
of 120 Ω/cm2, which was approximately 10-fold lower than the desired in vivo resistance 
values. The major drawback of the mono-culture model was that the cells were grown without 
the influence of another cell type unlike the in vivo situation and therefore showed a limited 
expression of the phenotype. The absence of stimulating factors derived from other cellular 
components of the neurovascular unit leads to low TEER values and high permeability 
(Kumar et al., 2014; Wilhelm et al., 2011b; Cucullo et al., 2002; Eigenmann et al., 2013). 
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The monoculture formation of endothelial cells was therefore rejected as a suitable model for 
the BBB studies presented in this thesis. 
It was established that the presence of cerebral components, along with the endothelial cells, 
were essential for maintenance of the BBB phenotype. All of the BBB models were designed 
on a porous membrane which enabled the cells to interact with each other physically and 
chemically thus creating an in vivo like environment. The introduction of astrocytes and 
pericytes enhanced the in vitro BBB properties by direct interaction with the endothelial cells 
as shown here and reported in the literature (Li et al., 2010). In vivo, the astrocytes are not in 
contact with the endothelial cells due to the presence of the basal membrane. To mimic the 
in vivo situation, a number of different experimental setups were designed including an ECM. 
The different co-cultures of HBMEC (endothelial cells seeded apically) were designed with 
HA (astrocytes) or HBVP (pericytes) (seeded basolaterally (in-contact) or at bottom of well 
(out of contact)). The TEER values of HBMEC and HA (in-contact) and HBMEC and HA 
(out of contact) gave TEER of 208 Ω/cm2 and 153 Ω/cm2. The TEER values of HBMEC and 
HBVP (in-contact) and HBMEC and HBVP (out of contact) gave TEER of 189 Ω/cm2 and 
115 Ω/cm2. This suggested that when pericytes and astrocytes were cultured in-contact with 
the endothelial cells the TEER showed a higher value. Some papers suggested culturing 
astrocytes on the basolateral side of the insert instead of apically, to permitted direct contact 
of the astrocytic foot process with the endothelial cells (Franke et al., 1999; Duport et al., 
1998; Hatherell et al., 2011). Gu et al., (2011) suggested that a co-culture could be set up by 
seeding astrocyte ‘out of contact’ at the bottom of the well (Gu et al., 2011), this method 
would permit the interaction between the astrocyte secreted soluble factors and the 
endothelial cells only but not the astrocytic foot processes. The TEER values for HBMEC 
and HA (out of contact) was 153 Ω/cm2 which was lower than the HBMEC and HA (in-
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contact) giving TEER of 208 Ω/cm2. Although the pericytes are found next to the endothelial 
cells in vivo, their effect on the formation of the barrier is not well understood. The pericytes 
secrete extracellular matrices like laminin, type IV collagen and glycosaminoglycans, which 
contribute to the formation of the basement membrane (Sá-Pereira et al., 2012). As found in 
the studies here and in the literature, introduction of pericytes to the co-culture strengthens 
the barrier and induces the functional activity of the ABC transporters (Berezowski et al., 
2004b; Al Ahmad et al., 2011). Nakagawa et al., described that co-culture of pericytes with 
endothelial cells gave a high TEER value of 388 Ω/ cm2 and low permeability (Nakagawa et 
al., 2007a; Nakagawa et al., 2009b).  
After concluding that pericytes and astrocytes both played an important role in modulating 
the properties of the BBB, the tri-culture models were developed. The HBMEC was cultured 
with HA (in-contact) and HBVP (out of contact) which gave the highest TEER value of 258 
Ω/ cm2. A tri-culture model involved the culturing of endothelial cells, astrocytes and 
pericytes together in a single culture system, and was found to increase the TEER 
significantly. Many other papers have shown similar findings, traditionally, the endothelial 
cells are seeded on the apical side of the insert, however the location of astrocyte and pericyte 
is not predetermined. Nakagawa et al. (2009), patented a tri-culture model giving a TEER 
value of 350 Ω/ cm2 on day 8 of TEER measurements, the model comprised of endothelial 
cells on the apical side of the insert, the pericytes on the basolateral side of the insert and the 
astrocyte seeded at the bottom of the well (Nakagawa et al., 2009a). Hatherell et al., on the 
other hand reported that culturing of pericytes in an endothelial and astrocyte co-culture 
disrupted the barrier and decreased the TEER values. According to Hatherell et al., the best 
model was the co-culture of endothelial cells with the astrocytes seeded on the basolateral 
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side of the insert since the TEER reading for co-culture was higher than the tri-culture model. 
(Hatherell et al., 2011).   
All these models presented in the thesis were studied for expression and activity of the efflux 
transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and CYP2D6. The highest expression 
and activity was exhibited by the tri-culture model indicating that culturing of the three 
primary cells was the best arrangement to get a high TEER and high protein activity as well 
as expression. No data was found in the literature reporting expression or activity of efflux 
transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and CYP2D6 in tri-culture models 
for comparison, highlighting the originality of the findings presented here. 
The structural component of the in vitro BBB was designed, however it lacked a component 
present in vivo which was the shear stress on the cells due to the blood flow. The endothelial 
cells in vivo are under constant shear stress due to blood flow through the capillaries. A 
similar shear stress on the in vitro endothelial cells and astrocytes co-cultures cells was 
induced by perfusion with media. In the current study we utilised the same arrangement of 
cells but seeded them in a 3D Alvetex fibronectin coated scaffold and applied a shear stress 
of 20 dyne/cm2. The Alvetex perfusion tri-culture model gave a TEER of 710 Ω/ cm2 which 
increased from 258 Ω/ cm2 in a static polycarbonate tri-culture model. The change from a 2D 
culture surface to a 3D scaffold, more representative of the 3D tissue architecture to provide 
the cells an in vivo like environment; which was reflected in the increase in TEER values. As 
shown here and reported in the literature, the induction of shear stress improved the 
expression of tight junction proteins and increased the TEER values in the dynamic in vitro 
BBB model (Davies, 1989; Tarbell, 2010). There have been numerous culture systems 
available in the market, which involve growing cells on scaffolds, tubular fibres, and 
polycarbonate membranes with flow causing a shear stress (approximately 5 dyne/ cm2).  
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The protein expression and activity also showed an increase in the Alvetex perfusion model 
as compared to tri-culture on the polycarbonate membrane. Cucullo et al., used dynamic in 
vitro (DIV) BBB models which include culturing of cell endothelial cell in a polypropylene 
hollow tube attached to a tunable shear stress. The DIV-BBB model when applied with shear 
stress of 5 dyne/cm2 gave a TEER of more than 500 Ω/ cm2 when grown for a period of 20 
days (Cucullo et al., 2008). In spite of having high TEER values, the DIV-BBB system is not 
suitable for commercial use due to its low throughput capacity. It takes a very long time 
period for its development (20 days) involves specialist technical skills to culture the cells in 
the hollow fibre and requires a very large number of cells > 1.5 x 106 cells/ tube, initially to 
be loaded in the hollow fibre (Wilhelm and Krizbai, 2014). In addition, the cells cannot be 
grown in a 3D formation within the hollow tube. 
In conclusion, an all human tri-culture model using only short-term cultures, rather than 
immortalised cells with incorporated shear stress and 3D environment was validated for 
maximum TEER, TJ protein expression, DME and transporter expression. This was the 
model we proposed for the physiologically relevant BBB, however, further characterisation 
and application was needed to prove its efficiency as an in vitro BBB model.  
The designed tri-culture was further characterised after studying TEER, expression and 
activity of efflux transporters; ABCB1 and ABCG2 and DMEs; CYP3A4 and CYP2D6 for 
its paracellular permeability. An appropriate in vitro BBB model should show a low apparent 
permeability (Papp) which was proved using FITC-Dextran and found to be comparable to 
others in the literature (Ma et al., 2007). The applicability of the in vitro BBB was further 
confirmed by screening novel NPs and aptamers synthesised in-house for potential use in 
glioma treatment, in the tri-culture model to determine if the NPs or aptamer were permeable 
through the BBB model. The reliability of the results was proved by screening a curcumin 
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loaded lipid NPs through the model which have already been reported to cross the BBB in 
vivo (Kakkar et al., 2013). The model was capable of identifying the NPs which cross the 
BBB model via paracellular transport. The NPs which were permeable through the 
paracellular pathway caused a sharp drop in the TEER values. The TEER then slowing 
increased and stabilised. This sharp drop in TEER was due to transient opening of the BBB. 
Thus it was confirmed that the molecules were passing through the paracellular pathway.  
The crossing of BBB can be undertaken by various mechanisms, as seen in Figure 8.1.  
 
Figure 8.1Schematic overview of the permeability pathways across the endothelial barrier (Kroll and 
Neuwelt, 1998). 
 
Drug delivery across BBB by transcytosis and transcellular permeability using enhanced 
vesicular transport can also be used as a method for delivering compounds into the brain 
(Gabathuler, 2010).BBB models can be designed to investigate other pathways of transport 
across the BBB by inhibiting different endocytic pathways. Designed NPs loaded with 
chemotherapeutics are thought to be delivered across the brain to the tumour site by 
transcellular or paracellular pathway (Lu et al., 2006). The transcellular route contributes to 
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both passive and active modes whereas paracellular is an exclusive passive mode of transport. 
Paracellular transport is less selective and has a higher conductance. Factors contributing to 
this mode of transport include hydrostatic and osmotic gradient (Bazzoni, 2006). The 
dynamic interaction of the endothelial cytoskeleton and the adhesive force developed due to 
cell-cell junction and cell-matrix contact controls the transient opening of the paracellular 
pathway. This serves as the fundamental mechanism of transport across the blood brain 
barrier and maintains the exchange between blood and brain (Garcia and Schaphorst, 1995; 
Garcia-Garcia et al., 2005).  
After proving the applicability of the tri-culture BBB model, we wanted to explore the effect 
of introducing GBM spheroids to an intact in vitro barrier of the model, to identify the 
changes caused at the BBB in presence of a tumour. It has been reported that the BBB is 
leaky and often not intact at the site of tumour in vivo (On et al., 2013). When GBM 
spheroids, derived from short term cultures of patient glioma biopsies BTNW914 and 
BTNW370 were added to the in vitro BBB model a similar effect was observed. The TEER 
values were higher as compared to the control and showed increased up to day 6 to 180 Ω/cm2 
but then shows declined. Similar work had been done in rat in vitro BBB model, Toyota et 
al., developed a tri-culture model using cells from rat, which involved the culturing of 
endothelial cells on the basolateral side of the insert and pericyte and astrocyte cell on the 
apical side of the insert. To the tri-culture, human GBM spheroids were added to the 
basolateral side along with the rat endothelial cells. The addition of human GBM cells in the 
tri-culture showed an increase in the TEER values in the first 72 h followed by a decrease in 
the TEER which when compared to culture without GBM did not show that high values. 
(Toyoda et al., 2013).  
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To further understand if the role of efflux transporters at the site of tumour, the expression of 
ABCB1 and ABCG2 were studied and the NPs were also screened through the brain tumour 
barrier model. Such a study is novel and has not be done before and hence there was no 
available date to compare the behaviour of drug loaded NPs at tumour site. The results 
showed the presence of active efflux transporters, effluxing the NPs out of the GBM 
spheroids which was identifiable when the efflux transporters where inhibited and the GBM 
spheroids showed an increase in the accumulation of NPs. 
To summarise, we have established culture conditions under which the brain primary cells 
show high expression and activity of efflux transporters; ABCB1 and ABCG2 and DMEs; 
CYP3A4 and CYP2D6. We have also established the expression and activity in a multi-cell 
type model, and provided a connecting link between the physically robust BBB models and 
the physiologically relevant in vivo model. This bridge between in vitro and in vivo will help 
it to screen established and novel anticancer glioma therapeutics to predict the efficacy of the 
drug, based on the therapeutic concentration achieved at the glioma protected by the BBB.  
8.2 Limitations of the project 
Some of the major limitations of the current study is the use of short term cell cultures; the 
short-term cell cultures used to set up the BBB model were difficult to maintain and only 
grew up to a certain passage number. The short-term cultures have unmatched value for basic 
and translational research however, it is not feasible to utilise models comprising of these 
cultures commercially due to low throughput. It is essential to derive a cell line with matched 
properties of HBMEC so that the model is easier to set up and can be used on a commercial 
scale. The EVOM instrument is a robust and reproducible method for the measurement of 
TEER, however, a TEER measuring system which could determine the value real time would 
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enable us to understand the TJs formation better. The in vitro model is much more expensive 
and time consuming compared to the most cost-effective method of modelling the BBB by 
the use of computer aided designing system (Song et al., 2009). In silico models mimic all 
the physiological properties of the blood brain barrier, the computer system incorporates in 
vivo permeability values and simulates the compound interaction in the BBB (Naik and 
Cucullo, 2012; Palmiotti et al., 2014). The system incorporates essential physiological 
parameters such as lipophilicity, charge, pH, size of molecule into simulation to get 
physiologically relevant data (Narayanan and Gunturi, 2005). A large number of compounds 
can be screened by such systems to determine the permeability co-efficient. The designed in 
vitro model cannot completely replace the use of in vivo models. The most widely recognised 
limitation of in vitro model is that the primary cells used to initiate short-term cultures are 
not the exact dissociated replicates of their in vivo counterparts. Finally, the artificial and 
controlled in vitro environment is not the same as what the cells experience in vivo and could 
have an effect, depending upon the measure being assessed (Reichert, 2007). 
8.3 Future works 
The present study involved the development of a functional, fully characterised BBB model 
which could be used for screening and determining the permeability of NPs and aptamers. 
Numerous challenges still remain in using this model commercially for screening of glioma 
therapeutics. Future work in this area could involve studying the mechanism of transport 
across the BBB; and deciphering whether the permeability of the NP and aptamers was 
paracellular or transcellular and further assessing the contribution of efflux transporters in 
the presence of efflux pump inhibitors In addition, HPLC methods could be established to 
quantify the release of entrapped drug from the NPs in the BBB model with respect to time. 
Another interesting study which could be done in future includes; tracking of fluorescent NPs 
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and aptamers across the BBB by live cell imaging over a time course in combination with 
co-localisation immunostaining to elucidate the transport mechanism and to prove that NPs 
had truly been taken across the BBB. The 3D Alvetex scaffold model needs to be further 
characterised for the polarity of the cells cultured on the 3D scaffold and used for 
permeability and screening of NPs. In future, the BBB models could be cultured serum free 
and this would rule out the interferences caused by the growth factors present in the serum 
which have been shown to disrupt the TJs protein expression (Chang et al., 1997; Jung et al., 
2007b). The most essential part which needs to be explored in detail is the applicability of 
the BTB model and its role in the screening novel glioma therapeutics. 
Another system in the literature which has drawn attention is the using of miniaturised 
microchips to construct a BBB model. The microfluidic models closely mimic the BBB and 
are comprised of a thin culture membrane with induced shear stress (Booth and Kim, 2012). 
The microfluidic chip is the smallest model of the BBB available, requiring a very small cell 
number <1 x 104 cells/chip to setup. Recently, Griep et al. (2013), developed a BBB model 
on a microfluidic device cultivating endothelial cells on a polycarbonate membrane of pore 
size 0.4 µm and 10 µm thickness. In static conditions the system gave a TEER reading of 36 
Ω/ cm2 however, this value increased to 120 Ω/ cm2 when a shear stress of 0.58 Pa was 
applied to the model (Griep et al., 2013). In future, we would like to miniturise our optimised 
and designed BBB model structure to a microfluidic chip, this will make efficient use of 
HBMEC cells and also give real time TEER measurement.  
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8.4 Conclusion  
To conclude the aim of developing an all human, fully characterised and physiologically 
relevant in vitro BBB model was achieved. The model established here is a novel 
breakthrough in the field of BBB modelling, which was found to be useful for screening 
novel NP and glioma targeting aptamers. Further research in this area would broaden interests 
and implications in the field of neuropharmacology.  
 
 
290 
 References 
Abbott, N., Dolman, D., Drndarski, S. & Fredriksson, S. (2012). An improved in vitro blood-
brain barrier model: rat brain endothelial cells co-cultured with astrocytes. Methods 
Mol Biol, 814, 415 - 430. 
Abbott, N., Hughes, C., Revest, P. & Greenwood, J. (1992). Development and 
characterisation of a rat brain capillary endothelial culture: towards an in vitro blood-
brain barrier. J Cell Sci, 103, 23 - 37. 
Abbott, N., Ronnback, L. & Hansson, E. (2006a). Astrocyte-endothelial interactions at the 
blood-brain barrier. Nature reviews, 7, 41 - 53. 
Abbott, N., Ronnback, L. & Hansson, E. (2006b). Astrocyte-endothelial interactions at the 
blood-brain barrier. Nat Rev Neurosci, 7, 41 - 53. 
Abbott, N. J. (2002). Astrocyte–endothelial interactions and blood–brain barrier 
permeability*. Journal of Anatomy, 200, 629-638. 
Abrey, L. E. & Mason, W. P. (2003). Fast Facts: Brain Tomours, Oxford, Health Press 
Limited. 
Agarwal, S., Hartz, A. M., Elmquist, W. F. & Bauer, B. (2011). Breast cancer resistance 
protein and p-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des, 
17, 2793-802. 
Agarwal, V., Kommaddi, R. P., Valli, K., Ryder, D., Hyde, T. M., Kleinman, J. E., Strobel, 
H. W. & Ravindranath, V. (2008). Drug Metabolism in Human Brain: High Levels of 
Cytochrome P4503A43 in Brain and Metabolism of Anti-Anxiety Drug Alprazolam to 
Its Active Metabolite. PLoS ONE, 3, e2337. 
Al Ahmad, A., Taboada, C. B., Gassmann, M. & Ogunshola, O. O. (2011). Astrocytes and 
pericytes differentially modulate blood-brain barrier characteristics during 
development and hypoxic insult. J Cereb Blood Flow Metab, 31, 693-705. 
Alge, C. S., Hauck, S. M., Priglinger, S. G., Kampik, A. & Ueffing, M. (2006). Differential 
Protein Profiling of Primary versus Immortalized Human RPE Cells Identifies 
Expression Patterns Associated with Cytoskeletal Remodeling and Cell Survival. 
Journal of Proteome Research, 5, 862-878. 
Allt, G. & Lawrenson, J. G. (2000). The blood–nerve barrier: enzymes, transporters and 
receptors—a comparison with the blood–brain barrier. Brain Research Bulletin, 52, 1-
12. 
Apps, R., Murphy, S. P., Fernando, R., Gardner, L., Ahad, T. & Moffett, A. (2009). Human 
leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell 
lines, determined using single antigen beads to characterize allotype specificities of 
anti-HLA antibodies. Immunology, 127, 26-39. 
Ballabh, P., Braun, A. & Nedergaard, M. (2004). The blood-brain barrier: an overview: 
structure, regulation, and clinical implications. Neurobiol Dis, 16, 1-13. 
Bandopadhyay, R., Orte, C., Lawrenson, J. G., Reid, A. R., De Silva, S. & Allt, G. (2001). 
Contractile proteins in pericytes at the blood-brain and blood-retinal barriers. J 
Neurocytol, 30, 35-44. 
 
 
291 
Banks, W. A. (1999). Physiology and pathology of the blood-brain barrier: implications for 
microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol, 
5, 538-55. 
Bauer, B., Hartz, A. M. S., Fricker, G. & Miller, D. S. (2004). Pregnane X receptor up-
regulation of P-glycoprotein expression and transport function at the blood-brain 
barrier. Molecular Pharmacology, 66, 413-419. 
Baxter, M., Withey, S., Harrison, S., Segeritz, C., Zhang, F., Atkinson-Dell, R., Rowe, C., 
Gerrard, D. T., Sison-Young, R., Jenkins, R., Henry, J., Berry, A. A., Mohamet, L., 
Best, M., Fenwick, S. W., Malik, H., Kitteringham, N. R., Goldring, C. E., Piper 
Hanley, K., Vallier, L. & Hanley, N. A. (2014). Phenotypic and functional analyses 
show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult 
hepatocytes. J Hepatol. 
Bazzoni, G. (2006). Endothelial tight junctions: permeable barriers of the vessel wall. 
Thromb Haemost, 95, 36-42. 
Begley, D. J. (2004). ABC transporters and the blood-brain barrier. Curr Pharm Des, 10, 
1295-1312. 
Behonick, D. J. & Werb, Z. (2003). A bit of give and take: the relationship between the 
extracellular matrix and the developing chondrocyte. Mech Dev, 120, 1327-36. 
Bellavance, M. A., Blanchette, M. & Fortin, D. (2008). Recent advances in blood-brain 
barrier disruption as a CNS delivery strategy. AAPS J, 10, 166-77. 
Bendayan, R., Lee, G. & Bendayan, M. (2002). Functional expression and localization of P-
glycoprotein at the blood brain barrier. Microscopy Research and Technique, 57, 365-
380. 
Benedetti, M. S., Whomsley, R., Poggesi, I., Cawello, W., Mathy, F.-X., Delporte, M.-L., 
Papeleu, P. & Watelet, J.-B. (2009). Drug metabolism and pharmacokinetics. Drug 
Metabolism Reviews, 41, 344-390. 
Benson, K., Cramer, S. & Galla, H. J. (2013). Impedance-based cell monitoring: barrier 
properties and beyond. Fluids Barriers CNS, 10, 5. 
Berezowski, V., Landry, C., Dehouck, M. P., Cecchelli, R. & Fenart, L. (2004a). 
Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and 
multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier. 
Brain Res, 1018, 1-9. 
Berezowski, V., Landry, C., Lundquist, S., Dehouck, L., Cecchelli, R., Dehouck, M. & 
Fenart, L. (2004b). Transport screening of drug cocktails through an in vitro blood-
brain barrier: is it a good strategy for increasing the throughput of the discovery 
pipeline? Pharm Res, 21, 756 - 760. 
Bhatia, P., Bernier, M., Sanghvi, M., Moaddel, R., Schwarting, R., Ramamoorthy, A. & 
Wainer, I. W. (2012). Breast cancer resistance protein (BCRP/ABCG2) localises to the 
nucleus in glioblastoma multiforme cells. Xenobiotica, 42, 748-55. 
Bicker, J., Alves, G., Fortuna, A. & Falcao, A. (2014). Blood-brain barrier models and their 
relevance for a successful development of CNS drug delivery systems: a review. Eur J 
Pharm Biopharm, 87, 409-32. 
 
 
292 
Bing, C., Ladouceur-Wodzak, M., Wanner, C. R., Shelton, J. M., Richardson, J. A. & Chopra, 
R. (2014). Trans-cranial opening of the blood-brain barrier in targeted regions using a 
stereotaxic brain atlas and focused ultrasound energy. J Ther Ultrasound, 2, 13. 
Bodó, A., Bakos, E., Szeri, F., Váradi, A. & Sarkadi, B. (2003). The role of multidrug 
transporters in drug availability, metabolism and toxicity. Toxicol Lett, 140-141, 133-
143. 
Booth, R. & Kim, H. (2012). Characterization of a microfluidic in vitro model of the blood-
brain barrier (muBBB). Lab Chip, 12, 1784-92. 
Borges-Walmsley, M. I., Mckeegan, K. S. & Walmsley, A. R. (2003). Structure and function 
of efflux pumps that confer resistance to drugs. Biochemical Journal, 376, 313-338. 
Bouffet, E., Doumi, N., Thiesse, P., Mottolese, C., Jouvet, A., Lacroze, M., Carrie, C., 
Frappaz, D. & Brunat-Mentigny, M. (1997). Brain metastases in children with solid 
tumors. Cancer, 79, 403-410. 
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Analytical 
Biochemistry, 72, 248-254. 
Braun, A., Hämmerle, S., Suda, K., Rothen-Rutishauser, B., Günthert, M., Krämer, S. D. & 
Wunderli-Allenspach, H. (2000). Cell cultures as tools in biopharmacy. European 
Journal of Pharmaceutical Sciences, 11, S51-S60. 
Brimelow, A. H. C. 2011. Cancer survival: Macmillan hails major improvement [Online]. 
BBC News. Available: http://www.bbc.co.uk/news/health-15726810 [Accessed 
06/01/2012 2012]. 
Britto, M. R. & Wedlund, P. J. (1992). Cytochrome P-450 in the brain. Potential evolutionary 
and therapeutic relevance of localization of drug-metabolizing enzymes. Drug Metab 
Dispos, 20, 446-50. 
Brown, M. T., Friedman, H. S., Oakes, W., Boyko, O. B., Hockenberger, B. & Schold, S. C. 
(1993). Chemotherapy for pilocytic astrocytoma. Cancer, 71, 3165 - 3172. 
Burgio, D. E., Gosland, M. P. & Mcnamara A, P. J. (1998). Effects of P-glycoprotein 
modulators on etoposide elimination and central nervous system distribution. J 
Pharmacol Exp Ther, 287, 911-7. 
Burkhard, C., Di Patre, P. L., Schuler, D., Schuler, G., Yasargil, M. G., Yonekawa, Y., Lutolf, 
U. M., Kleihues, P. & Ohgaki, H. (2003). A population-based study of the incidence 
and survival rates in patients with pilocytic astrocytoma. J Neurosurg, 98, 1170-4. 
Burns, E. M., Dobben, G. D., Kruckeberg, T. W. & Gaetano, P. K. (1981). Blood-brain 
barrier: morphology, physiology, and effects of contrast media. Advances in neurology, 
30, 159-65. 
Calatozzolo, C., Gelati, M., Ciusani, E., Sciacca, F. L., Pollo, B., Cajola, L., Marras, C., 
Silvani, A., Vitellaro-Zuccarello, L., Croci, D., Boiardi, A. & Salmaggi, A. (2005). 
Expression of Drug Resistance Proteins Pgp, MRP1, MRP3, MRP5 AND GST-π in 
Human Glioma. Journal of Neuro-Oncology, 74, 113-121. 
Capes-Davis, A., Theodosopoulos, G., Atkin, I., Drexler, H. G., Kohara, A., Macleod, R. A., 
Masters, J. R., Nakamura, Y., Reid, Y. A., Reddel, R. R. & Freshney, R. I. (2010). 
 
 
293 
Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J 
Cancer, 127, 1-8. 
Carman, A. J., Mills, J. H., Krenz, A., Kim, D.-G. & Bynoe, M. S. (2011). Adenosine 
Receptor Signaling Modulates Permeability of the Blood–Brain Barrier. The Journal 
of Neuroscience, 31, 13272-13280. 
Cecchelli, R., Aday, S., Sevin, E., Almeida, C., Culot, M., Dehouck, L., Coisne, C., 
Engelhardt, B., Dehouck, M. P. & Ferreira, L. (2014). A stable and reproducible human 
blood-brain barrier model derived from hematopoietic stem cells. PLoS One, 9, 
e99733. 
Cecchelli, R., Dehouck, B., Descamps, L., Fenart, L., Buée-Scherrer, V., Duhem, C., 
Lundquist, S., Rentfel, M., Torpier, G. & Dehouck, M. P. (1999). In vitro model for 
evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev, 36, 165-
178. 
Chaffer, C. L. & Weinberg, R. A. (2011). A perspective on cancer cell metastasis. Science, 
331, 1559-64. 
Chang, C. W., Ye, L., Defoe, D. M. & Caldwell, R. B. (1997). Serum inhibits tight junction 
formation in cultured pigment epithelial cells. Invest Ophthalmol Vis Sci, 38, 1082-93. 
Chang, G. (2003). Multidrug resistance ABC transporters. FEBS Letters, 555, 102-105. 
Chatterjee, M., Gupta, S., Bhar, A. & Das, S. (2012). Optimization of an Efficient Protein 
Extraction Protocol Compatible with Two-Dimensional Electrophoresis and Mass 
Spectrometry from Recalcitrant Phenolic Rich Roots of Chickpea (Cicer arietinum L.). 
International Journal of Proteomics, 2012, 10. 
Chu, X., Korzekwa, K., Elsby, R., Fenner, K., Galetin, A., Lai, Y., Matsson, P., Moss, A., 
Nagar, S., Rosania, G. R., Bai, J. P., Polli, J. W., Sugiyama, Y., Brouwer, K. L. & 
International Transporter, C. (2013). Intracellular drug concentrations and transporters: 
measurement, modeling, and implications for the liver. Clin Pharmacol Ther, 94, 126-
41. 
Cisternino, S., Mercier, C., Bourasset, F., Roux, F. & Scherrmann, J. M. (2004). Expression, 
up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the 
mouse blood-brain barrier. Cancer Res, 64, 3296-301. 
Coecke, S., Blaauboer, B. J., Elaut, G., Freeman, S., Freidig, A., Gensmantel, N., Hoet, P., 
Kapoulas, V. M., Ladstetter, B., Langley, G., Leahy, D., Mannens, G., Meneguz, A., 
Monshouwer, M., Nemery, B., Pelkonen, O., Pfaller, W., Prieto, P., Proctor, N., 
Rogiers, V., Rostami-Hodjegan, A., Sabbioni, E., Steiling, W. & Van De Sandt, J. J. 
(2005). Toxicokinetics and metabolism. Altern Lab Anim, 33 Suppl 1, 147-75. 
Cohen-Kashi Malina, K., Cooper, I. & Teichberg, V. (2009). Closing the gap between the in-
vivo and in-vitro blood-brain barrier tightness. Brain Res, 1284, 12 - 21. 
Cooray, H. C., Blackmore, C. G., Maskell, L. & Barrand, M. A. (2002). Localisation of breast 
cancer resistance protein in microvessel endothelium of human brain. NeuroReport, 
13, 2059-2063. 
 
 
294 
Cordon-Cardo, C., O'brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. 
R. & Bertino, J. R. (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by 
endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A, 86, 695-698. 
Cornford, E. & Hyman, S. (2005). Localization of brain endothelial luminal and abluminal 
transporters with immunogold electron microscopy. NeuroRx, 2, 27 - 43. 
Crocetti, E., Trama, A., Stiller, C., Caldarella, A., Soffietti, R., Jaal, J., Weber, D. C., Ricardi, 
U., Slowinski, J. & Brandes, A. (2012). Epidemiology of glial and non-glial brain 
tumours in Europe. European Journal of Cancer. 
Crofton, K. M., Makris, S. L., Sette, W. F., Mendez, E. & Raffaele, K. C. (2004). A 
qualitative retrospective analysis of positive control data in developmental 
neurotoxicity studies. Neurotoxicol Teratol, 26, 345-52. 
Crone, C. & Olesen, S. P. (1982). Electrical resistance of brain microvascular endothelium. 
Brain Res, 241, 49-55. 
Cucullo, L., Couraud, P.-O., Weksler, B., Romero, I.-A., Hossain, M., Rapp, E. & Janigro, 
D. (2007). Immortalized human brain endothelial cells and flow-based vascular 
modeling: a marriage of convenience for rational neurovascular studies. J Cereb Blood 
Flow Metab, 28, 312-328. 
Cucullo, L., Couraud, P., Weksler, B., Romero, I., Hossain, M., Rapp, E. & Janigro, D. 
(2008). Immortalized human brain endothelial cells and flow-based vascular modeling: 
a marriage of convenience for rational neurovascular studies. J Cereb Blood Flow 
Metab, 28, 312 - 328. 
Cucullo, L., Mcallister, M. S., Kight, K., Krizanac-Bengez, L., Marroni, M., Mayberg, M. 
R., Stanness, K. A. & Janigro, D. (2002). A new dynamic in vitro model for the 
multidimensional study of astrocyte-endothelial cell interactions at the blood-brain 
barrier. Brain Res, 951, 243-54. 
Daniel, W. N. & Timothy, P. D. (2006). The role of cytochrome P450 enzymes in 
endogenous signalling pathways and environmental carcinogenesis. Nature Reviews 
Cancer, 6, 947-960. 
Davies, P. (1989). How Do Vascular Endothelial Cells Respond to Flow? 
De Boer, A. G. & Gaillard, P. J. (2007). Strategies to Improve Drug Delivery Across the 
Blood-Brain Barrier. Clinical Pharmacokinetics, 46, 553-576. 
De Lange, E. C. M. (2004). Potential role of ABC transporters as a detoxification system at 
the blood-CSF barrier. Adv Drug Deliv Rev, 56, 1793-1809. 
Dean, M., Rzhetsky, A. & Allikmets, R. (2001). The human ATP-binding cassette (ABC) 
transporter superfamily. Genome Research, 11, 1156-1166. 
Deenen, M. J., Cats, A., Beijnen, J. H. & Schellens, J. H. (2011a). Part 1: background, 
methodology, and clinical adoption of pharmacogenetics. Oncologist, 16, 811-9. 
Deenen, M. J., Cats, A., Beijnen, J. H. & Schellens, J. H. (2011b). Part 2: pharmacogenetic 
variability in drug transport and phase I anticancer drug metabolism. Oncologist, 16, 
820-34. 
 
 
295 
Dehouck, M.-P., Jolliet-Riant, P., Brée, F., Fruchart, J.-C., Cecchelli, R. & Tillement, J.-P. 
(1992). Drug Transfer Across the Blood-Brain Barrier: Correlation Between In Vitro 
and In Vivo Models. Journal of Neurochemistry, 58, 1790-1797. 
Deli, M., Ábrahám, C., Kataoka, Y. & Niwa, M. (2005). Permeability Studies on In Vitro 
Blood–Brain Barrier Models: Physiology, Pathology, and Pharmacology. Cellular and 
Molecular Neurobiology, 25, 59-127. 
Demeule, M., Régina, A., Jodoin, J., Laplante, A., Dagenais, C., Berthelet, F., Moghrabi, A. 
& Béliveau, R. (2002). Drug transport to the brain: Key roles for the efflux pump P-
glycoprotein in the blood-brain barrier. Vascul Pharmacol, 38, 339-348. 
Di, L., Kerns, E. H., Fan, K., Mcconnell, O. J. & Carter, G. T. (2003). High throughput 
artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem, 38, 
223-32. 
Donato, M. T., Jiménez, N., Castell, J. V. & Gómez-Lechón, M. J. (2004). Fluorescence-
based assays for screening nine cytochrome P450 (CYP450) activities in intact cells 
expressing individual human P450 enzymes. Drug Metabolism and Disposition, 32, 
699-706. 
Doyle, L. & Ross, D. D. (2003). Multidrug resistance mediated by the breast cancer 
resistance protein BCRP (ABCG2). Oncogene, 22, 7340-58. 
Duffner, P. K., Cohen, M. E. & Freeman, A. I. (1985). Pediatric brain tumors: An overview. 
CA: A Cancer Journal for Clinicians, 35, 287-301. 
Duport, S., Robert, F., Muller, D., Grau, G., Parisi, L. & Stoppini, L. (1998). An in vitro 
blood–brain barrier model: Cocultures between endothelial cells and organotypic brain 
slice cultures. Proceedings of the National Academy of Sciences, 95, 1840-1845. 
Dutheil, F., Beaune, P. & Loriot, M.-A. (2008). Xenobiotic metabolizing enzymes in the 
central nervous system: Contribution of cytochrome P450 enzymes in normal and 
pathological human brain. Biochimie, 90, 426-436. 
Eggstein, G. R., Liebner, S. & Wolburg, H. 2004. 27 - The Blood-Brain Barrier in the Human 
Glioma. In: Hari Shanker, S. & Jan, W. (eds.) Blood-Spinal Cord and Brain Barriers 
in Health and Disease. San Diego: Academic Press. 
Eigenmann, D. E., Xue, G., Kim, K. S., Moses, A. V., Hamburger, M. & Oufir, M. (2013). 
Comparative study of four immortalized human brain capillary endothelial cell lines, 
hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an 
in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS, 
10, 33. 
Eisenblatter, T. & Galla, H. J. (2002). A new multidrug resistance protein at the blood-brain 
barrier. Biochem Biophys Res Commun, 293, 1273-8. 
Eisenblatter, T., Huwel, S. & Galla, H. J. (2003). Characterisation of the brain multidrug 
resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain 
Res, 971, 221-31. 
Ekins, S. & Erickson, J. A. (2002). A pharmacophore for human pregnane X receptor ligands. 
Drug Metab Dispos, 30, 96-9. 
 
 
296 
Erben, M., Decker, S., Franke, H. & Galla, H.-J. (1995). Electrical resistance measurements 
on cerebral capillary endothelial cells — a new technique to study small surface areas. 
Journal of Biochemical and Biophysical Methods, 30, 227-238. 
Esquenet, M., Swinnen, J. V., Heyns, W. & Verhoeven, G. (1997). LNCaP prostatic 
adenocarcinoma cells derived from low and high passage numbers display divergent 
responses not only to androgens but also to retinoids. The Journal of Steroid 
Biochemistry and Molecular Biology, 62, 391-399. 
Eyupoglu, I. Y., Buchfelder, M. & Savaskan, N. E. (2013). Surgical resection of malignant 
gliomas[mdash]role in optimizing patient outcome. Nat Rev Neurol, 9, 141-151. 
Ferguson, C. S. & Tyndale, R. F. (2011). Cytochrome P450 enzymes in the brain: emerging 
evidence of biological significance. Trends Pharmacol Sci, 32, 708-14. 
Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis 
revisited. Nat Rev Cancer, 3, 453-8. 
Franke, H., Galla, H. J. & Beuckmann, C. T. (1999). An improved low-permeability in vitro-
model of the blood-brain barrier: transport studies on retinoids, sucrose, haloperidol, 
caffeine and mannitol. Brain Res, 818, 65-71. 
Freshney, R. (2000). New York, N.Y.: Wiley-Liss. 
Fromm, M. F. (2004). Importance of P-glycoprotein at blood-tissue barriers. Trends 
Pharmacol Sci, 25, 423-9. 
Gabathuler, R. (2010). Approaches to transport therapeutic drugs across the blood-brain 
barrier to treat brain diseases. Neurobiol Dis, 37, 48-57. 
Gaillard, P. & De Boer, A. (2000). Relationship between permeability status of the blood-
brain barrier and in vitro permeability coefficient of a drug. Eur J Pharm Sci, 12, 95 - 
102. 
Gaillard, P., Voorwinden, L., Nielsen, J., Ivanov, A., Atsumi, R., Engman, H., Ringbom, C., 
De Boer, A. & Breimer, D. (2001). Establishment and functional characterization of an 
in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary 
endothelial cells and astrocytes. Eur J Pharm Sci, 12, 215 - 222. 
Garberg, P., Ball, M., Borg, N., Cecchelli, R., Fenart, L., Hurst, R., Lindmark, T., Mabondzo, 
A., Nilsson, J. & Raub, T. (2005a). In vitro models for the blood-brain barrier. Toxicol 
In Vitro, 19, 299 - 334. 
Garberg, P., Ball, M., Borg, N., Cecchelli, R., Fenart, L., Hurst, R. D., Lindmark, T., 
Mabondzo, A., Nilsson, J. E., Raub, T. J., Stanimirovic, D., Terasaki, T., Öberg, J. O. 
& Österberg, T. (2005b). In vitro models for the blood-brain barrier. Toxicology in 
Vitro, 19, 299-334. 
Garcia-Garcia, E., Gil, S., Andrieux, K., Desmaele, D., Nicolas, V., Taran, F., Georgin, D., 
Andreux, J., Roux, F. & Couvreur, P. (2005). A relevant in vitro rat model for the 
evaluation of blood-brain barrier translocation of nanoparticles. Cell Mol Life Sci, 62, 
1400 - 1408. 
Garcia, J. G. & Schaphorst, K. L. (1995). Regulation of endothelial cell gap formation and 
paracellular permeability. J Investig Med, 43, 117-26. 
 
 
297 
Gerk, P. M. & Vore, M. (2002). Regulation of Expression of the Multidrug Resistance-
Associated Protein 2 (MRP2) and Its Role in Drug Disposition. Journal of 
Pharmacology and Experimental Therapeutics, 302, 407-415. 
Ghersi-Egea, J. F., Leninger-Muller, B., Suleman, G., Siest, G. & Minn, A. (1994). 
Localization of drug-metabolizing enzyme activities to blood-brain interfaces and 
circumventricular organs. J Neurochem, 62, 1089-96. 
Gil-Gil, M. J., Martinez-Garcia, M., Sierra, A., Conesa, G., Del Barco, S., González-Jimenez, 
S. & Villà, S. (2014). Breast cancer brain metastases: a review of the literature and a 
current multidisciplinary management guideline. Clinical and Translational Oncology, 
16, 436-446. 
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, 
J. G., Bolleyn, J., Borner, C., Bottger, J., Braeuning, A., Budinsky, R. A., Burkhardt, 
B., Cameron, N. R., Camussi, G., Cho, C. S., Choi, Y. J., Craig Rowlands, J., Dahmen, 
U., Damm, G., Dirsch, O., Donato, M. T., Dong, J., Dooley, S., Drasdo, D., Eakins, R., 
Ferreira, K. S., Fonsato, V., Fraczek, J., Gebhardt, R., Gibson, A., Glanemann, M., 
Goldring, C. E., Gomez-Lechon, M. J., Groothuis, G. M., Gustavsson, L., Guyot, C., 
Hallifax, D., Hammad, S., Hayward, A., Haussinger, D., Hellerbrand, C., Hewitt, P., 
Hoehme, S., Holzhutter, H. G., Houston, J. B., Hrach, J., Ito, K., Jaeschke, H., Keitel, 
V., Kelm, J. M., Kevin Park, B., Kordes, C., Kullak-Ublick, G. A., Lecluyse, E. L., Lu, 
P., Luebke-Wheeler, J., Lutz, A., Maltman, D. J., Matz-Soja, M., Mcmullen, P., 
Merfort, I., Messner, S., Meyer, C., Mwinyi, J., Naisbitt, D. J., Nussler, A. K., Olinga, 
P., Pampaloni, F., Pi, J., Pluta, L., Przyborski, S. A., Ramachandran, A., Rogiers, V., 
Rowe, C., Schelcher, C., Schmich, K., Schwarz, M., Singh, B., Stelzer, E. H., Stieger, 
B., Stober, R., Sugiyama, Y., Tetta, C., Thasler, W. E., Vanhaecke, T., Vinken, M., 
Weiss, T. S., Widera, A., Woods, C. G., Xu, J. J., Yarborough, K. M. & Hengstler, J. 
G. (2013). Recent advances in 2D and 3D in vitro systems using primary hepatocytes, 
alternative hepatocyte sources and non-parenchymal liver cells and their use in 
investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol, 
87, 1315-530. 
Goldstein, G. W. (1988). Endothelial Cell-Astrocyte Interactions. Annals of the New York 
Academy of Sciences, 529, 31-39. 
Golestaneh, N. & Mishra, B. (2005). TGF-[beta], Neuronal Stem Cells and Glioblastoma. 
Oncogene, 24, 5722-5730. 
Gomes, F. C. A., Paulin, D. & Moura Neto, V. (1999). Glial fibrillary acidic protein (GFAP): 
modulation by growth factors and its implication in astrocyte differentiation. Brazilian 
Journal of Medical and Biological Research, 32, 619-631. 
Gomes, J., Al Zayadi, A. & Guzman, A. (2011). Occupational and environmental risk factors 
of adult primary brain cancers: a systematic review. Int J Occup Environ Med, 2, 82-
111. 
Gonzalez, F. J. & Gelboin, H. V. (1994). Role of human cytochromes P450 in the metabolic 
activation of chemical carcinogens and toxins. Drug Metab Rev, 26, 165-83. 
 
 
298 
Graham, C. A. & Cloughesy, T. F. (2004). Brain tumor treatment: chemotherapy and other 
new developments. Semin Oncol Nurs, 20, 260-72. 
Griep, L. M., Wolbers, F., De Wagenaar, B., Ter Braak, P. M., Weksler, B. B., Romero, I. 
A., Couraud, P. O., Vermes, I., Van Der Meer, A. D. & Van Den Berg, A. (2013). BBB 
on chip: microfluidic platform to mechanically and biochemically modulate blood-
brain barrier function. Biomed Microdevices, 15, 145-50. 
Grier, J. T. & Batchelor, T. (2006). Low-Grade Gliomas in Adults. The Oncologist, 11, 681-
693. 
Grippo, M., Penteado, P., Carelli, E., Cruz-Hofling, M. & Verinaud, L. (2001). Establishment 
and Partial Characterization of a Continuous Human Malignant Glioma Cell Line: 
NG97. Cell Mol Neurobiol, 21, 421 - 428. 
Grover, A., Hirani, A., Pathak, Y. & Sutariya, V. (2014). Brain-Targeted Delivery of 
Docetaxel by Glutathione-Coated Nanoparticles for Brain Cancer. AAPS 
PharmSciTech. 
Grzmil, M. & Hemmings, B. A. (2010). Deregulated signalling networks in human brain 
tumours. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1804, 476-
483. 
Gu, F., Wang, J., Fu, L. & Ma, Y. J. (2011). Co-culture with microglia promotes neural stem 
cells differentiation into astrocytes. Chin Med J (Engl), 124, 3394-8. 
Gunaratna, C. (2000). Drug metabolism and pharmacokinetics in drug discovery: A primer 
for bioanalytical chemists, Part I. Current separations, 19, 17- 23. 
Gupta, T. & Sarin, R. (2002). Poor-prognosis high-grade gliomas: evolving an evidence-
based standard of care. The Lancet Oncology, 3, 557-564. 
Gynther, M. (2010). Blood-Brain Barrier Transporters in CNS Drug Delivery : Design and 
Biological Evaluation of LAT1 and GluT1 
–Targeted Prodrugs. University of Eastern Finland. 
Haimeur, A., Conseil, G., Deeley, R. G. & Cole, S. P. C. (2004). The MRP-related and 
BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and 
regulation. Curr Drug Metab, 5, 21-53. 
Halfter, H., Kremerskothen, J., Webwe, J., Hacker-Klom, U., Barnekow, A., Ringlestein, E. 
& Stogbauer, F. (1998). Growth inhibition of newly established human glioma cell 
lines by leukemia inhibitory factor. J Neuro-Oncol, 39, 1 - 18. 
Haluska, M. & Anthony, M. L. (2004). Osmotic blood-brain barrier modification for the 
treatment of malignant brain tumors. Clin J Oncol Nurs, 8, 263-7. 
Hanada, S., Fujoka, K., Inoue, Y., Kanaya, F., Manome, Y. & Yamamoto, K. (2013). 
Application of in vitro BBB model to measure permeability of nanoparticles. Journal 
of Physics: Conference Series, 429, 012028. 
Hanahan, D. & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57-70. 
Hanahan, D. & Weinberg, Robert a. (2011 
). Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. 
 
 
299 
Haorah, J., Ramirez, S. H., Schall, K., Smith, D., Pandya, R. & Persidsky, Y. (2007). 
Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading 
to blood-brain barrier dysfunction. J Neurochem, 101, 566-76. 
Hartsock, A. & Nelson, W. J. (2008). Adherens and tight junctions: structure, function and 
connections to the actin cytoskeleton. Biochim Biophys Acta, 1778, 660-9. 
Hartz, A. M. & Bauer, B. (2010). Regulation of ABC transporters at the blood-brain barrier: 
new targets for CNS therapy. Mol Interv, 10, 293-304. 
Harvey, K., Siddiqui, R. A., Sliva, D., Garcia, J. G. & English, D. (2002). Serum factors 
involved in human microvascular endothelial cell morphogenesis. J Lab Clin Med, 140, 
188-98. 
Haseloff, R. F., Blasig, I. E., Bauer, H. C. & Bauer, H. (2005). In search of the astrocytic 
factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells 
in vitro. Cell Mol Neurobiol, 25, 25-39. 
Hass, R. & Bertram, C. (2009). Characterization of human breast cancer epithelial cells 
(HBCEC) derived from long term cultured biopsies. Journal of Experimental & 
Clinical Cancer Research, 28, 127. 
Hatherell, K., Couraud, P., Romero, I., Weksler, B. & Pilkington, G. (2011). Development 
of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-
, co- and tri-Transwell cultivation methods. J Neurosci Meth, 199, 223 - 229. 
Hayashi, K., Nakao, S., Nakaoke, R., Nakagawa, S., Kitagawa, N. & Niwa, M. (2004). 
Effects of hypoxia on endothelial/pericytic co-culture model of the blood-brain barrier. 
Regulatory Peptides, 123, 77-83. 
He, J., Du, Y., Guo, Y., Hancock, M. J., Wang, B., Shin, H., Wu, J., Li, D. & 
Khademhosseini, A. (2011). Microfluidic synthesis of composite cross-gradient 
materials for investigating cell-biomaterial interactions. Biotechnol Bioeng, 108, 175-
85. 
Healey, J. (2010). Editorial: The Imperative to Authenticate Cell Lines. Clinical 
Orthopaedics and Related Research®, 468, 3413-3414. 
Hedlund, E., Gustafsson, J. A. & Warner, M. (2001). Cytochrome P450 in the brain; a review. 
Curr Drug Metab, 2, 245-63. 
Higgins, S. C., Steingrimsdottir, H. & Pilkington, G. J. (2010). Human, mouse or rat? Species 
authentication of glioma-derived cell cultures. J Neurosci Methods, 194, 139-43. 
Hitchcock, S. A. (2008). Blood-brain barrier permeability considerations for CNS-targeted 
compound library design. Curr Opin Chem Biol, 12, 318-23. 
Hoffmann, A., Bredno, J., Wendland, M., Derugin, N., Ohara, P. & Wintermark, M. (2011). 
High and Low Molecular Weight Fluorescein Isothiocyanate (FITC)-Dextrans to 
Assess Blood-Brain Barrier Disruption: Technical Considerations. Transl Stroke Res, 
2, 106-11. 
Huang, H.-L., Hsing, H.-W., Lai, T.-C., Chen, Y.-W., Lee, T.-R., Chan, H.-T., Lyu, P.-C., 
Wu, C.-L., Lu, Y.-C., Lin, S.-T., Lin, C.-W., Lai, C.-H., Chang, H.-T., Chou, H.-C. & 
Chan, H.-L. (2010). Trypsin-induced proteome alteration during cell subculture in 
mammalian cells. Journal of Biomedical Science, 17, 36. 
 
 
300 
Hughes, P., Marshall, D., Reid, Y., Parkes, H. & Gelber, C. (2007). The costs of using 
unauthenticated, over-passaged cell lines: how much more data do we need? 
Biotechniques, 43, 575, 577-8, 581-2 passim. 
Huse, J. T. & Holland, E. C. (2010). Targeting brain cancer: advances in the molecular 
pathology of malignant glioma and medulloblastoma. Nat Rev Cancer, 10, 319-331. 
Ignatova, T. N., Kukekov, V. G., Laywell, E. D., Suslov, O. N., Vrionis, F. D. & Steindler, 
D. A. (2002). Human cortical glial tumors contain neural stem-like cells expressing 
astroglial and neuronal markers in vitro. Glia, 39, 193-206. 
Inda, M. M., Bonavia, R. & Seoane, J. (2014). Glioblastoma multiforme: a look inside its 
heterogeneous nature. Cancers (Basel), 6, 226-39. 
Ingelman-Sundberg, M. (2004). Pharmacogenetics of cytochrome P450 and its applications 
in drug therapy: the past, present and future. Trends Pharmacol Sci, 25, 193-200. 
Inoue, A., Takahashi, H., Harada, H., Kohno, S., Ohue, S., Kobayashi, K., Yano, H., Tanaka, 
J. & Ohnishi, T. (2010). Cancer stem-like cells of glioblastoma characteristically 
express MMP-13 and display highly invasive activity. Int J Oncol, 37, 1121-31. 
Ishihara, H., Kubota, H., Lindberg, R. L., Leppert, D., Gloor, S. M., Errede, M., Virgintino, 
D., Fontana, A., Yonekawa, Y. & Frei, K. (2008). Endothelial cell barrier impairment 
induced by glioblastomas and transforming growth factor beta2 involves matrix 
metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol, 67, 435-48. 
Ishikawa, T., Onishi, Y., Hirano, H., Oosumi, K., Nagakura, M. & Tarui, S. (2004). 
Pharmacogenomics of drug transporters: A new approach to functional analysis of the 
genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biological and 
Pharmaceutical Bulletin, 27, 939-948. 
Jemal, A., Siegel, R., Xu, J. & Ward, E. (2010). Cancer statistics, 2010. CA Cancer J Clin, 
60, 277-300. 
Jensen, R. & Chkheidze, R. 2011. The Role of Glucose Transporter-1 (GLUT-1) in 
Malignant Gliomas. In: Hayat, M. A. (ed.) Tumors of the Central Nervous System, 
Volume 1. Springer Netherlands. 
Joseph, J. V., Balasubramaniyan, V., Walenkamp, A. & Kruyt, F. A. (2013). TGF-beta as a 
therapeutic target in high grade gliomas - promises and challenges. Biochem 
Pharmacol, 85, 478-85. 
Jung, C. S., Foerch, C., Schänzer, A., Heck, A., Plate, K. H., Seifert, V., Steinmetz, H., 
Raabe, A. & Sitzer, M. (2007a). Serum GFAP is a diagnostic marker for glioblastoma 
multiforme. 
Jung, S., Moon, K.-S., Kim, S.-T., Ryu, H.-H., Lee, Y.-H., Jeong, Y.-I., Jung, T.-Y., Kim, I.-
Y., Kim, K.-K. & Kang, S.-S. (2007b). Increased expression of intracystic matrix 
metalloproteinases in brain tumors: relationship to the pathogenesis of brain tumor-
associated cysts and peritumoral edema. Journal of Clinical Neuroscience, 14, 1192-
1198. 
Kago, T., Takagi, N., Date, I., Takenaga, Y., Takagi, K. & Takeo, S. (2006). Cerebral 
ischemia enhances tyrosine phosphorylation of occludin in brain capillaries. Biochem 
Biophys Res Commun, 339, 1197-203. 
 
 
301 
Kakkar, V., Mishra, A. K., Chuttani, K. & Kaur, I. P. (2013). Proof of concept studies to 
confirm the delivery of curcumin loaded solid lipid nanoparticles (C-SLNs) to brain. 
Int J Pharm, 448, 354-9. 
Kaplan, J. & Hukku, B. (1998). Cell line characterization and authentication. Methods Cell 
Biol, 57, 203-16. 
Kapoor, N., Pant, A., Dhawan, A., Dwievedi, U., Seth, P. & Parmar, D. (2007). Differences 
in the expression and inducibility of cytochrome P450 2B isoenzymes in cultured rat 
brain neuronal and glial cells. Molecular and Cellular Biochemistry, 305, 199-207. 
Karnezis, T., Shayan, R., Caesar, C., Roufail, S., Harris, Nicole c., Ardipradja, K., Zhang, 
You f., Williams, Steven p., Farnsworth, Rae h., Chai, Ming g., Rupasinghe, 
Thusitha w. T., Tull, Dedreia l., Baldwin, Megan e., Sloan, Erica k., Fox, Stephen b., 
Achen, Marc g. & Stacker, Steven a. (2012). VEGF-D Promotes Tumor Metastasis by 
Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium. 
Cancer cell, 21, 181-195. 
Kavanagh, E., Tsapara, A., Matter, K. & Balda, M. 2006. Tight Junctions and the Regulation 
of Epithelial Cell Proliferation and Gene Expression. Tight Junctions. Springer US. 
Kemper, E. M., Van Zandbergen, A. E., Cleypool, C., Mos, H. A., Boogerd, W., Beijnen, J. 
H. & Van Tellingen, O. (2003). Increased penetration of paclitaxel into the brain by 
inhibition of P-Glycoprotein. Clin Cancer Res, 9, 2849-55. 
Kido, Y., Tamai, I., Nakanishi, T., Kagami, T., Hirosawa, I., Sai, Y. & Tsuji, A. (2002). 
Evaluation of blood-brain barrier transporters by co-culture of brain capillary 
endothelial cells with astrocytes. Drug Metab Pharmacokinet, 17, 34-41. 
Kim, L. & Glantz, M. (2006). Chemotherapeutic options for primary brain tumors. Current 
Treatment Options in Oncology, 7, 467-478. 
Kimelberg, H. K. & Nedergaard, M. (2010). Functions of astrocytes and their potential as 
therapeutic targets. Neurotherapeutics, 7, 338-53. 
Kleihues, P. & Ohgaki, H. (1999). Primary and secondary glioblastomas: from concept to 
clinical diagnosis. Neuro Oncol, 1, 44-51. 
Krizanac-Bengez, L., Kapural, M., Parkinson, F., Cucullo, L., Hossain, M., Mayberg, M. R. 
& Janigro, D. (2003). Effects of transient loss of shear stress on blood-brain barrier 
endothelium: role of nitric oxide and IL-6. Brain Res, 977, 239-46. 
Kroll, R. A. & Neuwelt, E. A. (1998). Outwitting the blood-brain barrier for therapeutic 
purposes: osmotic opening and other means. Neurosurgery, 42, 1083-99; discussion 
1099-100. 
Kumar, N., Gammell, P., Meleady, P., Henry, M. & Clynes, M. (2008). Differential protein 
expression following low temperature culture of suspension CHO-K1 cells. BMC 
Biotechnology, 8, 42. 
Kumar, S., Shaw, L., Lawrence, C., Lea, R. & Alder, J. (2014). P50DEVELOPING A 
PHYSIOLOGICALLY RELEVANT BLOOD BRAIN BARRIER MODEL FOR THE 
STUDY OF DRUG DISPOSITION IN GLIOMA. Neuro-Oncology, 16, vi8. 
Kuteykin-Teplyakov, K., Luna-Tortos, C., Ambroziak, K. & Loscher, W. (2010). 
Differences in the expression of endogenous efflux transporters in MDR1-transfected 
 
 
302 
versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br J 
Pharmacol, 160, 1453-63. 
Lacombe, O., Videau, O., Chevillon, D., Guyot, A., Contreras, C., Blondel, S., Nicolas, L., 
Ghettas, A., Benech, H. & Thevenot, E. (2011). In vitro primary human and animal 
cell-based blood-brain barrier models as a screening tool in drug discovery. Mol 
Pharm, 8, 651 - 663. 
Lai, C. H. & Kuo, K. H. (2005). The critical component to establish in vitro BBB model: 
Pericyte. Brain Res Brain Res Rev, 50, 258-65. 
Langner, C., Ratschek, M., Rehak, P., Schips, L. & Zigeuner, R. (2003). Expression of 
MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic 
immunohistochemical analysis of 188 cases. Mod Pathol, 17, 180-188. 
Lee, G., Babakhanian, K., Ramaswamy, M., Prat, A., Wosik, K. & Bendayan, R. (2007). 
Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and 
rodent brain microvessel endothelial and glial cell culture systems. Pharm Res, 24, 
1262-74. 
Lee, J., Lilly, G. D., Doty, R. C., Podsiadlo, P. & Kotov, N. A. (2009). In vitro toxicity testing 
of nanoparticles in 3D cell culture. Small, 5, 1213-21. 
Lee, Y. J., Kusuhara, H., Jonker, J. W., Schinkel, A. H. & Sugiyama, Y. (2005). Investigation 
of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse 
blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp 
Ther, 312, 44-52. 
Li, G., Simon, M. J., Cancel, L. M., Shi, Z. D., Ji, X., Tarbell, J. M., Morrison, B., 3rd & Fu, 
B. M. (2010). Permeability of endothelial and astrocyte cocultures: in vitro blood-brain 
barrier models for drug delivery studies. Ann Biomed Eng, 38, 2499-511. 
Liebner, S., Corada, M., Bangsow, T., Babbage, J., Taddei, A., Czupalla, C., Reis, M., Felici, 
A., Wolburg, H., Fruttiger, M., Taketo, M., Von Melchner, H., Plate, K., Gerhardt, H. 
& Dejana, E. (2008). Wnt/beta-catenin signaling controls development of the blood-
brain barrier. J Cell Biol, 183, 409 - 417. 
Liebner, S., Fischmann, A., Rascher, G., Duffner, F., Grote, E. H., Kalbacher, H. & Wolburg, 
H. (2000). Claudin-1 and claudin-5 expression and tight junction morphology are 
altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol, 100, 
323-31. 
Lin, J. H. & Lu, A. Y. H. (1997). Role of Pharmacokinetics and Metabolism in Drug 
Discovery and Development. Pharmacological Reviews, 49, 403-449. 
Lockhart, A. C., Tirona, R. G. & Kim, R. B. (2003). Pharmacogenetics of ATP-binding 
cassette transporters in cancer and chemotherapy. Molecular cancer therapeutics, 2, 
685-698. 
Lohmann, C., Krischke, M., Wegener, J. & Galla, H. J. (2004). Tyrosine phosphatase 
inhibition induces loss of blood-brain barrier integrity by matrix metalloproteinase-
dependent and -independent pathways. Brain Res, 995, 184-96. 
Loscher, W. & Potschka, H. (2005a). Blood-brain barrier active efflux transporters: ATP-
binding cassette gene family. NeuroRx, 2, 86-98. 
 
 
303 
Loscher, W. & Potschka, H. (2005b). Drug resistance in brain diseases and the role of drug 
efflux transporters. Nat Rev Neurosci, 6, 591-602. 
Loscher, W. & Potschka, H. (2005c). Role of drug efflux transporters in the brain for drug 
disposition and treatment of brain diseases. Prog Neurobiol, 76, 22-76. 
Löscher, W. & Potschka, H. (2005). Role of drug efflux transporters in the brain for drug 
disposition and treatment of brain diseases. Progress in Neurobiology, 76, 22-76. 
Louis, D., Ohgaki, H., Wiestler, O., Cavenee, W., Burger, P., Jouvet, A., Scheithauer, B. & 
Kleihues, P. (2007). The 2007 WHO Classification of Tumours of the Central Nervous 
System. Acta Neuropathologica, 114, 97-109. 
Lu, W., Tan, Y. Z. & Jiang, X. G. (2006). Establishment of coculture model of blood-brain 
barrier in vitro for nanoparticle's transcytosis and toxicity evaluation. Yao Xue Xue Bao, 
41, 296-304. 
Lucey, B. P., Nelson-Rees, W. A. & Hutchins, G. M. (2009). Henrietta Lacks, HeLa cells, 
and cell culture contamination. Arch Pathol Lab Med, 133, 1463-7. 
Luissint, A., Artus, C., Glacial, F., Ganeshamoorthy, K. & Couraud, P. (2012a). Tight 
junctions of the blood-brain barrier: physiological architecture and disease-associated 
dysregulation. Fluids Barriers CNS, 9, 23. 
Luissint, A., Federici, C., Guillonneau, F., Chretien, F., Camoin, L., Glacial, F., 
Ganeshamoorthy, K. & Couraud, P. (2012b). Guanine nucleotide-binding protein 
Galphai2: a new partner of claudin-5 that regulates tight junction integrity in human 
brain endothelial cells. J Cereb Blood Flow Metab, 32, 860 - 873. 
Lundquist, S. & Renftel, M. (2002). The use of in vitro cell culture models for mechanistic 
studies and as permeability screens for the blood-brain barrier in the pharmaceutical 
industry - Background and current status in the drug discovery process. Vascul 
Pharmacol, 38, 355-364. 
Ma, L., Kuang, K., Smith, R. W., Rittenband, D., Iserovich, P., Diecke, F. P. & Fischbarg, J. 
(2007). Modulation of tight junction properties relevant to fluid transport across rabbit 
corneal endothelium. Exp Eye Res, 84, 790-8. 
Macleod, R. A., Dirks, W. G., Matsuo, Y., Kaufmann, M., Milch, H. & Drexler, H. G. (1999). 
Widespread intraspecies cross-contamination of human tumor cell lines arising at 
source. Int J Cancer, 83, 555-63. 
Malina, K. C. K., Cooper, I. & Teichberg, V. I. (2009). Closing the gap between the in-vivo 
and in-vitro blood-brain barrier tightness. Brain Res, 1284, 12-21. 
Mann, A., Miksys, S. L., Gaedigk, A., Kish, S. J., Mash, D. C. & Tyndale, R. F. (2012). The 
neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in 
Parkinson's disease patients. Neurobiol Aging, 33, 2160-71. 
Marini, G., Luchese, M., Argondizzo, A. P., De Goes, A. C. M. A., Galler, R., Alves, T. L., 
Medeiros, M. & Larentis, A. (2014). Experimental design approach in recombinant 
protein expression: determining medium composition and induction conditions for 
expression of pneumolysin from Streptococcus pneumoniae in Escherichia coli and 
preliminary purification process. BMC Biotechnology, 14, 1. 
Masserini, M. (2013). Nanoparticles for Brain Drug Delivery. ISRN Biochemistry, 2013, 18. 
 
 
304 
Masters, J. R. W. (2000). Human cancer cell lines: fact and fantasy. Nat Rev Mol Cell Biol, 
1, 233-236. 
Mather, J. P. & Roberts, P. E. 1998. Standard Cell Culture Techniques. Introduction to Cell 
and Tissue Culture. Springer US. 
Mcfadyen, M. C. E., Melvin, W. T. & Murray, G. I. (2004). Cytochrome P450 enzymes: 
Novel options for cancer therapeutics. Molecular Cancer Therapeutics, 3, 363-371. 
Medical Research Council Brain Tumor Working, P. (2001). Randomized trial of 
procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade 
astrocytoma: a Medical Research Council trial. J Clin Oncol, 19, 509-18. 
Mertsch, K. & Maas, J. (2002). Blood-Brain Barrier Penetration and Drug Development from 
an Industrial Point of View. Current Medicinal Chemistry -Central Nervous System 
Agents, 2, 187-201. 
Meyer, R., Gehlhaus, M., Knoth, R. & Volk, B. (2007). Expression and function of 
cytochrome p450 in brain drug metabolism. Curr Drug Metab, 8, 297 - 306. 
Miao, Z., Dong, Y., Fang, W., Shang, D., Liu, D., Zhang, K., Li, B. & Chen, Y. H. (2014). 
VEGF increases paracellular permeability in brain endothelial cells via upregulation of 
EphA2. Anat Rec (Hoboken), 297, 964-72. 
Miksys, S. & Tyndale, R. F. (2004). The Unique Regulation of Brain Cytochrome P450 2 
(CYP2) Family Enzymes by Drugs and Genetics. Drug Metabolism Reviews, 36, 313-
333. 
Miksys, S. & Tyndale, R. F. (2009). Brain drug-metabolizing cytochrome P450 enzymes are 
active in vivo, demonstrated by mechanism-based enzyme inhibition. 
Neuropsychopharmacology, 34, 634-40. 
Miller, D. S. (2010). Regulation of P-glycoprotein and other ABC drug transporters at the 
blood-brain barrier. Trends Pharmacol Sci, 31, 246-54. 
Miller, G. (2002). Drug targeting. Breaking down barriers. Science, 297, 1116-8. 
Modi, G., Pillay, V., Choonara, Y. E., Ndesendo, V. M., Du Toit, L. C. & Naidoo, D. (2009). 
Nanotechnological applications for the treatment of neurodegenerative disorders. Prog 
Neurobiol, 88, 272-85. 
Montgomery, D. L. (1994). Astrocytes: form, functions, and roles in disease. Vet Pathol, 31, 
145-67. 
Moore, K. & Kim, L. (2010). Primary Brain Tomors: Characteristics Practical Daignostic 
and Treatment Approaches, New York NY, Springer Science. 
Naik, P. & Cucullo, L. (2012). In vitro blood-brain barrier models: current and perspective 
technologies. J Pharm Sci, 101, 1337-54. 
Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V. & Hamada, J.-I. 
(2011). Aberrant Signaling Pathways in Glioma. Cancers, 3, 3242-3278. 
Nakagawa, S., Deli, M., Kawaguchi, H., Shimizudani, T., Shimono, T., Kittel, A., Tanaka, 
K. & Niwa, M. (2009a). A new blood-brain barrier model using primary rat brain 
endothelial cells, pericytes and astrocytes. Neurochem Int, 54, 253 - 263. 
 
 
305 
Nakagawa, S., Deli, M., Nakao, S., Honda, M., Hayashi, K., Nakaoke, R., Kataoka, Y. & 
Niwa, M. (2007a). Pericytes from brain microvessels strengthen the barrier integrity in 
primary cultures of rat brain endothelial cells. Cell Mol Neurobiol, 27, 687 - 694. 
Nakagawa, S., Deli, M. A., Kawaguchi, H., Shimizudani, T., Shimono, T., Kittel, A., Tanaka, 
K. & Niwa, M. (2009b). A new blood-brain barrier model using primary rat brain 
endothelial cells, pericytes and astrocytes. Neurochemistry International, 54, 253-263. 
Nakagawa, S., Deli, M. A., Nakao, S., Honda, M., Hayashi, K., Nakaoke, R., Kataoka, Y. & 
Niwa, M. (2007b). Pericytes from brain microvessels strengthen the barrier integrity in 
primary cultures of rat brain endothelial cells. Cellular and Molecular Neurobiology, 
27, 687-694. 
Narayanan, R. & Gunturi, S. B. (2005). In silico ADME modelling: prediction models for 
blood-brain barrier permeation using a systematic variable selection method. Bioorg 
Med Chem, 13, 3017-28. 
Nathoo, N., Toms, S. A. & Barnett, G. H. (2004). Metastases to the brain: current 
management perspectives. Expert Rev Neurother, 4, 633-40. 
Nebert, D. W., Wikvall, K. & Miller, W. L. (2013). Human cytochromes P450 in health and 
disease. Philos Trans R Soc Lond B Biol Sci, 368, 20120431. 
Nelson, S. D. & Gordon, W. P. (1983). Mammalian Drug Metabolism. Journal of Natural 
Products, 46, 71-78. 
Nir, I., Levanon, D. & Iosilevsky, G. (1989). Permeability of blood vessels in experimental 
gliomas: uptake of 99mTc-glucoheptonate and alteration in blood-brain barrier as 
determined by cytochemistry and electron microscopy. Neurosurgery, 25, 523-31; 
discussion 531-2. 
Noguchi, K., Katayama, K., Mitsuhashi, J. & Sugimoto, Y. (2009). Functions of the breast 
cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev, 61, 
26-33. 
Oberdorster, G., Elder, A. & Rinderknecht, A. (2009). Nanoparticles and the brain: cause for 
concern? J Nanosci Nanotechnol, 9, 4996-5007. 
Obermeier, B., Daneman, R. & Ransohoff, R. M. (2013). Development, maintenance and 
disruption of the blood-brain barrier. Nat Med, 19, 1584-1596. 
Ohgaki, H. & Kleihues, P. (2005). Epidemiology and etiology of gliomas. Acta 
Neuropathologica, 109, 93-108. 
Ohgaki, H. & Kleihues, P. (2007). Genetic pathways to primary and secondary glioblastoma. 
Am J Pathol, 170, 1445-53. 
Ohgaki, H. & Kleihues, P. (2013). The definition of primary and secondary glioblastoma. 
Clin Cancer Res, 19, 764-72. 
Oldendorf, W. H. (1971). Blood Brain Barrier Permeability to Lactate. European Neurology, 
6, 49-55. 
Omidi, Y. & Barar, J. (2012). Impacts of blood-brain barrier in drug delivery and targeting 
of brain tumors. Bioimpacts, 2, 5-22. 
 
 
306 
On, N. H., Mitchell, R., Savant, S. D., Bachmeier, C. J., Hatch, G. M. & Miller, D. W. (2013). 
Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model. J 
Neurooncol, 111, 133-43. 
Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, 
M., Schwartzbaum, J. A., Turner, M. C., Walsh, K. M., Wrensch, M. R. & Barnholtz-
Sloan, J. S. (2014). The epidemiology of glioma in adults: a “state of the science” 
review. Neuro-Oncology, 16, 896-913. 
Oyama, T., Kagawa, N., Kunugita, N., Kitagawa, K., Ogawa, M., Yamaguchi, T., Suzuki, 
R., Kinaga, T., Yashima, Y., Ozaki, S., Isse, T., Kim, Y. D., Kim, H. & Kawamoto, T. 
(2004). Expression of cytochrome P450 in tumor tissues and its association with cancer 
development. Front Biosci, 9, 1967-76. 
Palmiotti, C. A., Prasad, S., Naik, P., Abul, K. M., Sajja, R. K., Achyuta, A. H. & Cucullo, 
L. (2014). In Vitro Cerebrovascular Modeling in the 21st Century: Current and 
Prospective Technologies. Pharm Res. 
Pan, C., Kumar, C., Bohl, S., Klingmueller, U. & Mann, M. (2009). Comparative proteomic 
phenotyping of cell lines and primary cells to assess preservation of cell type-specific 
functions. Mol Cell Proteomics, 8, 443-50. 
Pardridge, W. M. (1999). Blood-brain barrier biology and methodology. J Neurovirol, 5, 
556-69. 
Pardridge, W. M. (2003). Blood-brain barrier drug targeting: the future of brain drug 
development. Mol Interv, 3, 90-105, 51. 
Pardridge, W. M. (2005). The blood-brain barrier: bottleneck in brain drug development. 
NeuroRx, 2, 3-14. 
Parkinson, F. E., Ferguson, J., Zamzow, C. R. & Xiong, W. (2006). Gene expression for 
enzymes and transporters involved in regulating adenosine and inosine levels in rat 
forebrain neurons, astrocytes and C6 glioma cells. J Neurosci Res, 84, 801-8. 
Patabendige, A., Skinner, R. A., Morgan, L. & Joan Abbott, N. (2013). A detailed method 
for preparation of a functional and flexible blood–brain barrier model using porcine 
brain endothelial cells. Brain Research. 
Poller, B., Gutmann, H., Krähenbühl, S., Weksler, B., Romero, I., Couraud, P.-O., Tuffin, 
G., Drewe, J. & Huwyler, J. (2008). The human brain endothelial cell line hCMEC/D3 
as a human blood-brain barrier model for drug transport studies. Journal of 
Neurochemistry, 107, 1358-1368. 
Rachet, B., Maringe, C., Nur, U., Quaresma, M., Shah, A., Woods, L. M., Ellis, L., Walters, 
S., Forman, D., Steward, J. & Coleman, M. P. (2009). Population-based cancer survival 
trends in England and Wales up to 2007: an assessment of the NHS cancer plan for 
England. Lancet Oncol, 10, 351-69. 
Ragnaill, M. N., Brown, M., Ye, D., Bramini, M., Callanan, S., Lynch, I. & Dawson, K. A. 
(2011). Internal benchmarking of a human blood–brain barrier cell model for screening 
of nanoparticle uptake and transcytosis. European Journal of Pharmaceutics and 
Biopharmaceutics, 77, 360-367. 
 
 
307 
Rajkumar, S. V., Buckner, J. C., Schomberg, P. J., Reid, J. M., Bagniewski, P. J., Ames, M. 
M., Cascino, T. L. & Marks, R. S. (1998). Phase I and pharmacokinetic study of 
preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated 
radiation therapy in patients with high-grade glioma. Int J Radiat Oncol Biol Phys, 42, 
969-75. 
Raleigh, D. R., Boe, D. M., Yu, D., Weber, C. R., Marchiando, A. M., Bradford, E. M., 
Wang, Y., Wu, L., Schneeberger, E. E., Shen, L. & Turner, J. R. (2011). Occludin S408 
phosphorylation regulates tight junction protein interactions and barrier function. J Cell 
Biol, 193, 565-82. 
Reichel, A., Begley, D. J. & Abbott, N. J. (2003). An overview of in vitro techniques for 
blood-brain barrier studies. Methods in molecular medicine, 89, 307-324. 
Reichert, W. M. (2007). Indwelling Neural Implants: Strategies for Contending with the In 
Vivo Environment, CRC Press. 
Reni, M., Ferreri, A. J., Guha-Thakurta, N., Blay, J. Y., Dell'oro, S., Biron, P. & Hochberg, 
F. H. (2001). Clinical relevance of consolidation radiotherapy and other main 
therapeutic issues in primary central nervous system lymphomas treated with upfront 
high-dose methotrexate. Int J Radiat Oncol Biol Phys, 51, 419-25. 
Rieder, C. R., Ramsden, D. B. & Williams, A. C. (1998). Cytochrome P450 1B1 mRNA in 
the human central nervous system. Mol Pathol, 51, 138-42. 
Ritschel & Kerns (2004). Handbook of Basic Pharmacokinetics including Clinical 
applications, Washington, DC, Americal Pharmaceutical Association. 
Rivlin, N., Brosh, R., Oren, M. & Rotter, V. (2011). Mutations in the p53 Tumor Suppressor 
Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes & Cancer, 
2, 466-474. 
Robertson, G. R., Field, J., Goodwin, B., Bierach, S., Tran, M., Lehnert, A. & Liddle, C. 
(2003). Transgenic Mouse Models of Human CYP3A4 Gene Regulation. Molecular 
Pharmacology, 64, 42-50. 
Rodríguez-Escudero, I., Oliver, M. D., Andrés-Pons, A., Molina, M., Cid, V. J. & Pulido, R. 
(2011). A comprehensive functional analysis of PTEN mutations: implications in 
tumor- and autism-related syndromes. Human Molecular Genetics. 
Rojas, A. (2011). Cell line cross-contamination: who wins? J Biol Chem, 286, le20; author 
reply le21. 
Roth, M., Obaidat, A. & Hagenbuch, B. (2012). OATPs, OATs and OCTs: the organic anion 
and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol, 
165, 1260-87. 
Roux, F. & Couraud, P. (2005). Rat brain endothelial cell lines for the study of blood-brain 
barrier permeability and transport functions. Cell Mol Neurobiol, 25, 41 - 58. 
Rubenstein, B. M. & Kaufman, L. J. (2008). The Role of Extracellular Matrix in Glioma 
Invasion: A Cellular Potts Model Approach. Biophysical Journal, 95, 5661-5680. 
Rubin, L., Hall, D., Porter, S., Barbu, K., Cannon, C., Horner, H., Janatpour, M., Liaw, C., 
Manning, K. & Morales, J. (1991). A cell culture model of the blood-brain barrier. J 
Cell Biol, 115, 1725 - 1735. 
 
 
308 
Rucker, H. K., Wynder, H. J. & Thomas, W. E. (2000). Cellular mechanisms of CNS 
pericytes. Brain Research Bulletin, 51, 363-369. 
Ruoslahti, E. (1996). Brain extracellular matrix. Glycobiology, 6, 489-92. 
Sá-Pereira, I., Brites, D. & Brito, M. A. (2012). Neurovascular unit: a focus on pericytes. 
Molecular neurobiology, 45, 327-347. 
Scherer, H. J. (1938). Structural Development in Gliomas. The American Journal of Cancer, 
34, 333-351. 
Scherer, H. J. (1940). Cerebral Astrocytomas and Their Derivatives. The American Journal 
of Cancer, 40, 159-198. 
Schinkel, A. H. (1999). P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug 
Deliv Rev, 36, 179-194. 
Schlie-Wolter, S., Ngezahayo, A. & Chichkov, B. N. (2013). The selective role of ECM 
components on cell adhesion, morphology, proliferation and communication in vitro. 
Experimental Cell Research, 319, 1553-1561. 
Schuetz, E. & Strom, S. (2001). Promiscuous regulator of xenobiotic removal. Nat Med, 7, 
536-7. 
Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D. & Wrensch, M. (2006). Epidemiology and 
molecular pathology of glioma. Nat Clin Pract Neuro, 2, 494-503. 
Scotto, K. W. (2003). Transcriptional regulation of ABC drug transporters. Oncogene, 22, 
7496-7511. 
Shawahna, R., Decleves, X. & Scherrmann, J. M. (2012). Hurdles with Using In Vitro 
Models to Predict Human Blood-brain Barrier Drug Permeability: A Special Focus on 
Transporters and Metabolizing Enzymes. Curr Drug Metab. 
Shen, S. & Zhang, W. (2010). ABC transporters and drug efflux at the blood-brain barrier. 
Rev Neurosci, 21, 29-53. 
Siddharthan, V., Kim, Y. V., Liu, S. & Kim, K. S. (2007). Human astrocytes/astrocyte-
conditioned medium and shear stress enhance the barrier properties of human brain 
microvascular endothelial cells. Brain Res, 1147, 39-50. 
Simionescu, N., Siminoescu, M. & Palade, G. E. (1975). Permeability of muscle capillaries 
to small heme-peptides. Evidence for the existence of patent transendothelial channels. 
J Cell Biol, 64, 586-607. 
Singh, P., Carraher, C. & Schwarzbauer, J. E. (2010). Assembly of fibronectin extracellular 
matrix. Annu Rev Cell Dev Biol, 26, 397-419. 
Smythe, E. & Ayscough, K. R. (2006). Actin regulation in endocytosis. J Cell Sci, 119, 4589-
98. 
Sobue, K., Yamamoto, N., Yoneda, K., Hodgson, M., Yamashiro, K., Tsuruoka, N., Tsuda, 
T., Katsuya, H., Miura, Y. & Asai, K. (1999). Induction of blood-brain barrier 
properties in immortalized bovine brain endothelial cells by astrocytic factors. 
Neurosci Res, 35, 155 - 164. 
Song, C. M., Lim, S. J. & Tong, J. C. (2009). Recent advances in computer-aided drug design. 
Briefings in Bioinformatics, 10, 579-591. 
 
 
309 
Sonoda, J., Rosenfeld, J. M., Xu, L., Evans, R. M. & Xie, W. (2003). A nuclear receptor-
mediated xenobiotic response and its implication in drug metabolism and host 
protection. Curr Drug Metab, 4, 59-72. 
Stacey, G. 2001. Primary Cell Cultures and Immortal Cell Lines. eLS. John Wiley & Sons, 
Ltd. 
Stamatovic, S. M., Dimitrijevic, O. B., Keep, R. F. & Andjelkovic, A. V. (2006). Protein 
kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial 
permeability. J Biol Chem, 281, 8379-88. 
Stamatovic, S. M., Keep, R. F. & Andjelkovic, A. V. (2008). Brain endothelial cell-cell 
junctions: how to "open" the blood brain barrier. Curr Neuropharmacol, 6, 179-92. 
Stamatovic, S. M., Keep, R. F., Kunkel, S. L. & Andjelkovic, A. V. (2003). Potential role of 
MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. 
J Cell Sci, 116, 4615-28. 
Staud, F., Ceckova, M., Micuda, S. & Pavek, P. (2010). Expression and function of p-
glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol, 596, 
199-222. 
Strobel, H. W., Kawashima, H., Geng, J., Sequeira, D., Bergh, A., Hodgson, A. V., Wang, 
H. & Shen, S. (1995). Expression of multiple forms of brain cytochrome P450. Toxicol 
Lett, 82-83, 639-43. 
Strobel, H. W., Thompson, C. M. & Antonovic, L. (2001). Cytochromes P450 in brain: 
function and significance. Curr Drug Metab, 2, 199-214. 
Stummer, W. & Kamp, M. A. (2009). The importance of surgical resection in malignant 
glioma. Curr Opin Neurol, 22, 645-9. 
Stupp, R., Mason, W. P., Van Den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., 
Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., 
Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., 
Mirimanoff, R. O., European Organisation For, R., Treatment of Cancer Brain, T., 
Radiotherapy, G. & National Cancer Institute of Canada Clinical Trials, G. (2005). 
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J 
Med, 352, 987-96. 
Swartz, A. M., Li, Q. J. & Sampson, J. H. (2014). Rindopepimut: a promising 
immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy, 6, 
679-90. 
Synold, T. W., Dussault, I. & Forman, B. M. (2001). The orphan nuclear receptor SXR 
coordinately regulates drug metabolism and efflux. Nat Med, 7, 584-90. 
Takakura, Y., Audus, K. L. & Borchardt, R. T. (1991). Blood-Brain Barrier: Transport 
Studies in Isolated Brain Capillaries and in Cultured Brain Endothelial Cells. 
Tarbell, J. M. (2010). Shear stress and the endothelial transport barrier. Cardiovasc Res, 87, 
320-30. 
Taylor, L. P. (2010). Diagnosis, treatment, and prognosis of glioma: Five new things. 
Neurology, 75, S28-S32. 
 
 
310 
Theaker, J. M., Gatter, K. C., Esiri, M. M. & Fleming, K. A. (1986). Epithelial membrane 
antigen and cytokeratin expression by meningiomas: an immunohistological study. J 
Clin Pathol, 39, 435-9. 
Tian, X. H., Wei, F., Wang, T. X., Wang, P., Lin, X. N., Wang, J., Wang, D. & Ren, L. 
(2012). In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with 
SynB peptide to increase drug delivery to the brain. Int J Nanomedicine, 7, 1031-41. 
Toth, A., Veszelka, S., Nakagawa, S., Niwa, M. & Deli, M. (2011). Patented in vitro blood-
brain barrier models in CNS drug discovery. Recent Pat CNS Drug Discov, 6, 107 - 
118. 
Toyoda, K., Tanaka, K., Nakagawa, S., Thuy, D. H., Ujifuku, K., Kamada, K., Hayashi, K., 
Matsuo, T., Nagata, I. & Niwa, M. (2013). Initial contact of glioblastoma cells with 
existing normal brain endothelial cells strengthen the barrier function via fibroblast 
growth factor 2 secretion: a new in vitro blood-brain barrier model. Cell Mol Neurobiol, 
33, 489-501. 
Tsujino, K., Yamate, J., Tsukamoto, Y., Kumagai, D., Kannan, Y., Jippo, T., Kuwamura, M., 
Kotani, T., Takeya, M. & Sakuma, S. (1997). Establishment and Characterization of 
cell lines derived from a transplantable rat malignant meningioma: morphological 
heterogeneity and production of nerve growth factor. Acta Neuropathol, 93, 461 - 470. 
Tsuneki, M. & Madri, J. A. (2014). CD44 regulation of endothelial cell proliferation and 
apoptosis via modulation of CD31 and VE-cadherin expression. Journal of Biological 
Chemistry. 
Ulbrich, K., Hekmatara, T., Herbert, E. & Kreuter, J. (2009). Transferrin- and transferrin-
receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain 
barrier (BBB). Eur J Pharm Biopharm, 71, 251-6. 
Ulrich, T. A., De Juan Pardo, E. M. & Kumar, S. (2009). The mechanical rigidity of the 
extracellular matrix regulates the structure, motility, and proliferation of glioma cells. 
Cancer Res, 69, 4167-74. 
Urich, E., Lazic, S., Molnos, J., Wells, I. & Freskgard, P. (2012). Transcriptional profiling 
of human brain endothelial cells reveals key properties crucial for predictive in vitro 
blood-brain barrier models. PLoS One, 7, e38149. 
Van Hinsbergh, V. W. & Van Nieuw Amerongen, G. P. (2002). Intracellular signalling 
involved in modulating human endothelial barrier function. J Anat, 200, 549-60. 
Van Schaik, R. H. (2008). CYP450 pharmacogenetics for personalizing cancer therapy. Drug 
Resist Updat, 11, 77-98. 
Vartanian, A., Singh, S. K., Agnihotri, S., Jalali, S., Burrell, K., Aldape, K. D. & Zadeh, G. 
(2014). GBM's multifaceted landscape: highlighting regional and microenvironmental 
heterogeneity. Neuro-Oncology, 16, 1167-1175. 
Veringa, S. J. E., Biesmans, D., Van Vuurden, D. G., Jansen, M. H. A., Wedekind, L. E., 
Horsman, I., Wesseling, P., Vandertop, W. P., Noske, D. P., Kaspers, G. J. L. & 
Hulleman, E. (2013). <italic>In Vitro</italic> Drug Response and Efflux Transporters 
Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic 
Pontine Glioma. PLoS ONE, 8, e61512. 
 
 
311 
Vescovi, A. L., Galli, R. & Reynolds, B. A. (2006). Brain tumour stem cells. Nat Rev Cancer, 
6, 425-36. 
Vierck, J. L. & Dodson, M. V. (2000). Interpretation of cell culture phenomena. Methods 
Cell Sci, 22, 79-81. 
Virgintino, D., Robertson, D., Errede, M., Benagiano, V., Girolamo, F., Maiorano, E., 
Roncali, L. & Bertossi, M. (2002). Expression of P-glycoprotein in human cerebral 
cortex microvessels. J Histochem Cytochem, 50, 1671-6. 
Vulic, M. & Kolter, R. (2002). Alcohol-induced delay of viability loss in stationary-phase 
cultures of Escherichia coli. J Bacteriol, 184, 2898-905. 
Warren, M., Zerangue, N., Woodford, K., Roberts, L., Tate, E. & Feng, B. (2009). 
Comparative gene expression profiles of ABC transporters in brain microvessel 
endothelial cells and brain in five species including human. Pharmacol Res, 59, 404 - 
413. 
Weidenfeller, C., Schrot, S., Zozulya, A. & Galla, H. (2005). Murine brain capillary 
endothelial cells exhibit improved barrier properties under the influence of 
hydrocortisone. Brain Res, 1053, 162 - 174. 
Weksler, B., Romero, I. & Couraud, P.-O. (2013). The hCMEC/D3 cell line as a model of 
the human blood brain barrier. Fluids and Barriers of the CNS, 10, 16. 
Wen, P. Y. & Loeffler, J. S. (2000). Brain metastases. Curr Treat Options Oncol, 1, 447-58. 
Wenger, S. L., Senft, J. R., Sargent, L. M., Bamezai, R., Bairwa, N. & Grant, S. G. (2004). 
Comparison of established cell lines at different passages by karyotype and 
comparative genomic hybridization. Biosci Rep, 24, 631-9. 
Wilhelm, I., Fazakas, C. & Krizbai, I. (2011a). In vitro models of the blood-brain barrier. 
Acta Neurobiol Exp, 71, 113 - 128. 
Wilhelm, I., Fazakas, C. & Krizbai, I. A. (2011b). In vitro models of the blood-brain barrier. 
Acta Neurobiol Exp (Wars), 71, 113-28. 
Wilhelm, I. & Krizbai, I. A. (2014). In Vitro Models of the Blood–Brain Barrier for the Study 
of Drug Delivery to the Brain. Molecular Pharmaceutics, 11, 1949-1963. 
Williams, R. T. (1959). Detoxification Mechanisms, New York, Wiley. 
Willis, C. L., Meske, D. S. & Davis, T. P. (2010). Protein kinase C activation modulates 
reversible increase in cortical blood-brain barrier permeability and tight junction 
protein expression during hypoxia and posthypoxic reoxygenation. J Cereb Blood Flow 
Metab, 30, 1847-59. 
Wolburg, H., Neuhaus, J., Kniesel, U., Krauss, B., Schmid, E. M., Ocalan, M., Farrell, C. & 
Risau, W. (1994). Modulation of tight junction structure in blood-brain barrier 
endothelial cells. Effects of tissue culture, second messengers and cocultured 
astrocytes. Journal of Cell Science, 107, 1347-1357. 
Wong, A., Ye, M., Levy, A., Rothstein, J., Bergles, D. & Searson, P. C. (2013). The Blood-
Brain Barrier: An Engineering Perspective. Frontiers in Neuroengineering, 6. 
Xiao, G. & Gan, L.-S. (2013). Receptor-Mediated Endocytosis and Brain Delivery of 
Therapeutic Biologics. International Journal of Cell Biology, 2013, 14. 
 
 
312 
Xu, C., Li, C. Y. & Kong, A. N. (2005). Induction of phase I, II and III drug 
metabolism/transport by xenobiotics. Arch Pharm Res, 28, 249-68. 
Xu, F., Wu, J., Wang, S., Durmus, N. G., Gurkan, U. A. & Demirci, U. (2011). 
Microengineering methods for cell-based microarrays and high-throughput drug-
screening applications. Biofabrication, 3, 034101. 
Ye, D., Dawson, K. A. & Lynch, I. (2014). A TEM protocol for quality assurance of in vitro 
cellular barrier models and its application to the assessment of nanoparticle transport 
mechanisms across barriers. Analyst. 
Yuan, S. Y. & Rigor, R. R. (2011). Regulation of Endothelial Barrier Function, Morgan & 
Claypool. 
Zenker, D., Begley, D., Bratzke, H., Rubsamen-Waigmann, H. & Von Briesen, H. (2003). 
Human blood-derived macrophages enhance barrier function of cultured primary 
bovine and human brain capillary endothelial cells. J Physiol, 551, 1023-32. 
Zlokovic, B. (2008). The blood-brain barrier in health and chronic neurodegenerative 
disorders. Neuron, 57, 178 - 201. 
  
 
 
313 
 Appendices 
1) Cell culture 
Cell Counting 
From the trypsinised cell suspension, 10 µl was aliquotted in a 1 mL sterile eppendorf tube 
to which 10 µl of trypan blue dye was added. Trypan blue is a vital dye with a negatively 
charged chromophore (Strober, 2001). It reacts only with cells with a lysed membrane and 
stains them blue. Hence, the cells that exclude the dye were counted as viable. The neubauer 
counting chamber / haemocytometer was used for counting cells. 
 
Diagram showing haemocytometer and its dimensions.  
Ten microliter of trypan blue stained suspension was loaded on to the haemocytometer and 
the cells were counted under the inverted light microscope at 10 X magnification (Leica 
DMIL, Bucks, UK). The microscope was focused on 25 squares of one chamber and the 
number of cells in these squares were counted, this step was then repeated for the other 
chambers as well (Figure 26). The average number of cells in the centre grid (1 mm2) of each 
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chamber was counted and this number was multiplied with the haemocytometer factor 1 x104 
and then cell count was corrected for dilution factors to obtain the number of cells per 1 mL 
of suspension. This number would then be used either for seeding the cells in 96 microtiter 
well plates, tissue culture flasks or for cryopreservation. The cells were seeded at density of 
2000 cells/ 200 µL/ well in 96 microtiter plate, 20,000 cells/ mL/ well in 24 well plate and 1 
x 106 cells/ mL/ flask in 75 cm2 flask. 
 
2) Setting up Transwell inserts for in contact co-cultures 
Diagrammatic representation of the protocol to set up transwell cultures 
 
 
 
 
 
 
 
315 
3) HBSS buffer recipe 
 400 mg Potassium Chloride (KCl, FW=75; Sigma #P-4504) 
 60 mg Potassium Phosphate, monobasic (KH2PO4, FW=136; Sigma #P-8416) 
 350 mg Sodium Bicarbonate (NaHCO3, FW=84; Sigma #S-5761) 
 8000 mg Sodium Chloride (NaCl, FW=158; Sigma #S-5629) 
 48 mg Sodium Phosphate, dibasic, anhydrous (Na2HPO4, FW=142; Sigma #S-5136) 
 1000 mg D-Glucose (Dextrose, FW=180; Sigma #G-7021) 
 10 mg Phenol Red (FW=376.4; Sigma #P-5530) 
 
4) Western blotting 
10 % SDS PAGE gel recipe 
Recipe for casting resolving and stacking gel for SDS-PAGE. 
Materials 10% Resolving Gel (for 
two gels) 
4% Stacking Gel (for two 
gels) 
dH2O 4.7 mL 4.5 mL 
1.5M Tris Buffer (pH 8.8) 2.6 mL - 
1M Tris Buffer (pH 6.8) - 0.76 mL 
10% SDS 100 µl 60 µl 
40% Acrylamide 2.5 mL 0.6 mL 
10% APS (freshly made only) 100 µl 60 µl 
TEMED (added prior to pouring gel) 10 µl 6 µl 
Total Volume 10 mL 6 mL 
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5) Buffer recipe used in Western blotting 
 Buffer Recipe 
1 RIPA buffer 150 mM sodium chloride 
1.0% Triton X-100 
0.5% sodium deoxycholate 
0.1% SDS (sodium dodecyl sulphate) 
50 mM Tris, pH 8.0 
 
2 Sample loading buffer 4% SDS 
10% 2-mercaptoehtanol 
20% glycerol 
0.004% bromophenol blue 
0.125 M Tris HCl 
3 Electrophoresis buffer (10X) 303 g Trisbase (FW 121.1) 
1440 g glycine (FW 75.07) 
100 g SDS 
4 Transfer buffer (10X) 303 g Trisbase, 
1440 g glycine 
5 Wash buffer (10X) 24.23 g Trizma HCl 
80.06 g NaCl 
800 ml distilled water. 
pH to 7.6  
6 Blocking buffer 
 
Wash buffer + 5 % milk powder 
 
7 Stripping buffer 
 
15 g glycine 
1 g SDS 
10 ml Tween 20 
800ml with ultrapure water 
Adjust pH to 2.2 
 
